{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 11428, "items": [{"indexed": {"date-parts": [[2018, 5, 5]], "date-time": "2018-05-05T00:46:42Z", "timestamp": 1525481202779}, "publisher-location": "Berlin, Heidelberg", "reference-count": 0, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783540543923", "type": "print"}, {"value": "9783642935039", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1991]]}, "DOI": "10.1007/978-3-642-93503-9_167", "type": "book-chapter", "created": {"date-parts": [[2012, 1, 16]], "date-time": "2012-01-16T09:50:22Z", "timestamp": 1326707422000}, "page": "934-938", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Application of Rule Induction Algorithm in Medical Research"], "prefix": "10.1007", "author": [{"given": "Miroslawa", "family": "Lasek", "sequence": "first", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Medical Informatics Europe 1991", "Lecture Notes in Medical Informatics"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-642-93503-9_167", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2012, 1, 16]], "date-time": "2012-01-16T09:51:44Z", "timestamp": 1326707504000}, "score": 30.211168, "issued": {"date-parts": [[1991]]}, "ISBN": ["9783540543923", "9783642935039"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-642-93503-9_167", "ISSN": ["0172-7788"], "issn-type": [{"value": "0172-7788", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 4, 17]], "date-time": "2018-04-17T14:19:43Z", "timestamp": 1523974783062}, "publisher-location": "Cham", "reference-count": 0, "publisher": "Springer International Publishing", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-46906-5", "type": "book", "created": {"date-parts": [[2016, 9, 23]], "date-time": "2016-09-23T09:42:15Z", "timestamp": 1474623735000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology"], "prefix": "10.1007", "author": [{"given": "Witold", "family": "Lasek", "sequence": "first", "affiliation": []}, {"given": "Radoslaw", "family": "Zagozdzon", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["SpringerBriefs in Immunology"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-46906-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-46906-5", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 9, 23]], "date-time": "2016-09-23T09:42:15Z", "timestamp": 1474623735000}, "score": 26.273235, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319469058", "9783319469065"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-319-46906-5", "ISSN": ["2194-2773", "2194-2781"], "issn-type": [{"value": "2194-2773", "type": "print"}, {"value": "2194-2781", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 4, 17]], "date-time": "2018-04-17T14:19:43Z", "timestamp": 1523974783456}, "publisher-location": "Cham", "reference-count": 130, "publisher": "Springer International Publishing", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-46906-5_2", "type": "book-chapter", "created": {"date-parts": [[2016, 9, 23]], "date-time": "2016-09-23T09:42:15Z", "timestamp": 1474623735000}, "page": "21-41", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Antitumor Effects of IL-12 in Preclinical Studies"], "prefix": "10.1007", "author": [{"given": "Witold", "family": "Lasek", "sequence": "first", "affiliation": []}, {"given": "Marek", "family": "Jak\u00f3bisiak", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 9, 24]]}, "reference": [{"key": "2_CR1", "unstructured": "Algazi A, Tsail KK, Takamura KT, Chen L, Twitty C, Dwyer M, Greaney S, Diep TT, Pierce RH, Le MH et al (2016) Priming response to anti-PD1/PDL1 blockade with intratumoral electroporation of plasmid IL-12 in advanced melanoma. http://oncosec.com/wp-content/uploads/2015/09/AACR-Presentation-Algazi-04192016.pdf"}, {"key": "2_CR2", "doi-asserted-by": "publisher", "first-page": "4781", "DOI": "10.1172/JCI74337", "volume": "124", "author": "M Ardolino", "year": "2014", "unstructured": "Ardolino M, Azimi CS, Ianello A, Trevino TN, Horan L, Zhang L, Deng W, Ring AM, Fischer S, Garcia KC et al (2014) Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 124:4781\u20134794. doi: 10.1172/JCI74337", "journal-title": "J Clin Invest"}, {"key": "2_CR3", "doi-asserted-by": "publisher", "first-page": "1173", "DOI": "10.3892/or.19.5.1173", "volume": "19", "author": "GW Basak", "year": "2008", "unstructured": "Basak GW, Zapala L, Wysocki PJ, Mackiewicz A, Jak\u00f3bisiak M, Lasek W (2008) Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma vaccines in a murine model. Oncol Rep 19:1173\u20131179. doi: 10.3892/or.19.5.1173", "journal-title": "Oncol Rep"}, {"key": "2_CR4", "doi-asserted-by": "publisher", "first-page": "e30434", "DOI": "10.1371/journal.pone.0030434", "volume": "7", "author": "LA Basile", "year": "2012", "unstructured": "Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gil K, Mar V, Mendonca S, Miller JD, Tom J, Trinh A, Gallaher TK (2012) HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS ONE 7:e30434. doi: 10.1371/journal.pone.0030434", "journal-title": "PLoS ONE"}, {"issue": "11", "key": "2_CR5", "doi-asserted-by": "publisher", "first-page": "2983", "DOI": "10.1158/1535-7163.MCT-09-0820", "volume": "8", "author": "TS Bekaii-Saab", "year": "2009", "unstructured": "Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 8(11):2983\u20132991. doi: 10.1158/1535-7163.MCT-09-0820", "journal-title": "Mol Cancer Ther"}, {"key": "2_CR6", "first-page": "4862", "volume": "42", "author": "D Berd", "year": "1982", "unstructured": "Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H (1982) Augmentation of the human immune response by cyclophosphamide. Cancer Res 42:4862\u20134866", "journal-title": "Cancer Res"}, {"key": "2_CR7", "doi-asserted-by": "publisher", "first-page": "445", "DOI": "10.1007/s002620100229", "volume": "50", "author": "ES Bergmann-Leitner", "year": "2001", "unstructured": "Bergmann-Leitner ES, Abrams SI (2001) Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 50:445\u2013455. doi: 10.1007/s002620100229", "journal-title": "Cancer Immunol Immunother"}, {"issue": "2", "key": "2_CR8", "doi-asserted-by": "publisher", "first-page": "421", "DOI": "10.1080/1645515.2015.1076953", "volume": "12", "author": "EN Bozeman", "year": "2016", "unstructured": "Bozeman EN, He S, Shafizadeh Y, Selvaraj P (2016) Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. Hum Vaccin Immunother 12(2):421\u2013430. doi: 10.1080/1645515.2015.1076953", "journal-title": "Hum Vaccin Immunother"}, {"issue": "4", "key": "2_CR9", "doi-asserted-by": "publisher", "first-page": "e1008814", "DOI": "10.1080/2162402X.2015.1008814", "volume": "4", "author": "A Buque", "year": "2015", "unstructured": "Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A et al (2015) Trial watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 4(4):e1008814. doi: 10.1080/2162402X.2015.1008814", "journal-title": "Oncoimmunology"}, {"key": "2_CR10", "doi-asserted-by": "publisher", "first-page": "66", "DOI": "10.1186/s12920-015-0142-9", "volume": "8", "author": "AR Campbell", "year": "2015", "unstructured": "Campbell AR, Regan K, Bhave N, Pattanayak A, Parihar R, Stiff AR, Trikha P, Scoville SD, Liyanarachchi S, Kondadasula SV et al (2015) Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleuki-12. BMC Med Genomics 8:66. doi: 10.1186/s12920-015-0142-9", "journal-title": "BMC Med Genomics"}, {"key": "2_CR11", "doi-asserted-by": "publisher", "first-page": "1804", "DOI": "10.1021/mp300602j", "volume": "10", "author": "L Cao", "year": "2013", "unstructured": "Cao L, Zeng Q, Xu C, Shi S, Zhang Z, Sun X (2013) Enhanced antitumor response mediated by the codelivery of paclitaxel and adenoviral vector expressing IL-12. Mol Pharm 10:1804\u20131814. doi: 10.1021/mp300602j", "journal-title": "Mol Pharm"}, {"key": "2_CR12", "unstructured": "Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, Tesic N, Lampreht Tratar U, Rak M, Tozon N (2016) Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours. Vet Compar Oncol (Epub ahead of print). doi: 10.1111/vco.12208", "DOI": "10.1111/vco.12208", "doi-asserted-by": "publisher"}, {"key": "2_CR13", "doi-asserted-by": "publisher", "first-page": "38", "DOI": "10.1038/gt.2015.85", "volume": "23", "author": "M-C Chang", "year": "2016", "unstructured": "Chang M-C, Chen Y-L, Chiang Y-C, Chen T-C, Tang Y-C, Chen C-A, Sun W-Z, Cheng W-F (2016) Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator. Gene Ther 23:38\u201349. doi: 10.1038/gt.2015.85", "journal-title": "Gene Ther"}, {"key": "2_CR14", "doi-asserted-by": "publisher", "first-page": "512", "DOI": "10.1038/cgt.2010.12", "volume": "17", "author": "P Charoensit", "year": "2010", "unstructured": "Charoensit P, Kawakami S, Higuchi Y, Yamashita F, Hashida M (2010) Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther 17:512\u2013522. doi: 10.1038/cgt.2010.12", "journal-title": "Cancer Gene Ther"}, {"key": "2_CR15", "doi-asserted-by": "publisher", "first-page": "93", "DOI": "10.1186/s12967-015-0451-y", "volume": "13", "author": "PY Chen", "year": "2015", "unstructured": "Chen PY, Hsieh HY, Huang CY, Lin CY, Wei KC, Liu HL (2015) Focused ultrasound-induced blood-brain opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study. J Transl Med 13:93. doi: 10.1186/s12967-015-0451-y", "journal-title": "J Transl Med"}, {"issue": "8", "key": "2_CR16", "doi-asserted-by": "publisher", "first-page": "1145", "DOI": "10.1517/14712598.2015.1046430", "volume": "15", "author": "M Chmielewski", "year": "2015", "unstructured": "Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15(8):1145\u20131154. doi: 10.1517/14712598.2015.1046430", "journal-title": "Expert Opin Biol Ther"}, {"issue": "17", "key": "2_CR17", "doi-asserted-by": "publisher", "first-page": "5697", "DOI": "10.1158/0008-5472.CAN-11-0103", "volume": "71", "author": "M Chmielewski", "year": "2011", "unstructured": "Chmielewski M, Kopecky C, Hombach AA, Abken H (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster and antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71(17):5697\u20135706. doi: 10.1158/0008-5472.CAN-11-0103", "journal-title": "Cancer Res"}, {"key": "2_CR18", "unstructured": "Choi I-K, Lee J-S, Zhang S-N, Park J, Lee K-M, Sonn CH, Yun C-O (2011) Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12R\u03b22 or IL-18R\u03b1. doi: 10.1038/gt.2011.37", "DOI": "10.1038/gt.2011.37", "doi-asserted-by": "publisher"}, {"key": "2_CR19", "doi-asserted-by": "publisher", "first-page": "341", "DOI": "10.1007/s00005-014-0268-z", "volume": "62", "author": "T Cichon", "year": "2014", "unstructured": "Cichon T, Smolarczyk R, Matuszczak S, Barczyk M, Jarosz M, Szala S (2014) D-K6L9 peptide combination with IL-12 inhibits the recurrence of tumors in mice. Arch Immunol Ther Exp 62:341\u2013351. doi: 10.1007/s00005-014-0268-z", "journal-title": "Arch Immunol Ther Exp"}, {"key": "2_CR20", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.1007/s00005-013-0259-5", "volume": "62", "author": "A Ciomber", "year": "2014", "unstructured": "Ciomber A, Smagur A, Mitrus I, Cichon T, Smolarczyk R, Sochanik A, Szala S, Jarosz M (2014) Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy. Arch Immunol Ther Exp 62:161\u2013168. doi: 10.1007/s00005-013-0259-5", "journal-title": "Arch Immunol Ther Exp"}, {"key": "2_CR21", "unstructured": "Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM (2012) Preclinical evaluation of oncolytic deltagamma(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer 2012: 628697. doi: 10.1155/2012/628697", "DOI": "10.1155/2012/628697", "doi-asserted-by": "publisher"}, {"key": "2_CR22", "first-page": "2531", "volume": "56", "author": "MP Colombo", "year": "1996", "unstructured": "Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, MelaniC Stoppacciaro A (1996) Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56:2531\u20132534", "journal-title": "Cancer Res"}, {"key": "2_CR23", "unstructured": "Lesinski GB, Badgwell B, Zimmerer J, Crespin, T, Hu Y, Abood G, Carson WE. III (2004) IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J Immunol 172(12): 7368\u20137376. doi: 10.4049/jimmunol.172.12.7368", "DOI": "10.4049/jimmunol.172.12.7368", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "2_CR24", "doi-asserted-by": "publisher", "first-page": "44", "DOI": "10.2174/1566523214666141127093654", "volume": "15", "author": "J Cutrera", "year": "2014", "unstructured": "Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S (2014) Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions. Curr Gene Ther 15(1):44\u201354. doi: 10.2174/1566523214666141127093654", "journal-title": "Curr Gene Ther"}, {"issue": "3", "key": "2_CR25", "doi-asserted-by": "publisher", "first-page": "664", "DOI": "10.1111/jcmm.12382", "volume": "19", "author": "J Cutrera", "year": "2015", "unstructured": "Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, Li S (2015) Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy. J Cell Mol Med 19(3):664\u2013675. doi: 10.1111/jcmm.12382", "journal-title": "J Cell Mol Med"}, {"key": "2_CR26", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1016/j.jconrel.2014.05.045", "volume": "187", "author": "S Denies", "year": "2014", "unstructured": "Denies S, Cicchelero L, Van Audenhove I, Sanders NN (2014) Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release 187:175\u2013182. doi: 10.1016/j.jconrel.2014.05.045", "journal-title": "J Control Release"}, {"key": "2_CR27", "unstructured": "Eckert F, Schmitt J, Zips D, Krueger MA, Pichler BJ, Gillies SD, Strittmatter W, Handgretinger R, Schilbach K (2016) Cancer Immunol Immunother (Epub ahead of print). doi: 10.1007/s00262-016-1863-0", "DOI": "10.1007/s00262-016-1863-0", "doi-asserted-by": "publisher"}, {"key": "2_CR01", "unstructured": "El-Shemi AG, Ashishi AM, Na Y, Li Y, Basalamah M, Al-Allaf FA, Oh E, Jung B-K, Yun C-O (2016) Combined therapy with oncolytic adenovirus encoding TRAIL and IL-12 genes markedly suppressedhuman hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model. J Exp Clin Cancer Res 35:74. doi: 10.1186/s13046-016-0353-8 \u00a0 \u00a0", "DOI": "10.1186/s13046-016-0353-8", "doi-asserted-by": "publisher"}, {"issue": "7", "key": "2_CR28", "doi-asserted-by": "publisher", "first-page": "1869", "DOI": "10.18632/oncotarget.1853", "volume": "5", "author": "J Fallon", "year": "2014", "unstructured": "Fallon J, Tighe R, Krafjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW (2014) The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 5(7):1869\u20131884. doi: 10.18632/oncotarget.1853", "journal-title": "Oncotarget"}, {"issue": "4", "key": "2_CR29", "doi-asserted-by": "publisher", "first-page": "256", "DOI": "10.1093/jnci/djs629", "volume": "105", "author": "SC Formenti", "year": "2013", "unstructured": "Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105(4):256\u2013265. doi: 10.1093/jnci/djs629", "journal-title": "J Natl Cancer Inst"}, {"key": "2_CR30", "doi-asserted-by": "publisher", "first-page": "1971", "DOI": "10.1002/ijc.27755", "volume": "132", "author": "MF Fransen", "year": "2013", "unstructured": "Fransen MF, Arnes R, Melief CJM (2013) Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. Int J Cancer 132:1971\u20131976. doi: 10.1002/ijc.27755", "journal-title": "Int J Cancer"}, {"issue": "10", "key": "2_CR31", "doi-asserted-by": "publisher", "first-page": "e0140744", "DOI": "10.1371/journal.pone.0140744", "volume": "10", "author": "DL Galvan", "year": "2015", "unstructured": "Galvan DL, O\u2019Neil RT, Foster AE, Huye L, Bear A, Rooney CM, Wilson MH (2015) Anti-tumor effects after adoptive transfer of IL-12 transposon-modified murine splenocytes in the OT-I-melanoma mouse model. PLoS ONE 10(10):e0140744. doi: 10.1371/journal.pone.0140744", "journal-title": "PLoS ONE"}, {"issue": "6", "key": "2_CR32", "doi-asserted-by": "publisher", "first-page": "2199", "DOI": "10.1021/acs.biomac.6b00433", "volume": "17", "author": "M Gao", "year": "2016", "unstructured": "Gao M, Zhu X, Wu L, Qiu L (2016) Cationic polyphosphazene vesicles for cancer immunotherapy by efficient in vivo cytokine IL-12 plasmid delivery. Biomacromolecules 17(6):2199\u20132209. doi: 10.1021/acs.biomac.6b00433", "journal-title": "Biomacromolecules"}, {"key": "2_CR33", "doi-asserted-by": "publisher", "first-page": "72", "DOI": "10.1667/RR13802.1", "volume": "183", "author": "SA Gerber", "year": "2015", "unstructured": "Gerber SA, Cummings RJ, Judge JL, Barlow ML, Nanduri J, Milano Johnson DE, Palis J, Pentland AP, Lord EM, Ryan JL (2015) Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure. Radiat Res 183:72\u201381. doi: 10.1667/RR13802.1", "journal-title": "Radiat Res"}, {"issue": "5", "key": "2_CR34", "doi-asserted-by": "publisher", "first-page": "641", "DOI": "10.1007/s00262-006-0225-8", "volume": "56", "author": "F Ghiringhelli", "year": "2007", "unstructured": "Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56(5):641\u2013648. doi: 10.1007/s00262-006-0225-8", "journal-title": "Cancer Immunol Immunother"}, {"key": "2_CR35", "doi-asserted-by": "publisher", "first-page": "537", "DOI": "10.3892/ijmm.3.5.537", "volume": "3", "author": "J Golab", "year": "1999", "unstructured": "Golab J, Zagozdzon R (1999) Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). Int J Mol Med 3:537\u2013544. doi: 10.3892/ijmm.3.5.537", "journal-title": "Int J Mol Med"}, {"issue": "4", "key": "2_CR36", "first-page": "613", "volume": "15", "author": "J Golab", "year": "2001", "unstructured": "Golab J, Zagozdzon R, Kaminski R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stok\u0142osa T, Giermasz A, Lasek W et al (2001) Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 15(4):613\u2013620", "journal-title": "Leukemia"}, {"key": "2_CR37", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1016/j.semradonc.2014.07.005", "volume": "25", "author": "EB Golden", "year": "2015", "unstructured": "Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death. Semin Radiat Oncol 25:11\u201317. doi: 10.1016/j.semradonc.2014.07.005", "journal-title": "Semin Radiat Oncol"}, {"key": "2_CR38", "doi-asserted-by": "publisher", "first-page": "1330", "DOI": "10.3892/etm.2014.1918", "volume": "8", "author": "J Han", "year": "2014", "unstructured": "Han J, Zhao J, Xu J, Wen Y (2014) Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice. Exp Ther Med 8:1330\u20131334. doi: 10.3892/etm.2014.1918", "journal-title": "Exp Ther Med"}, {"key": "2_CR39", "doi-asserted-by": "publisher", "first-page": "467", "DOI": "10.1002/ijc.28359", "volume": "134", "author": "T Hemmerle", "year": "2014", "unstructured": "Hemmerle T, Neri T (2014) The antibody-based targeted of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 134:467\u2013477. doi: 10.1002/ijc.28359", "journal-title": "Int J Cancer"}, {"key": "2_CR40", "doi-asserted-by": "publisher", "first-page": "34", "DOI": "10.1186/1476-4598-13-34", "volume": "13", "author": "J Hu", "year": "2014", "unstructured": "Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S (2014) CD8+ T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+ T cell accumulation in tumors. Mol Cancer 13:34. doi: 10.1186/1476-4598-13-34", "journal-title": "Mol Cancer"}, {"key": "2_CR41", "doi-asserted-by": "publisher", "first-page": "573", "DOI": "10.1007/s00262-011-1198-9", "volume": "61", "author": "C Huang", "year": "2012", "unstructured": "Huang C, Ramakrishnan R, Trkulja M, Ren X, Gabrilovich DI (2012) Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother 61:573\u2013579. doi: 10.1007/s00262-011-1198-9", "journal-title": "Cancer Immunol Immunother"}, {"key": "2_CR42", "doi-asserted-by": "publisher", "first-page": "39", "DOI": "10.1038/cdd.2013.84", "volume": "21", "author": "H Inoue", "year": "2014", "unstructured": "Inoue H, Tani K (2014) Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatment. Cell Death Differ 21:39\u201349. doi: 10.1038/cdd.2013.84", "journal-title": "Cell Death Differ"}, {"issue": "9", "key": "2_CR43", "doi-asserted-by": "publisher", "first-page": "e44482", "DOI": "10.1371/journal.pone.0044482", "volume": "7", "author": "T Jahn", "year": "2012", "unstructured": "Jahn T, Zuther M, Friedrichs B, Heuser C, Guhlke S, Abken H, Hombach AA (2012) An IL12-IL2-antibody fusion protein targeting Hodgkin\u2019s lymphoma cells potentiates activation of NK and T cells for anti-tumor attack. PLoS ONE 7(9):e44482. doi: 10.1371/journal.pone.0044482", "journal-title": "PLoS ONE"}, {"key": "2_CR44", "doi-asserted-by": "publisher", "first-page": "3401", "DOI": "10.4049/jimmunol.1000328", "volume": "186", "author": "AC Jaime-Ramirez", "year": "2011", "unstructured": "Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM et al (2011) IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-\u03b3 production. J Immunol 186:3401\u20133409. doi: 10.4049/jimmunol.1000328", "journal-title": "J Immunol"}, {"key": "2_CR45", "doi-asserted-by": "publisher", "first-page": "451", "DOI": "10.1007/s00005-015-0337-y", "volume": "63", "author": "M Jarosz-Biej", "year": "2015", "unstructured": "Jarosz-Biej M, Smolarczyk R, Cichon T, Kulach N, Czapla J, Matuszczak S, Szala S (2015) Combined tumor cell-based vaccination and interleukin-12 gene therapy polarizes the tumor microenvironmnt in mice. Arch Immunol Ther Exp 63:451\u2013464. doi: 10.1007/s00005-015-0337-y", "journal-title": "Arch Immunol Ther Exp"}, {"key": "2_CR46", "doi-asserted-by": "publisher", "first-page": "721", "DOI": "10.1002/ijc.29428", "volume": "137", "author": "K-Y Jeong", "year": "2015", "unstructured": "Jeong K-Y, Lee E-J, Kim SJ, Yang S-H, Sung YC, Seong J (2015) Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. Int J Cancer 137:721\u2013730. doi: 10.1002/ijc.29428", "journal-title": "Int J Cancer"}, {"key": "2_CR47", "doi-asserted-by": "publisher", "first-page": "136", "DOI": "10.1186/1476-4598-12-136", "volume": "12", "author": "U Kamensek", "year": "2013", "unstructured": "Kamensek U, Sersa G, Cemazar M (2013) Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model. Mol Cancer 12:136. doi: 10.1186/1476-4598-12-136", "journal-title": "Mol Cancer"}, {"key": "2_CR48", "doi-asserted-by": "publisher", "first-page": "2569", "DOI": "10.4049/jimmunol.167.5.2569", "volume": "167", "author": "C Karnbach", "year": "2001", "unstructured": "Karnbach C, Daws MR, Niemi EC, Nakamura MC (2001) Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population. J Immunol 167:2569\u20132576. doi: 10.4049/jimmunol.167.5.2569", "journal-title": "J Immunol"}, {"issue": "7", "key": "2_CR49", "doi-asserted-by": "publisher", "first-page": "1369", "DOI": "10.1038/mt.2013.58", "volume": "21", "author": "SP Kerkar", "year": "2013", "unstructured": "Kerkar SP, Leonardi AJ, Van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA et al (2013) Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21(7):1369\u20131377. doi: 10.1038/mt.2013.58", "journal-title": "Mol Ther"}, {"key": "2_CR50", "unstructured": "Kersten K, Salvagno C, De Visser KE (2015) Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy. Front Immunol 6: article 516. doi: 10.3389/fimmu.2015.00516", "DOI": "10.3389/fimmu.2015.00516", "doi-asserted-by": "publisher"}, {"issue": "11", "key": "2_CR51", "doi-asserted-by": "publisher", "first-page": "1714", "DOI": "10.4161/hv.22346", "volume": "8", "author": "H Kim", "year": "2012", "unstructured": "Kim H, Sin J-I (2012) Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism. Hum Vaccines Immunother 8(11):1714\u20131721. doi: 10.4161/hv.22346", "journal-title": "Hum Vaccines Immunother"}, {"key": "2_CR52", "doi-asserted-by": "publisher", "first-page": "646", "DOI": "10.1269/jrr.10185", "volume": "52", "author": "W Kim", "year": "2011", "unstructured": "Kim W, Seong J, Oh HJ, Koom WS, Choi K-J, Yun C-O (2011) A novel combination treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res 52:646\u2013654. doi: 10.1269/jrr.10185", "journal-title": "J Radiat Res"}, {"issue": "11", "key": "2_CR53", "doi-asserted-by": "publisher", "first-page": "e81919", "DOI": "10.1371/journal.pone.0081919", "volume": "8", "author": "H Kim", "year": "2013", "unstructured": "Kim H, Gao W, Ho M (2013a) Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice. PLoS ONE 8(11):e81919. doi: 10.1371/journal.pone.0081919", "journal-title": "PLoS ONE"}, {"issue": "4", "key": "2_CR54", "doi-asserted-by": "publisher", "first-page": "209", "DOI": "10.3727/096504014X13907540404798", "volume": "21", "author": "HS Kim", "year": "2013", "unstructured": "Kim HS, Jeong HY, Lee YK, Kim KS, Park YS (2013b) Synergistic antitumoral effect of IL-12 gene cotransfected with antiangiogenic genes for angiostatin, endostatin, and saxatilin. Oncol Res 21(4):209\u2013216. doi: 10.3727/096504014X13907540404798", "journal-title": "Oncol Res"}, {"issue": "7", "key": "2_CR55", "doi-asserted-by": "publisher", "first-page": "112", "DOI": "10.1002/jgm.2884", "volume": "18", "author": "JS Kim", "year": "2016", "unstructured": "Kim JS, Kim MW, Jeong HY, Kang SJ, Park SI, Lee YK, Kim HS, Kim KS, Park YS (2016) Sendai viroplexes for EGF receptor-directed delivery of IL12 and salmosin genes to cancer cells. J Gene Med 18(7):112\u2013123. doi: 10.1002/jgm.2884", "journal-title": "J Gene Med"}, {"issue": "3", "key": "2_CR56", "doi-asserted-by": "publisher", "first-page": "e994446", "DOI": "10.4161/2162402X.2014.994446", "volume": "4", "author": "M Koneru", "year": "2015", "unstructured": "Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ (2015) IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian cancer tumors in vivo. Oncoimmunology 4(3):e994446. doi: 10.4161/2162402X.2014.994446", "journal-title": "Oncoimmunology"}, {"key": "2_CR57", "unstructured": "Kramer MG, Masner M, Casales E, Moreno M, Smerdou C, Chabalgoity JA (2015) BMC Cancer 15: 620. doi: 10.1186/s12885-015-1618-x", "DOI": "10.1186/s12885-015-1618-x", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "2_CR58", "first-page": "345", "volume": "10", "author": "W Lasek", "year": "1999", "unstructured": "Lasek W, Golab J, Maslinski W, Switaj T, Balkowiec EZ, Stok\u0142osa T, Giermasz A, Malejczyk M, Jak\u00f3bisiak m (1999) Subtherapeutic doses of interleukin 15 augment the antitumor effect of interleukin 12 in a B16F10 melanoma model in mice. Eur Cytokine Netw 10(3):345\u2013356", "journal-title": "Eur Cytokine Netw"}, {"issue": "4", "key": "2_CR59", "doi-asserted-by": "publisher", "first-page": "363", "DOI": "10.1007/s00262-003-0449-9", "volume": "53", "author": "W Lasek", "year": "2004", "unstructured": "Lasek W, Basak G, Switaj T, Jakubowska AB, Wysocki PJ, Mackiewicz A, Drela N, Jalili A, Kaminski R, Kozar K et al (2004) Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother 53(4):363\u2013372. doi: 10.1007/s00262-003-0449-9", "journal-title": "Cancer Immunol Immunother"}, {"key": "2_CR60", "doi-asserted-by": "publisher", "first-page": "419", "DOI": "10.1007/s00262-014-1523-1", "volume": "63", "author": "W Lasek", "year": "2014", "unstructured": "Lasek W, Zago\u017cd\u017con R, Jakobisiak M (2014) Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 63:419\u2013435. doi: 10.1007/s00262-014-1523-1", "journal-title": "Cancer Immunol Immunother"}, {"key": "2_CR61", "doi-asserted-by": "publisher", "first-page": "6765", "DOI": "10.4049/jimmunol.167.12.6765", "volume": "167", "author": "HN Le", "year": "2001", "unstructured": "Le HN, Lee NC, Tsung K, Norton JA (2001) Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J Immunol 167:6765\u20136772. doi: 10.4049/jimmunol.167.12.6765", "journal-title": "J Immunol"}, {"issue": "1", "key": "2_CR62", "doi-asserted-by": "publisher", "first-page": "e0146463", "DOI": "10.1371/journal.pone.0146463", "volume": "11", "author": "E-J Lee", "year": "2016", "unstructured": "Lee E-J, Lee SJ, Kim J-H, Kim K-J, Yang S-H, Jeong K-Y, Seong J (2016) Radiation inhibits interleukin-12 production via inhibition of c-Rel through the interleukin-6/ signal transducer and activator of transcription 3 signaling pathway in dendritc cells. PLoS ONE 11(1):e0146463. doi: 10.1371/journal.pone.0146463", "journal-title": "PLoS ONE"}, {"key": "2_CR63", "doi-asserted-by": "publisher", "first-page": "576", "DOI": "10.3892/o1.2013.1743", "volume": "7", "author": "Y Li", "year": "2014", "unstructured": "Li Y, Li X, Liu H, Zhuang S, Yang J, Zhang F (2014) Intranasal immunization with recombinant Lactococci carying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice. Oncol Lett 7:576\u2013582. doi: 10.3892/o1.2013.1743", "journal-title": "Oncol Lett"}, {"key": "2_CR64", "doi-asserted-by": "publisher", "first-page": "542", "DOI": "10.1038/cgt.2015.53", "volume": "22", "author": "C Lorenzo", "year": "2015", "unstructured": "Lorenzo C, Perez-Chacon G, Garaulet G, Mallorquin Z, Zapata JM, Rodriguez A (2015) Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines. Cancer Gene Ther 22:542\u2013551. doi: 10.1038/cgt.2015.53", "journal-title": "Cancer Gene Ther"}, {"key": "2_CR65", "doi-asserted-by": "publisher", "first-page": "431", "DOI": "10.1016/j.surg.2012.05.035", "volume": "152", "author": "E Luedke", "year": "2012", "unstructured": "Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd (2012) Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152:431\u2013440. doi: 10.1016/j.surg.2012.05.035", "journal-title": "Surgery"}, {"key": "2_CR02", "unstructured": "Luo M, Liang X, Luo ST, Wei XW, Liu T, Ren J, Ma CC, Yang YH, Wang BL, Liu L (2015) Folate-modified lipoplexes delivering the interleukin-12 gene for targeting colon cancer immunogene therapy. J Biomed Nanotechnol 11(11):2011\u20132023. doi: dx.doi.org/10.1166/jbn.2015.2136", "DOI": "10.1166/jbn.2015.2136", "doi-asserted-by": "crossref"}, {"issue": "7", "key": "2_CR66", "doi-asserted-by": "publisher", "first-page": "2862", "DOI": "10.1182/blood-2004-06-2410", "volume": "105", "author": "MEC Lutsiak", "year": "2005", "unstructured": "Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H (2005) Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7):2862\u20132868. doi: 10.1182/blood-2004-06-2410", "journal-title": "Blood"}, {"issue": "7", "key": "2_CR67", "doi-asserted-by": "publisher", "first-page": "1038", "DOI": "10.4161/onci.20684", "volume": "1", "author": "M Malvicini", "year": "2012", "unstructured": "Malvicini M, Alaniz L, Bayo J, Garcia M, Piccioni F, Fiore E, Atorrasagasti C, Aquino JB, Matar P, Mazzolini G (2012) Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimunology 1(7):1038\u20131047. doi: 10.4161/onci.20684", "journal-title": "Oncoimunology"}, {"key": "2_CR68", "first-page": "3293", "volume": "34", "author": "DK Martin", "year": "2014", "unstructured": "Martin DK, Uckermann O, Bertram A, Liebner C, Hendruschk S, Hakan Sitoci-Ficici K, Schackert G, Lord EM, Temme A, Kirsch M (2014) Differential growth inhibition of cerebral metastases by anti-angiogenic compounds. Anticancer Res 34:3293\u20133302", "journal-title": "Anticancer Res"}, {"key": "2_CR69", "doi-asserted-by": "publisher", "first-page": "807", "DOI": "10.4049/jimmunol.1001483", "volume": "186", "author": "J Medina-Echeverz", "year": "2011", "unstructured": "Medina-Echeverz J, Fioravanti J, Zabala M, Adaiz N, Prieto J, Berraondo P (2011) Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 186:807\u2013815. doi: 10.4049/jimmunol.1001483", "journal-title": "J Immunol"}, {"issue": "3", "key": "2_CR70", "doi-asserted-by": "publisher", "first-page": "497", "DOI": "10.1158/0008-5472.CAN-13-3356", "volume": "75", "author": "I Melero", "year": "2015", "unstructured": "Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez JR, Mancheno U, Casales E, Riezu-Boj JI, Ruiz-Guillen M, Ochoa MC et al (2015) Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12. Cancer Res 75(3):497\u2013507. doi: 10.1158/0008-5472.CAN-13-3356", "journal-title": "Cancer Res"}, {"key": "2_CR71", "doi-asserted-by": "publisher", "first-page": "3484", "DOI": "10.1021/mp5002697", "volume": "11", "author": "IM Meraz", "year": "2014", "unstructured": "Meraz IM, Savage DJ, Segura-Ibarra V, Li J, Rhudy J, Gu J, Serda RE (2014) Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer. Mol Pharm 11:3484\u20133492. doi: 10.1021/mp5002697", "journal-title": "Mol Pharm"}, {"key": "2_CR72", "doi-asserted-by": "publisher", "first-page": "576", "DOI": "10.1038/cgt.2013.54", "volume": "20", "author": "A Miguel", "year": "2013", "unstructured": "Miguel A, Herrero MJ, Sendra L, Botella R, Algas R, Sanchez M, Alino SF (2013) Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+ IL-12 genetically modified tumor cell vaccines. Cancer Gene Ther 20:576\u2013581. doi: 10.1038/cgt.2013.54", "journal-title": "Cancer Gene Ther"}, {"key": "2_CR73", "doi-asserted-by": "publisher", "first-page": "2471", "DOI": "10.1002/ijc.27801", "volume": "132", "author": "MS Nars", "year": "2013", "unstructured": "Nars MS, Kaneno R (2013) Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 132:2471\u20132478. doi: 10.1002/ijc.27801", "journal-title": "Int J Cancer"}, {"issue": "6", "key": "2_CR74", "doi-asserted-by": "publisher", "first-page": "e0129954", "DOI": "10.1371/journal.pone.0129954", "volume": "10", "author": "M Paoloni", "year": "2015", "unstructured": "Paoloni M, Mazcko C, Selting K, Lana S, Barber L, Phillips J, Skorupski K, Vail D, Wilson H, Biller B et al (2015) Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma. PLoS ONE 10(6):e0129954. doi: 10.1371/journal.pone.0129954", "journal-title": "PLoS ONE"}, {"key": "2_CR75", "doi-asserted-by": "publisher", "first-page": "89", "DOI": "10.1038/labinvest.2015.126", "volume": "96", "author": "RS Parhar", "year": "2016", "unstructured": "Parhar RS, Zou M, Al-Mohanna FA, Baitei EY, Assiri AM, Meyer BF, Shi Y (2016) IL-12 immunotherapy of BrafV600E-induced papillary thyroid cancer in a mouse model. Lab Invest 96:89\u201397. doi: 10.1038/labinvest.2015.126", "journal-title": "Lab Invest"}, {"key": "2_CR76", "doi-asserted-by": "publisher", "first-page": "983", "DOI": "10.1172/JCI15950", "volume": "110", "author": "R Parihar", "year": "2002", "unstructured": "Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110:983\u2013992. doi: 10.1172/JCI15950", "journal-title": "J Clin Invest"}, {"issue": "1", "key": "2_CR77", "doi-asserted-by": "publisher", "first-page": "17", "DOI": "10.1038/cgt.2012.75", "volume": "20", "author": "BJ Passer", "year": "2013", "unstructured": "Passer BJ, Cheema T, Wu S, Wu C-I, Rabkin SD, Martuza RL (2013) Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther 20(1):17\u201324. doi: 10.1038/cgt.2012.75", "journal-title": "Cancer Gene Ther"}, {"issue": "18", "key": "2_CR78", "doi-asserted-by": "publisher", "first-page": "4133", "DOI": "10.1182/blood-2011-12-400044", "volume": "119", "author": "HJ Pegram", "year": "2012", "unstructured": "Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18):4133\u20134141. doi: 10.1182/blood-2011-12-400044", "journal-title": "Blood"}, {"issue": "2", "key": "2_CR79", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.1038/leu.2014.215", "volume": "29", "author": "HJ Pegram", "year": "2015", "unstructured": "Pegram HJ, Purdon TJ, Van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ (2015) IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 29(2):415\u2013422. doi: 10.1038/leu.2014.215", "journal-title": "Leukemia"}, {"key": "2_CR80", "doi-asserted-by": "publisher", "first-page": "133", "DOI": "10.1007/s00262-002-0356-5", "volume": "52", "author": "JEA Portielje", "year": "2003", "unstructured": "Portielje JEA, Gratama JW, van Ojik HH, Stoter G, Kruit WHJ (2003) IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52:133\u2013144. doi: 10.1007/s00262-002-0356-5", "journal-title": "Cancer Immunol Immunother"}, {"key": "2_CR81", "doi-asserted-by": "publisher", "first-page": "1664", "DOI": "10.1038/mt.2012.56", "volume": "20", "author": "JI Quetglas", "year": "2012", "unstructured": "Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I (2012) Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther 20:1664\u20131675. doi: 10.1038/mt.2012.56", "journal-title": "Mol Ther"}, {"key": "2_CR82", "doi-asserted-by": "publisher", "first-page": "2994", "DOI": "10.4049/jimmunol.1201791", "volume": "190", "author": "JI Quetglas", "year": "2013", "unstructured": "Quetglas JI, Rodriguez-Madoz JR, Bezunartea J, Ruiz-Guillen M, Casales E, Medina-Echeverz J, Prieto J, Barraondo P, Hervas-Stubbs S, Smerdou C (2013) Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses. J Immunol 190:2994\u20133004. doi: 10.4049/jimmunol.1201791", "journal-title": "J Immunol"}, {"issue": "2", "key": "2_CR83", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.2174/1568009614666140113115651", "volume": "14", "author": "J Ren", "year": "2014", "unstructured": "Ren J, Yu C, Wu S, Peng F, Jiang Q, Zhang X, Zhong G, Shi H, Chen X, Su X et al (2014) Cationic liposome mediated delivery of FUS1 and hIL-12 coexpression plasmid demonstrates enhanced activity against human lung cancer. Curr Cancer Drug Targets 14(2):167\u2013180. doi: 10.2174/1568009614666140113115651", "journal-title": "Curr Cancer Drug Targets"}, {"key": "2_CR84", "unstructured": "Ren G, Tian G, Liu Y, He J, Gao X, Yu Y, Liu X, Zhang X, Sun T, Liu S et al (2015) Recombinant Newcastle disease virus encoding IL-12 and/or IL-2 as potential candidate for hepatoma carcinoma therapy. Technol Cancer Res Treat 1533034615601521. doi: 10.1177/1533034615601521", "DOI": "10.1177/1533034615601521", "doi-asserted-by": "publisher"}, {"issue": "9", "key": "2_CR85", "doi-asserted-by": "publisher", "first-page": "427", "DOI": "10.1097/CJI.0000000000000054", "volume": "37", "author": "J Rossowska", "year": "2014", "unstructured": "Rossowska J, Pajtasz-Piasecka E, Anger N, Wojas-Turek J, Kicieli\u0144ska J, Piasecki E, Du\u015b D (2014) Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSC number. J Immunother 37(9):427\u2013439. doi: 10.1097/CJI.0000000000000054", "journal-title": "J Immunother"}, {"issue": "7", "key": "2_CR86", "doi-asserted-by": "publisher", "first-page": "1998", "DOI": "10.1158/1078-0432.CCR-10-2490", "volume": "17", "author": "SM Rudman", "year": "2011", "unstructured": "Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF (2011) A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res 17(7):1998\u20132005. doi: 10.1158/1078-0432.CCR-10-2490", "journal-title": "Clin Cancer Res"}, {"key": "2_CR87", "doi-asserted-by": "publisher", "first-page": "325", "DOI": "10.1007/s10549-009-0570-3", "volume": "122", "author": "MS Sabel", "year": "2010", "unstructured": "Sabel MS, Su G, Griffith KA, Chang AE (2010) Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-a in a model of metastatic breast cancer. Breast Cancer Res Treat 122:325\u2013336. doi: 10.1007/s10549-009-0570-3", "journal-title": "Breast Cancer Res Treat"}, {"issue": "1", "key": "2_CR88", "doi-asserted-by": "publisher", "first-page": "98", "DOI": "10.1002/ijc.27990", "volume": "133", "author": "I Schevchenko", "year": "2013", "unstructured": "Schevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin AV (2013) Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic panc02 model of pancreatic cancer. Int J Cancer 133(1):98\u2013107. doi: 10.1002/ijc.27990", "journal-title": "Int J Cancer"}, {"issue": "7", "key": "2_CR89", "doi-asserted-by": "publisher", "first-page": "e1014760", "DOI": "10.1080/2162402X.2015.1014760", "volume": "4", "author": "K Schilbach", "year": "2015", "unstructured": "Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Muller F, Sonntag K, Wieder T et al (2015) Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncoimmunology 4(7):e1014760. doi: 10.1080/2162402X.2015.1014760", "journal-title": "Oncoimmunology"}, {"issue": "4", "key": "2_CR90", "doi-asserted-by": "publisher", "first-page": "302", "DOI": "10.2478/v10019-012-0044-9", "volume": "46", "author": "A Sedlar", "year": "2012", "unstructured": "Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, Blagus T, Cemzar M, Sersa G (2012) Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sacoma and carcinoma with different immunogenicity. Radiol Oncol 46(4):302\u2013311. doi: 10.2478/v10019-012-0044-9", "journal-title": "Radiol Oncol"}, {"key": "2_CR91", "doi-asserted-by": "publisher", "first-page": "38", "DOI": "10.1186/1471-2407-13-38", "volume": "13", "author": "A Sedlar", "year": "2013", "unstructured": "Sedlar A, Kranjc S, Dolinsek T, Cemazar M, Coer A, Sersa G (2013) Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma. BMC Cancer 13:38. doi: 10.1186/1471-2407-13-38", "journal-title": "BMC Cancer"}, {"issue": "4", "key": "2_CR92", "doi-asserted-by": "publisher", "first-page": "769", "DOI": "10.3892/ijo.15.4.769", "volume": "15", "author": "S Seetharam", "year": "1999", "unstructured": "Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR (1999) Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol 15(4):769\u2013773. doi: 10.3892/ijo.15.4.769", "journal-title": "Int J Oncol"}, {"key": "2_CR93", "doi-asserted-by": "publisher", "first-page": "488", "DOI": "10.1038/gt.2010.170", "volume": "18", "author": "SH Seo", "year": "2011", "unstructured": "Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun S-S, Sung YC (2011) The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 18:488\u20134905. doi: 10.1038/gt.2010.170", "journal-title": "Gene Ther"}, {"key": "2_CR94", "doi-asserted-by": "publisher", "first-page": "1315", "DOI": "10.1007/s00262-015-1724-2", "volume": "64", "author": "G Sersa", "year": "2015", "unstructured": "Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, Miklavcic D (2015) Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 64:1315\u20131327. doi: 10.1007/s00262-015-1724-2", "journal-title": "Cancer Immunol Immunother"}, {"key": "2_CR95", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1016/j.bbrc.2007.12.112", "volume": "367", "author": "T Shimizu", "year": "2008", "unstructured": "Shimizu T, Kishida T, Hasegawa U, Ueda Y, Imanishi J, Yamagishi H, Akiyoshi K, Otsuji E, Mazda O (2008) Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy. Biochem Biophys Res Commun 367:330\u2013335. doi: 10.1016/j.bbrc.2007.12.112", "journal-title": "Biochem Biophys Res Commun"}, {"issue": "1", "key": "2_CR96", "doi-asserted-by": "publisher", "first-page": "137", "DOI": "10.4049/jimmunol.0900734", "volume": "183", "author": "GV Shurin", "year": "2009", "unstructured": "Shurin GV, Tourkova IL, Kaneno R, Shurin MR (2009) Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183(1):137\u2013144. doi: 10.4049/jimmunol.0900734", "journal-title": "J Immunol"}, {"issue": "1", "key": "2_CR97", "doi-asserted-by": "publisher", "first-page": "380", "DOI": "10.1158/1535-7163.MCT-06-0342", "volume": "6", "author": "F Siddiqui", "year": "2007", "unstructured": "Siddiqui F, Li C-Y, LaRue SM, Poulson JM, Avery PR, Pruitt AF, Zhang X, Ullrich RL, Thrall DE, Dewhirst MW et al (2007) A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneous arising feline soft tissue sarcomas. Mol Cancer Ther 6(1):380\u2013389. doi: 10.1158/1535-7163.MCT-06-0342", "journal-title": "Mol Cancer Ther"}, {"key": "2_CR98", "doi-asserted-by": "publisher", "first-page": "689", "DOI": "10.1007/s00262-015-1672-x", "volume": "64", "author": "SG Smith", "year": "2015", "unstructured": "Smith SG, Koppolu BP, Ravindranathan S, Kurtz SL, YangL Katz MD, Zaharoff DA (2015) Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer. Cancer Immunol Immunother 64:689\u2013696. doi: 10.1007/s00262-015-1672-x", "journal-title": "Cancer Immunol Immunother"}, {"key": "2_CR99", "doi-asserted-by": "publisher", "first-page": "4165", "DOI": "10.1158/1078-0432.CCR-04-0022", "volume": "10", "author": "T Switaj", "year": "2004", "unstructured": "Switaj T, Jalili A, Jakubowska AB, Drela N, Stoksik M, Nowis D, Basak G, Golab J, Wysocki PJ, Mackiewicz A et al (2004) CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin Cancer Res 10:4165\u20134175. doi: 10.1158/1078-0432.CCR-04-0022", "journal-title": "Clin Cancer Res"}, {"key": "2_CR100", "doi-asserted-by": "publisher", "first-page": "904", "DOI": "10.1016/j.jss.2013.06.045", "volume": "185", "author": "C Tan", "year": "2013", "unstructured": "Tan C, Dannull J, Nair S, Ding E, Tyler DS, Pruitt SK, Lee WT (2013) Local secretion of IL-12 augments the therapeutic impact od dendritic cell-tumor cell fusion vaccination. J Surg Res 185:904\u2013911. doi: 10.1016/j.jss.2013.06.045", "journal-title": "J Surg Res"}, {"issue": "9", "key": "2_CR101", "first-page": "1661", "volume": "3", "author": "BA Teicher", "year": "1997", "unstructured": "Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG (1997) Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res 3(9):1661\u20131667", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "2_CR102", "doi-asserted-by": "publisher", "first-page": "38", "DOI": "10.1038/cgt.2013.81", "volume": "21", "author": "B Thaci", "year": "2014", "unstructured": "Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Buffinger B, Tobias AL, Han Y, Zhang L, Moon K-S et al (2014) Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther 21(1):38\u201344. doi: 10.1038/cgt.2013.81", "journal-title": "Cancer Gene Ther"}, {"issue": "12", "key": "2_CR103", "doi-asserted-by": "publisher", "first-page": "e968001", "DOI": "10.4161/21624011.2014.968001", "volume": "3", "author": "JLN Vo", "year": "2014", "unstructured": "Vo JLN, Yang L, Kurtz SL, Smith SG, Koppolu BP, Ravindranathan S, Zaharoff DA (2014) Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis. Oncoimmunology 3(12):e968001. doi: 10.4161/21624011.2014.968001", "journal-title": "Oncoimmunology"}, {"key": "2_CR104", "doi-asserted-by": "publisher", "first-page": "447", "DOI": "10.1111/liv.12284", "volume": "34", "author": "A Vogt", "year": "2014", "unstructured": "Vogt A, Sievers E, Lukacs-Kornek V, Decker G, Raskopf E, Meumann N, Buning H, Sauerbruch T, Strassburg CP, Schmidt-Wolf IGH et al (2014) Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int 34:447\u2013461. doi: 10.1111/liv.12284", "journal-title": "Liver Int"}, {"issue": "13", "key": "2_CR105", "doi-asserted-by": "publisher", "first-page": "2803", "DOI": "10.1084/jem.20130678", "volume": "210", "author": "J Vom Berg", "year": "2013", "unstructured": "Vom Berg J, Vhrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B (2013) Intratumoral IL-12 combined with CTLA-4 blockade slicits T cell-mediated glioma rejection. J Exp Med 210(13):2803\u20132811. doi: 10.1084/jem.20130678", "journal-title": "J Exp Med"}, {"issue": "8", "key": "2_CR106", "doi-asserted-by": "publisher", "first-page": "1234", "DOI": "10.1038/nm.2883", "volume": "18", "author": "S Walter", "year": "2012", "unstructured": "Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich P-Y, Mendrzyk T et al (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18(8):1234\u20131261. doi: 10.1038/nm.2883", "journal-title": "Nat Med"}, {"key": "2_CR107", "doi-asserted-by": "publisher", "first-page": "282", "DOI": "10.1097/CAD.0000000000000058", "volume": "25", "author": "X Wang", "year": "2014", "unstructured": "Wang X, Feng X, Wang J, Shao N, Ji C, Ma D, Henter J-I, Fadeel B, Zheng C (2014) Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells. Anticancer Drugs 25:282\u2013288. doi: 10.1097/CAD.0000000000000058", "journal-title": "Anticancer Drugs"}, {"key": "2_CR03", "unstructured": "Wang A, Zhou X, Zhao J, Liu T, Xu J (2015) Therapeutic effects of bone marrow mesenchymal stem cells expressing interleukin-12 in mice bearing malignant ascites tumor. Int J Clin Exp Med 8(9):15840\u201315845"}, {"key": "2_CR108", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1007/s11010-016-2687-0", "volume": "415", "author": "Q Wang", "year": "2016", "unstructured": "Wang Q, Cheng F, T-t Ma, Xiong H-Y, Li Z-W, Xie C-L, Liu C-Y, Tu Z-G (2016) Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3. Mol Cell Biochem 415:157\u2013168. doi: 10.1007/s11010-016-2687-0", "journal-title": "Mol Cell Biochem"}, {"key": "2_CR109", "doi-asserted-by": "publisher", "first-page": "5", "DOI": "10.1186/1756-9966-32-5", "volume": "32", "author": "F Wei", "year": "2013", "unstructured": "Wei F, Wang H, Zhang J, Chen X, Li C, Huang Q (2013) Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. J Exp Clin Cancer Res 32:5. doi: 10.1186/1756-9966-32-5", "journal-title": "J Exp Clin Cancer Res"}, {"issue": "11", "key": "2_CR110", "doi-asserted-by": "publisher", "first-page": "1705", "DOI": "10.1517/14712598.7.11.1705", "volume": "7", "author": "JM Weiss", "year": "2007", "unstructured": "Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7(11):1705\u20131721. doi: 10.1517/14712598.7.11.1705", "journal-title": "Expert Opin Biol Ther"}, {"issue": "7", "key": "2_CR111", "doi-asserted-by": "publisher", "first-page": "1643", "DOI": "10.1002/ijc.28163", "volume": "133", "author": "E Wennerberg", "year": "2013", "unstructured": "Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D\u2019Arcy P, Zhivotovsky B, Childs R, Lundqvist A (2013) Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer 133(7):1643\u20131652. doi: 10.1002/ijc.28163", "journal-title": "Int J Cancer"}, {"issue": "6", "key": "2_CR112", "doi-asserted-by": "publisher", "first-page": "684", "DOI": "10.1177/0284185113480072", "volume": "54", "author": "X Xia", "year": "2013", "unstructured": "Xia X, Li X, Feng G, Zheng C, Liang H, Zhou G (2013) Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model. Acta Radiol 54(6):684\u2013689. doi: 10.1177/0284185113480072", "journal-title": "Acta Radiol"}, {"issue": "12", "key": "2_CR113", "doi-asserted-by": "publisher", "first-page": "1079", "DOI": "10.1001/archotol.131.12.1079", "volume": "131", "author": "J Xian", "year": "2005", "unstructured": "Xian J, Yang H, Lin Y, Liu S (2005) Combination nnonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 131(12):1079\u20131085. doi: 10.1001/archotol.131.12.1079", "journal-title": "Arch Otolaryngol Head Neck Surg"}, {"issue": "5", "key": "2_CR114", "first-page": "1900", "volume": "96", "author": "L Yao", "year": "2000", "unstructured": "Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96(5):1900\u20131905", "journal-title": "Blood"}, {"issue": "2", "key": "2_CR115", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1042/BST20150291", "volume": "44", "author": "OO Yeku", "year": "2016", "unstructured": "Yeku OO, Brentjens RJ (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumor efficacy. Biochem Soc Trans 44(2):412\u2013418. doi: 10.1042/BST20150291", "journal-title": "Biochem Soc Trans"}, {"key": "2_CR116", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1016/j.bbrc.2015.08.003", "volume": "465", "author": "X Yin", "year": "2015", "unstructured": "Yin X, Wang W, Zhu X, Wang Y, Wu S, Wang Z, Wang L, Du Z, Gao J, Yu J (2015) Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis. Biochem Biophys Res Commun 465:239\u2013244. doi: 10.1016/j.bbrc.2015.08.003", "journal-title": "Biochem Biophys Res Commun"}, {"key": "2_CR117", "doi-asserted-by": "publisher", "first-page": "720", "DOI": "10.1002/(SICI)1097-0215(19980831)77:5<655::AID-IJC1>3.0.CO;2-U", "volume": "77", "author": "R Zagozdzon", "year": "1998", "unstructured": "Zagozdzon R, Golab J, Stoklosa T, Giermasz A, Nowicka D, Feleszko W, Lasek W, Jakobisiak M (1998) Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 77:720\u2013727. doi: 10.1002/(SICI)1097-0215(19980831)77:5<655:AID-IJC1>3.0.CO;2-U", "journal-title": "Int J Cancer"}, {"key": "2_CR118", "doi-asserted-by": "publisher", "first-page": "645", "DOI": "10.3892/ijmm.4.6.645", "volume": "4", "author": "R Zagozdzon", "year": "1999", "unstructured": "Zagozdzon R, Golab J, Mucha K, Foroncewicz B, Jakobisiak M (1999) Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo. Int J Mol Med 4:645\u2013648. doi: 10.3892/ijmm.4.6.645", "journal-title": "Int J Mol Med"}, {"key": "2_CR119", "doi-asserted-by": "publisher", "first-page": "1208", "DOI": "10.3892/or.2012.2193", "volume": "29", "author": "L Zapa\u0142a", "year": "2013", "unstructured": "Zapa\u0142a L, Wolny R, Wachowska M, Jak\u00f3bisiak M, Lasek W (2013) Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model. Oncol Rep 29:1208\u20131214. doi: 10.3892/or.2012.2193", "journal-title": "Oncol Rep"}, {"issue": "4", "key": "2_CR120", "doi-asserted-by": "publisher", "first-page": "751", "DOI": "10.1038/mt.2010.313", "volume": "19", "author": "L Zhang", "year": "2011", "unstructured": "Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19(4):751\u2013759. doi: 10.1038/mt.2010.313", "journal-title": "Mol Ther"}, {"issue": "6", "key": "2_CR121", "doi-asserted-by": "publisher", "first-page": "1061", "DOI": "10.1007/s00262-013-1417-7", "volume": "62", "author": "L Zhang", "year": "2013", "unstructured": "Zhang L, Feng D, Yu LX, Tsung K, Norton JA (2013a) Preexisting antitumor immunity augments the antitumor effects of chemotherapy. Cancer Immunol Immunother 62(6):1061\u20131071. doi: 10.1007/s00262-013-1417-7", "journal-title": "Cancer Immunol Immunother"}, {"issue": "6", "key": "2_CR122", "doi-asserted-by": "publisher", "first-page": "591", "DOI": "10.1593/neo.13158", "volume": "15", "author": "W Zhang", "year": "2013", "unstructured": "Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL (2013b) Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma model. Neoplasia 15(6):591\u2013599. doi: 10.1593/neo.13158", "journal-title": "Neoplasia"}, {"key": "2_CR123", "doi-asserted-by": "publisher", "first-page": "580", "DOI": "10.1111/lam.12322", "volume": "59", "author": "Y-L Zhang", "year": "2014", "unstructured": "Zhang Y-L, Lu R, Chang Z-S, Wang Q-B, Ding S-Y, Zhao W (2014) Clostridium sporogenes delivers interleukin-12 to hypoxic tumors, producing antitumor activity without significant toxicity. Lett Appl Microbiol 59:580\u2013586. doi: 10.1111/lam.12322", "journal-title": "Lett Appl Microbiol"}, {"issue": "4", "key": "2_CR124", "doi-asserted-by": "publisher", "first-page": "137", "DOI": "10.1097/CJI.0000000000000074", "volume": "38", "author": "L Zhang", "year": "2015", "unstructured": "Zhang L, Feng D, Hu Y, Tsung K, Norton JA (2015a) IL-12 augments antitumor responses to cycled chemotherapy. J Immunother 38(4):137\u2013144. doi: 10.1097/CJI.0000000000000074", "journal-title": "J Immunother"}, {"issue": "10", "key": "2_CR125", "doi-asserted-by": "publisher", "first-page": "2278", "DOI": "10.1158/1078-0432.CCR-14-2085", "volume": "21", "author": "L Zhang", "year": "2015", "unstructured": "Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ et al (2015b) Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 21(10):2278\u20132288. doi: 10.1158/1078-0432.CCR-14-2085", "journal-title": "Clin Cancer Res"}, {"key": "2_CR126", "doi-asserted-by": "publisher", "first-page": "2348", "DOI": "10.4049/jimmunol.0902371", "volume": "184", "author": "S Zhu", "year": "2010", "unstructured": "Zhu S, Lee DA, Li S (2010) IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184:2348\u20132354. doi: 10.4049/jimmunol.0902371", "journal-title": "J Immunol"}, {"key": "2_CR127", "doi-asserted-by": "publisher", "first-page": "661", "DOI": "10.3892/ijo.2012.1466", "volume": "41", "author": "L Zhu", "year": "2012", "unstructured": "Zhu L, Zhao Z, Wei Y, Marcotte W Jr, Wagner TE, Yu X (2012) An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation. Int J Oncol 41:661\u2013669. doi: 10.3892/ijo.2012.1466", "journal-title": "Int J Oncol"}], "container-title": ["Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology", "SpringerBriefs in Immunology"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-46906-5_2", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T23:32:34Z", "timestamp": 1498347154000}, "score": 26.273235, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319469058", "9783319469065"], "references-count": 130, "URL": "http://dx.doi.org/10.1007/978-3-319-46906-5_2", "relation": {"cites": []}, "ISSN": ["2194-2773", "2194-2781"], "issn-type": [{"value": "2194-2773", "type": "print"}, {"value": "2194-2781", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 4, 17]], "date-time": "2018-04-17T14:19:43Z", "timestamp": 1523974783488}, "publisher-location": "Cham", "reference-count": 120, "publisher": "Springer International Publishing", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-46906-5_1", "type": "book-chapter", "created": {"date-parts": [[2016, 9, 23]], "date-time": "2016-09-23T09:42:15Z", "timestamp": 1474623735000}, "page": "1-19", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Biology of IL-12"], "prefix": "10.1007", "author": [{"given": "Radoslaw", "family": "Zagozdzon", "sequence": "first", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 9, 24]]}, "reference": [{"issue": "1", "key": "1_CR1", "doi-asserted-by": "publisher", "first-page": "53", "DOI": "10.1016/j.cyto.2015.07.026", "volume": "76", "author": "K Abdi", "year": "2015", "unstructured": "Abdi K, Singh NJ (2015) Making many from few: IL-12p40 as a model for the combinatorial assembly of heterodimeric cytokines. Cytokine 76(1):53\u201357. doi: 10.1016/j.cyto.2015.07.026", "journal-title": "Cytokine"}, {"issue": "7", "key": "1_CR2", "doi-asserted-by": "publisher", "first-page": "e6119", "DOI": "10.1371/journal.pone.0006119", "volume": "4", "author": "I Airoldi", "year": "2009", "unstructured": "Airoldi I, Di Carlo E, Cocco C, Caci E, Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G et al (2009) IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS ONE 4(7):e6119. doi: 10.1371/journal.pone.0006119", "journal-title": "PLoS ONE"}, {"issue": "9", "key": "1_CR3", "doi-asserted-by": "publisher", "first-page": "584", "DOI": "10.1038/nrc3349", "volume": "12", "author": "GK Alderton", "year": "2012", "unstructured": "Alderton GK (2012) Immunology: TIM3 suppresses antitumour DCs. Nat Rev Cancer 12(9):584. doi: 10.1038/nrc3349", "journal-title": "Nat Rev Cancer"}, {"key": "1_CR4", "doi-asserted-by": "crossref", "first-page": "158", "DOI": "10.1111/j.1749-6632.1996.tb52664.x", "volume": "795", "author": "AL Angiolillo", "year": "1996", "unstructured": "Angiolillo AL, Sgadari C, Tosato G (1996) A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci 795:158\u2013167", "journal-title": "Ann N Y Acad Sci"}, {"issue": "27", "key": "1_CR5", "doi-asserted-by": "crossref", "first-page": "17109", "DOI": "10.1074/jbc.273.27.17109", "volume": "273", "author": "HA Baden", "year": "1998", "unstructured": "Baden HA, Sarma SP, Kapust RB, Byrd RA, Waugh DS (1998) The amino-terminal domain of human STAT4. Overproduction, purification, and biophysical characterization. J Biol Chem 273(27):17109\u201317114", "journal-title": "J Biol Chem"}, {"key": "1_CR6", "doi-asserted-by": "publisher", "first-page": "26", "DOI": "10.1186/1479-5876-6-26", "volume": "6", "author": "LA Basile", "year": "2008", "unstructured": "Basile LA, Gallaher TK, Shibata D, Miller JD, Douer D (2008) Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med 6:26. doi: 10.1186/1479-5876-6-26", "journal-title": "J Transl Med"}, {"issue": "2", "key": "1_CR7", "first-page": "271", "volume": "71", "author": "KR Bastos", "year": "2002", "unstructured": "Bastos KR, Alvarez JM, Marinho CR, Rizzo LV, Lima MR (2002) Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J Leukoc Biol 71(2):271\u2013278", "journal-title": "J Leukoc Biol"}, {"issue": "5", "key": "1_CR8", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1089/jir.2007.0128", "volume": "27", "author": "KR Bastos", "year": "2007", "unstructured": "Bastos KR, Barboza R, Sardinha L, Russo M, Alvarez JM, Lima MR (2007) Role of endogenous IFN-gamma in macrophage programming induced by IL-12 and IL-18. J Interferon Cytokine Res 27(5):399\u2013410. doi: 10.1089/jir.2007.0128", "journal-title": "J Interferon Cytokine Res"}, {"issue": "2", "key": "1_CR9", "doi-asserted-by": "crossref", "first-page": "537", "DOI": "10.1016/S0002-9440(10)65149-8", "volume": "155", "author": "G Bellone", "year": "1999", "unstructured": "Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155(2):537\u2013547", "journal-title": "Am J Pathol"}, {"issue": "3", "key": "1_CR10", "doi-asserted-by": "publisher", "first-page": "2045", "DOI": "10.4049/jimmunol.0800276", "volume": "183", "author": "S Brahmachari", "year": "2009", "unstructured": "Brahmachari S, Pahan K (2009) Suppression of regulatory T cells by IL-12p40 homodimer via nitric oxide. J Immunol 183(3):2045\u20132058. doi: 10.4049/jimmunol.0800276", "journal-title": "J Immunol"}, {"issue": "8", "key": "1_CR11", "first-page": "4943", "volume": "162", "author": "WE Carson", "year": "1999", "unstructured": "Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R, Durbin J, Baldwin AS, Peschon J, Johnson PR et al (1999) A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 162(8):4943\u20134951", "journal-title": "J Immunol"}, {"issue": "12", "key": "1_CR12", "doi-asserted-by": "publisher", "first-page": "10235", "DOI": "10.1007/s11033-012-1899-y", "volume": "39", "author": "H Chen", "year": "2012", "unstructured": "Chen H, Cheng S, Wang J, Cao C, Bunjhoo H, Xiong W, Xu Y (2012a) Interleukin-12B rs3212227 polymorphism and cancer risk: a meta-analysis. Mol Biol Rep 39(12):10235\u201310242. doi: 10.1007/s11033-012-1899-y", "journal-title": "Mol Biol Rep"}, {"issue": "1", "key": "1_CR13", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1016/j.imlet.2012.09.002", "volume": "148", "author": "X Chen", "year": "2012", "unstructured": "Chen X, Du Y, Huang Z (2012b) CD4+\u00a0CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Immunol Lett 148(1):83\u201389. doi: 10.1016/j.imlet.2012.09.002", "journal-title": "Immunol Lett"}, {"issue": "1\u20132", "key": "1_CR14", "doi-asserted-by": "publisher", "first-page": "75", "DOI": "10.1016/j.jneuroim.2007.01.012", "volume": "185", "author": "X Cheng", "year": "2007", "unstructured": "Cheng X, Zhao Z, Ventura E, Gran B, Shindler KS, Rostami A (2007) The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. J Neuroimmunol 185(1\u20132):75\u201386. doi: 10.1016/j.jneuroim.2007.01.012", "journal-title": "J Neuroimmunol"}, {"issue": "14", "key": "1_CR15", "doi-asserted-by": "publisher", "first-page": "3890", "DOI": "10.1182/blood-2011-05-357111", "volume": "118", "author": "FZ Chowdhury", "year": "2011", "unstructured": "Chowdhury FZ, Ramos HJ, Davis LS, Forman J, Farrar JD (2011) IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. Blood 118(14):3890\u20133900. doi: 10.1182/blood-2011-05-357111", "journal-title": "Blood"}, {"issue": "1", "key": "1_CR16", "first-page": "128", "volume": "153", "author": "AO Chua", "year": "1994", "unstructured": "Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, Warrier RR, Presky DH, Levine JF, Gately MK et al (1994) Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 153(1):128\u2013136", "journal-title": "J Immunol"}, {"issue": "6", "key": "1_CR17", "doi-asserted-by": "publisher", "first-page": "952", "DOI": "10.1016/j.immuni.2007.11.014", "volume": "27", "author": "EY Chung", "year": "2007", "unstructured": "Chung EY, Liu J, Homma Y, Zhang Y, Brendolan A, Saggese M, Han J, Silverstein R, Selleri L, Ma X (2007) Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 27(6):952\u2013964. doi: 10.1016/j.immuni.2007.11.014", "journal-title": "Immunity"}, {"issue": "7169", "key": "1_CR18", "doi-asserted-by": "publisher", "first-page": "566", "DOI": "10.1038/nature06306", "volume": "450", "author": "LW Collison", "year": "2007", "unstructured": "Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA (2007) The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169):566\u2013569. doi: 10.1038/nature06306", "journal-title": "Nature"}, {"issue": "3", "key": "1_CR19", "doi-asserted-by": "publisher", "first-page": "171", "DOI": "10.1159/000363502", "volume": "164", "author": "L Cosmi", "year": "2014", "unstructured": "Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F (2014) Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol 164(3):171\u2013177. doi: 10.1159/000363502", "journal-title": "Int Arch Allergy Immunol"}, {"issue": "6", "key": "1_CR20", "doi-asserted-by": "publisher", "first-page": "381", "DOI": "10.1097/MD.0b013e3181fdd832", "volume": "89", "author": "L Beaucoudrey de", "year": "2010", "unstructured": "de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, Al-Muhsen S, Janniere L, Rose Y, de Suremain M et al (2010) Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89(6):381\u2013402. doi: 10.1097/MD.0b013e3181fdd832", "journal-title": "Medicine (Baltimore)"}, {"issue": "16", "key": "1_CR21", "doi-asserted-by": "publisher", "first-page": "4677", "DOI": "10.1158/1078-0432.CCR-07-0776", "volume": "13", "author": "M Vecchio Del", "year": "2007", "unstructured": "Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13(16):4677\u20134685. doi: 10.1158/1078-0432.CCR-07-0776", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "1_CR22", "doi-asserted-by": "crossref", "first-page": "163", "DOI": "10.1007/BF02698035", "volume": "24", "author": "D Derin", "year": "2007", "unstructured": "Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, Yasasever V, Topuz E (2007) Serum IL-8 and IL-12 levels in breast cancer. Med Oncol 24(2):163\u2013168", "journal-title": "Med Oncol"}, {"key": "1_CR23", "unstructured": "Durali D, de Goer de Herve MG, Giron-Michel J, Azzarone B, Delfraissy JF, Taoufik Y (2003) In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood 102(12):4084\u20134089. doi: 10.1182/blood-2003-02-0518", "DOI": "10.1182/blood-2003-02-0518", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "1_CR24", "doi-asserted-by": "crossref", "first-page": "145", "DOI": "10.1016/S0304-3835(01)00526-2", "volume": "168", "author": "T Felzmann", "year": "2001", "unstructured": "Felzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner H, Holter W (2001) Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. Cancer Lett 168(2):145\u2013154", "journal-title": "Cancer Lett"}, {"issue": "2", "key": "1_CR25", "doi-asserted-by": "publisher", "first-page": "99", "DOI": "10.1016/j.imlet.2010.08.002", "volume": "133", "author": "E Ferretti", "year": "2010", "unstructured": "Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, Montagna D, Pistoia V, Airoldi I (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 133(2):99\u2013105. doi: 10.1016/j.imlet.2010.08.002", "journal-title": "Immunol Lett"}, {"issue": "11", "key": "1_CR26", "first-page": "6014", "volume": "161", "author": "WE Fogler", "year": "1998", "unstructured": "Fogler WE, Volker K, Watanabe M, Wigginton JM, Roessler P, Brunda MJ, Ortaldo JR, Wiltrout RH (1998) Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 161(11):6014\u20136021", "journal-title": "J Immunol"}, {"issue": "1", "key": "1_CR27", "doi-asserted-by": "publisher", "first-page": "200", "DOI": "10.1002/eji.1830250133", "volume": "25", "author": "S Gillessen", "year": "1995", "unstructured": "Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, Familletti PC, Gubler U, Presky DH, Stern AS, Gately MK (1995) Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 25(1):200\u2013206. doi: 10.1002/eji.1830250133", "journal-title": "Eur J Immunol"}, {"issue": "1", "key": "1_CR28", "doi-asserted-by": "crossref", "first-page": "63", "DOI": "10.1023/A:1008266321552", "volume": "9", "author": "J Golab", "year": "1998", "unstructured": "Golab J, Stoklosa T, Zagozdzon R, Kaca A, Giermasz A, Pojda Z, Machaj E, Dabrowska A, Feleszko W, Lasek W et al (1998a) G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 9(1):63\u201369", "journal-title": "Ann Oncol"}, {"issue": "2", "key": "1_CR29", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1159/000029978", "volume": "19", "author": "J Golab", "year": "1998", "unstructured": "Golab J, Stoklosa T, Zagozdzon R, Kaca A, Kulchitska LA, Feleszko W, Kawiak J, Hoser G, Glowacka E, Dabrowska A et al (1998b) Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumour Biol 19(2):77\u201387", "journal-title": "Tumour Biol"}, {"issue": "3", "key": "1_CR30", "doi-asserted-by": "crossref", "first-page": "153", "DOI": "10.1016/S0165-2478(00)00178-4", "volume": "72", "author": "J Golab", "year": "2000", "unstructured": "Golab J, Zagozdzon Stoklosal T, Kaminski R, Kozar K, Jakobisiak M (2000) Direct stimulation of macrophages by IL-12 and IL-18\u2013a bridge too far? Immunol Lett 72(3):153\u2013157", "journal-title": "Immunol Lett"}, {"issue": "5", "key": "1_CR31", "first-page": "537", "volume": "3", "author": "J Golab", "year": "1999", "unstructured": "Golab J, Zagozdzon R (1999) Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (review). Int J Mol Med 3(5):537\u2013544", "journal-title": "Int J Mol Med"}, {"issue": "11", "key": "1_CR32", "first-page": "4387", "volume": "91", "author": "J Golab", "year": "1998", "unstructured": "Golab J, Zagozdzon R, Stoklosa T, Jakobisiak M, Pojda Z, Machaj E (1998c) Erythropoietin prevents the development of interleukin-12-induced anemia and thrombocytopenia but does not decrease its antitumor activity in mice. Blood 91(11):4387\u20134388", "journal-title": "Blood"}, {"issue": "4", "key": "1_CR33", "first-page": "1341", "volume": "91", "author": "JA Gollob", "year": "1998", "unstructured": "Gollob JA, Murphy EA, Mahajan S, Schnipper CP, Ritz J, Frank DA (1998) Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1. Blood 91(4):1341\u20131354", "journal-title": "Blood"}, {"issue": "1", "key": "1_CR34", "doi-asserted-by": "crossref", "first-page": "221", "DOI": "10.4049/jimmunol.167.1.221", "volume": "167", "author": "U Grohmann", "year": "2001", "unstructured": "Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, Fioretti MC, Puccetti P (2001) Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol 167(1):221\u2013227", "journal-title": "J Immunol"}, {"issue": "8", "key": "1_CR35", "first-page": "3593", "volume": "158", "author": "U Grohmann", "year": "1997", "unstructured": "Grohmann U, Bianchi R, Ayroldi E, Belladonna ML, Surace D, Fioretti MC, Puccetti P (1997) A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 158(8):3593\u20133602", "journal-title": "J Immunol"}, {"issue": "3", "key": "1_CR36", "doi-asserted-by": "publisher", "first-page": "789", "DOI": "10.3390/ijms11030789", "volume": "11", "author": "T Hamza", "year": "2010", "unstructured": "Hamza T, Barnett JB, Li B (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11(3):789\u2013806. doi: 10.3390/ijms11030789", "journal-title": "Int J Mol Sci"}, {"key": "1_CR37", "doi-asserted-by": "publisher", "first-page": "948098", "DOI": "10.1155/2012/948098", "volume": "2012", "author": "NB Hao", "year": "2012", "unstructured": "Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM (2012) Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012:948098. doi: 10.1155/2012/948098", "journal-title": "Clin Dev Immunol"}, {"issue": "5", "key": "1_CR38", "doi-asserted-by": "publisher", "first-page": "749", "DOI": "10.1093/infdis/jit126", "volume": "208", "author": "J Held", "year": "2013", "unstructured": "Held J, Preusse C, Doser A, Richter L, Heppner FL, Stenzel W (2013) Enhanced acute immune response in IL-12p35-/- mice is followed by accelerated distinct repair mechanisms in Staphylococcus aureus-induced murine brain abscess. J Infect Dis 208(5):749\u2013760. doi: 10.1093/infdis/jit126", "journal-title": "J Infect Dis"}, {"issue": "3", "key": "1_CR39", "doi-asserted-by": "publisher", "first-page": "659", "DOI": "10.1002/eji.1830260323", "volume": "26", "author": "C Heufler", "year": "1996", "unstructured": "Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G (1996) Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 26(3):659\u2013668. doi: 10.1002/eji.1830260323", "journal-title": "Eur J Immunol"}, {"issue": "5107", "key": "1_CR40", "doi-asserted-by": "crossref", "first-page": "547", "DOI": "10.1126/science.8097338", "volume": "260", "author": "CS Hsieh", "year": "1993", "unstructured": "Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O\u2019Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260(5107):547\u2013549", "journal-title": "Science"}, {"issue": "5", "key": "1_CR41", "doi-asserted-by": "crossref", "first-page": "1755", "DOI": "10.1084/jem.181.5.1755", "volume": "181", "author": "NG Jacobson", "year": "1995", "unstructured": "Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE Jr, Murphy KM (1995) Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J Exp Med 181(5):1755\u20131762", "journal-title": "J Exp Med"}, {"issue": "12", "key": "1_CR42", "first-page": "1189", "volume": "18", "author": "A Jafarzadeh", "year": "2015", "unstructured": "Jafarzadeh A, Minaee K, Farsinejad AR, Nemati M, Khosravimashizi A, Daneshvar H, Mohammadi MM, Sheikhi A, Ghaderi A (2015) Evaluation of the circulating levels of IL-12 and IL-33 in patients with breast cancer: influences of the tumor stages and cytokine gene polymorphisms. Iran J Basic Med Sci 18(12):1189\u20131198", "journal-title": "Iran J Basic Med Sci"}, {"issue": "2\u20133", "key": "1_CR43", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1016/j.imlet.2003.08.005", "volume": "90", "author": "M Jakobisiak", "year": "2003", "unstructured": "Jakobisiak M, Lasek W, Golab J (2003) Natural mechanisms protecting against cancer. Immunol Lett 90(2\u20133):103\u2013122", "journal-title": "Immunol Lett"}, {"issue": "9", "key": "1_CR44", "doi-asserted-by": "publisher", "first-page": "6763", "DOI": "10.1074/jbc.M112.436675", "volume": "288", "author": "R Jalah", "year": "2013", "unstructured": "Jalah R, Rosati M, Ganneru B, Pilkington GR, Valentin A, Kulkarni V, Bergamaschi C, Chowdhury B, Zhang GM, Beach RK et al (2013) The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem 288(9):6763\u20136776. doi: 10.1074/jbc.M112.436675", "journal-title": "J Biol Chem"}, {"issue": "1", "key": "1_CR45", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1093/intimm/12.1.103", "volume": "12", "author": "K Kawamoto", "year": "2000", "unstructured": "Kawamoto K, Paliwal V, Ramabhadran R, Szczepanik M, Tsuji RF, Matsuda H, Askenase PW (2000) IL-12 is produced by antigen-presenting cells stimulated with soluble alphabeta TCR and restores impaired T(h)1 responses. Int Immunol 12(1):103\u2013112", "journal-title": "Int Immunol"}, {"key": "1_CR46", "doi-asserted-by": "crossref", "first-page": "116", "DOI": "10.1111/j.1749-6632.1996.tb52660.x", "volume": "795", "author": "BL Kelsall", "year": "1996", "unstructured": "Kelsall BL, Stuber E, Neurath M, Strober W (1996) Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann NY Acad Sci 795:116\u2013126", "journal-title": "Ann NY Acad Sci"}, {"issue": "12", "key": "1_CR47", "doi-asserted-by": "publisher", "first-page": "4746", "DOI": "10.1172/JCI58814", "volume": "121", "author": "SP Kerkar", "year": "2011", "unstructured": "Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM et al (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 121(12):4746\u20134757. doi: 10.1172/JCI58814", "journal-title": "J Clin Invest"}, {"issue": "7", "key": "1_CR48", "doi-asserted-by": "publisher", "first-page": "1369", "DOI": "10.1038/mt.2013.58", "volume": "21", "author": "SP Kerkar", "year": "2013", "unstructured": "Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA et al (2013) Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21(7):1369\u20131377. doi: 10.1038/mt.2013.58", "journal-title": "Mol Ther"}, {"issue": "3", "key": "1_CR49", "doi-asserted-by": "crossref", "first-page": "827", "DOI": "10.1084/jem.170.3.827", "volume": "170", "author": "M Kobayashi", "year": "1989", "unstructured": "Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170(3):827\u2013845", "journal-title": "J Exp Med"}, {"key": "1_CR50", "doi-asserted-by": "publisher", "first-page": "1223", "DOI": "10.1038/ncomms2223", "volume": "3", "author": "M Kuka", "year": "2012", "unstructured": "Kuka M, Munitic I, Ashwell JD (2012) Identification and characterization of polyclonal alphabeta-T cells with dendritic cell properties. Nat Commun 3:1223. doi: 10.1038/ncomms2223", "journal-title": "Nat Commun"}, {"issue": "4", "key": "1_CR51", "doi-asserted-by": "publisher", "first-page": "363", "DOI": "10.1007/s00262-003-0449-9", "volume": "53", "author": "W Lasek", "year": "2004", "unstructured": "Lasek W, Basak G, Switaj T, Jakubowska AB, Wysocki PJ, Mackiewicz A, Drela N, Jalili A, Kaminski R, Kozar K et al (2004) Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother 53(4):363\u2013372. doi: 10.1007/s00262-003-0449-9", "journal-title": "Cancer Immunol Immunother"}, {"issue": "2", "key": "1_CR52", "doi-asserted-by": "crossref", "first-page": "100", "DOI": "10.1007/s002620050408", "volume": "45", "author": "W Lasek", "year": "1997", "unstructured": "Lasek W, Feleszko W, Golab J, Stoklosa T, Marczak M, Dabrowska A, Malejczyk M, Jakobisiak M (1997) Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 45(2):100\u2013108", "journal-title": "Cancer Immunol Immunother"}, {"issue": "5", "key": "1_CR53", "doi-asserted-by": "publisher", "first-page": "419", "DOI": "10.1007/s00262-014-1523-1", "volume": "63", "author": "W Lasek", "year": "2014", "unstructured": "Lasek W, Zagozdzon R, Jakobisiak M (2014) Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 63(5):419\u2013435. doi: 10.1007/s00262-014-1523-1", "journal-title": "Cancer Immunol Immunother"}, {"issue": "11", "key": "1_CR54", "doi-asserted-by": "publisher", "first-page": "3017", "DOI": "10.1002/eji.201040539", "volume": "40", "author": "MH Lexberg", "year": "2010", "unstructured": "Lexberg MH, Taubner A, Albrecht I, Lepenies I, Richter A, Kamradt T, Radbruch A, Chang HD (2010) IFN-gamma and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol 40(11):3017\u20133027. doi: 10.1002/eji.201040539", "journal-title": "Eur J Immunol"}, {"issue": "3", "key": "1_CR55", "doi-asserted-by": "publisher", "first-page": "347", "DOI": "10.1016/j.ymthe.2003.11.022", "volume": "9", "author": "S Li", "year": "2004", "unstructured": "Li S, Xia X, Mellieon FM, Liu J, Steele S (2004) Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 9(3):347\u2013354. doi: 10.1016/j.ymthe.2003.11.022", "journal-title": "Mol Ther"}, {"issue": "1", "key": "1_CR56", "first-page": "116", "volume": "154", "author": "P Ling", "year": "1995", "unstructured": "Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154(1):116\u2013127", "journal-title": "J Immunol"}, {"issue": "6", "key": "1_CR57", "doi-asserted-by": "publisher", "first-page": "e218", "DOI": "10.1016/S1470-2045(12)70582-X", "volume": "14", "author": "BE Lippitz", "year": "2013", "unstructured": "Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14(6):e218\u2013228. doi: 10.1016/S1470-2045(12)70582-X", "journal-title": "Lancet Oncol"}, {"issue": "8", "key": "1_CR58", "doi-asserted-by": "publisher", "first-page": "1265", "DOI": "10.1084/jem.20030026", "volume": "198", "author": "J Liu", "year": "2003", "unstructured": "Liu J, Cao S, Herman LM, Ma X (2003) Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med 198(8):1265\u20131276. doi: 10.1084/jem.20030026", "journal-title": "J Exp Med"}, {"issue": "53", "key": "1_CR59", "doi-asserted-by": "publisher", "first-page": "55609", "DOI": "10.1074/jbc.M406565200", "volume": "279", "author": "J Liu", "year": "2004", "unstructured": "Liu J, Guan X, Tamura T, Ozato K, Ma X (2004) Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein. J Biol Chem 279(53):55609\u201355617. doi: 10.1074/jbc.M406565200", "journal-title": "J Biol Chem"}, {"issue": "3", "key": "1_CR60", "doi-asserted-by": "publisher", "first-page": "431", "DOI": "10.1016/j.surg.2012.05.035", "volume": "152", "author": "E Luedke", "year": "2012", "unstructured": "Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd (2012) Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152(3):431\u2013440. doi: 10.1016/j.surg.2012.05.035", "journal-title": "Surgery"}, {"issue": "11", "key": "1_CR61", "doi-asserted-by": "crossref", "first-page": "6775", "DOI": "10.4049/jimmunol.172.11.6775", "volume": "172", "author": "RJ Lund", "year": "2004", "unstructured": "Lund RJ, Chen Z, Scheinin J, Lahesmaa R (2004) Early target genes of IL-12 and STAT4 signaling in th cells. J Immunol 172(11):6775\u20136782", "journal-title": "J Immunol"}, {"key": "1_CR62", "unstructured": "Ma TT, Wu BT, Lin Y, Xiong HY, Wang Q, Li ZW, Cheng F, Tu ZG (2015a) IL-12 could induce monocytic tumor cells directional differentiation. Mol Cell Biochem 402 (1-2):157-169. doi: 10.1007/s11010-014-2323-9", "DOI": "10.1007/s11010-014-2323-9", "doi-asserted-by": "publisher"}, {"key": "1_CR63", "unstructured": "Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, Li N, Wei F (2015b) Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells. F1000Res 4. doi: 10.12688/f1000research.7010.1", "DOI": "10.12688/f1000research.7010.1", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "1_CR64", "doi-asserted-by": "crossref", "first-page": "147", "DOI": "10.1084/jem.183.1.147", "volume": "183", "author": "X Ma", "year": "1996", "unstructured": "Ma X, Chow JM, Gri G, Carra G, Gerosa F, Wolf SF, Dzialo R, Trinchieri G (1996) The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 183(1):147\u2013157", "journal-title": "J Exp Med"}, {"issue": "10", "key": "1_CR65", "doi-asserted-by": "publisher", "first-page": "2329", "DOI": "10.1158/1078-0432.CCR-16-0224", "volume": "22", "author": "M Mandai", "year": "2016", "unstructured": "Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I (2016) Dual Faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res 22(10):2329\u20132334. doi: 10.1158/1078-0432.CCR-16-0224", "journal-title": "Clin Cancer Res"}, {"issue": "7", "key": "1_CR66", "doi-asserted-by": "crossref", "first-page": "3992", "DOI": "10.4049/jimmunol.174.7.3992", "volume": "174", "author": "E Marcenaro", "year": "2005", "unstructured": "Marcenaro E, Della Chiesa M, Bellora F, Parolini S, Millo R, Moretta L, Moretta A (2005) IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 174(7):3992\u20133998", "journal-title": "J Immunol"}, {"issue": "9", "key": "1_CR67", "first-page": "4298", "volume": "160", "author": "BL McRae", "year": "1998", "unstructured": "McRae BL, Semnani RT, Hayes MP, van Seventer GA (1998) Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol 160(9):4298\u20134304", "journal-title": "J Immunol"}, {"issue": "1", "key": "1_CR68", "doi-asserted-by": "publisher", "first-page": "531", "DOI": "10.1007/s13277-012-0578-x", "volume": "34", "author": "A Memarian", "year": "2013", "unstructured": "Memarian A, Nourizadeh M, Masoumi F, Tabrizi M, Emami AH, Alimoghaddam K, Hadjati J, Mirahmadian M, Jeddi-Tehrani M (2013) Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia. Tumour Biol 34(1):531\u2013542. doi: 10.1007/s13277-012-0578-x", "journal-title": "Tumour Biol"}, {"issue": "2", "key": "1_CR69", "doi-asserted-by": "publisher", "first-page": "77", "DOI": "10.1016/0167-5699(92)90140-3", "volume": "13", "author": "DM Merberg", "year": "1992", "unstructured": "Merberg DM, Wolf SF, Clark SC (1992) Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 13(2):77\u201378. doi: 10.1016/0167-5699(92)90140-3", "journal-title": "Immunol Today"}, {"key": "1_CR70", "doi-asserted-by": "publisher", "first-page": "75", "DOI": "10.4137/CMO.S11292", "volume": "7", "author": "MA Michelin", "year": "2013", "unstructured": "Michelin MA, Abdalla DR, Aleixo AA, Murta EF (2013) Peripheral helper lymphocytes produce interleukin 12 in cancer patients. Clin Med Insights Oncol 7:75\u201381. doi: 10.4137/CMO.S11292", "journal-title": "Clin Med Insights Oncol"}, {"issue": "3", "key": "1_CR71", "doi-asserted-by": "publisher", "first-page": "1523", "DOI": "10.3892/ol.2015.3470", "volume": "10", "author": "MA Michelin", "year": "2015", "unstructured": "Michelin MA, Montes L, Nomelini RS, Abdalla DR, Aleixo AA, Murta EF (2015) Interleukin-12 in patients with cancer is synthesized by peripheral helper T lymphocytes. Oncol Lett 10(3):1523\u20131526. doi: 10.3892/ol.2015.3470", "journal-title": "Oncol Lett"}, {"issue": "8", "key": "1_CR72", "doi-asserted-by": "publisher", "first-page": "1445", "DOI": "10.4161/onci.21318", "volume": "1", "author": "AJ Michielsen", "year": "2012", "unstructured": "Michielsen AJ, Ryan EJ, O\u2019Sullivan JN (2012) Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 1(8):1445\u20131447. doi: 10.4161/onci.21318", "journal-title": "Oncoimmunology"}, {"issue": "2", "key": "1_CR73", "doi-asserted-by": "publisher", "first-page": "322", "DOI": "10.1189/jlb.1203641", "volume": "76", "author": "M Mitsuhashi", "year": "2004", "unstructured": "Mitsuhashi M, Liu J, Cao S, Shi X, Ma X (2004) Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol 76(2):322\u2013332. doi: 10.1189/jlb.1203641", "journal-title": "J Leukoc Biol"}, {"issue": "12", "key": "1_CR74", "doi-asserted-by": "crossref", "first-page": "1996", "DOI": "10.1038/sj.leu.2402308", "volume": "15", "author": "J Miyauchi", "year": "2001", "unstructured": "Miyauchi J (2001) In vitro effects of interleukin-12 on the growth of blast progenitors in acute myelogenous leukemia. Leukemia 15(12):1996\u20131998", "journal-title": "Leukemia"}, {"issue": "13", "key": "1_CR75", "doi-asserted-by": "publisher", "first-page": "2351", "DOI": "10.1084/jem.20120944", "volume": "209", "author": "J Ni", "year": "2012", "unstructured": "Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A (2012) Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 209(13):2351\u20132365. doi: 10.1084/jem.20120944", "journal-title": "J Exp Med"}, {"key": "1_CR76", "author": "G Nizzoli", "year": "2013", "unstructured": "Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti MC et al (2013) Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses. Blood. doi: 10.1182/blood-2013-04-495424", "journal-title": "Blood", "DOI": "10.1182/blood-2013-04-495424", "doi-asserted-by": "publisher"}, {"issue": "5", "key": "1_CR77", "doi-asserted-by": "crossref", "first-page": "715", "DOI": "10.1016/S1074-7613(00)00070-4", "volume": "13", "author": "B Oppmann", "year": "2000", "unstructured": "Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5):715\u2013725", "journal-title": "Immunity"}, {"issue": "2", "key": "1_CR78", "doi-asserted-by": "publisher", "first-page": "111", "DOI": "10.1006/cimm.1999.1589", "volume": "198", "author": "T Otani", "year": "1999", "unstructured": "Otani T, Nakamura S, Toki M, Motoda R, Kurimoto M, Orita K (1999) Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice. Cell Immunol 198(2):111\u2013119. doi: 10.1006/cimm.1999.1589", "journal-title": "Cell Immunol"}, {"issue": "2", "key": "1_CR79", "doi-asserted-by": "publisher", "first-page": "218", "DOI": "10.1006/jsre.1995.1034", "volume": "58", "author": "I Pappo", "year": "1995", "unstructured": "Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT (1995) Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res 58(2):218\u2013226. doi: 10.1006/jsre.1995.1034", "journal-title": "J Surg Res"}, {"issue": "7", "key": "1_CR80", "doi-asserted-by": "publisher", "first-page": "983", "DOI": "10.1172/JCI15950", "volume": "110", "author": "R Parihar", "year": "2002", "unstructured": "Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110(7):983\u2013992. doi: 10.1172/JCI15950", "journal-title": "J Clin Invest"}, {"key": "1_CR81", "doi-asserted-by": "publisher", "first-page": "17", "DOI": "10.1007/978-3-319-15774-0_2", "volume": "850", "author": "S Piconese", "year": "2015", "unstructured": "Piconese S, Barnaba V (2015) Stability of regulatory T cells undermined or endorsed by different type-1 cytokines. Adv Exp Med Biol 850:17\u201330. doi: 10.1007/978-3-319-15774-0_2", "journal-title": "Adv Exp Med Biol"}, {"issue": "28", "key": "1_CR82", "doi-asserted-by": "publisher", "first-page": "4809", "DOI": "10.1200/JCO.2008.21.3579", "volume": "27", "author": "V Pistoia", "year": "2009", "unstructured": "Pistoia V, Cocco C, Airoldi I (2009) Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J Clin Oncol 27(28):4809\u20134816. doi: 10.1200/JCO.2008.21.3579", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "1_CR83", "doi-asserted-by": "publisher", "first-page": "109", "DOI": "10.1097/MD.0b013e31828a01f9", "volume": "92", "author": "C Prando", "year": "2013", "unstructured": "Prando C, Samarina A, Bustamante J, Boisson-Dupuis S, Cobat A, Picard C, AlSum Z, Al-Jumaah S, Al-Hajjar S, Frayha H et al (2013) Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 92(2):109\u2013122. doi: 10.1097/MD.0b013e31828a01f9", "journal-title": "Medicine (Baltimore)"}, {"issue": "24", "key": "1_CR84", "doi-asserted-by": "crossref", "first-page": "14002", "DOI": "10.1073/pnas.93.24.14002", "volume": "93", "author": "DH Presky", "year": "1996", "unstructured": "Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY, Gately MK, Gubler U (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 93(24):14002\u201314007", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "2", "key": "1_CR85", "doi-asserted-by": "publisher", "first-page": "348", "DOI": "10.1016/j.cyto.2014.11.018", "volume": "71", "author": "RT Robinson", "year": "2015", "unstructured": "Robinson RT (2015) IL12Rbeta1: the cytokine receptor that we used to know. Cytokine 71(2):348\u2013359. doi: 10.1016/j.cyto.2014.11.018", "journal-title": "Cytokine"}, {"issue": "5", "key": "1_CR86", "first-page": "1323", "volume": "83", "author": "AR Rossi", "year": "1994", "unstructured": "Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY (1994) Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 83(5):1323\u20131328", "journal-title": "Blood"}, {"issue": "4", "key": "1_CR87", "doi-asserted-by": "crossref", "first-page": "453", "DOI": "10.1016/S1074-7613(00)00045-5", "volume": "13", "author": "O Schulz", "year": "2000", "unstructured": "Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis e Sousa C (2000) CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13(4):453\u2013462", "journal-title": "Immunity"}, {"issue": "4", "key": "1_CR88", "doi-asserted-by": "publisher", "first-page": "731", "DOI": "10.1158/1535-7163.MCT-15-0706", "volume": "15", "author": "L Shi", "year": "2016", "unstructured": "Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C (2016) Targeting Androgen Receptor (AR)\u2192 IL12A signal enhances efficacy of Sorafenib plus NK cells immunotherapy to better suppress HCC progression. Mol Cancer Ther 15(4):731\u2013742. doi: 10.1158/1535-7163.MCT-15-0706", "journal-title": "Mol Cancer Ther"}, {"issue": "26", "key": "1_CR89", "doi-asserted-by": "publisher", "first-page": "23582", "DOI": "10.1074/jbc.M111.249235", "volume": "286", "author": "AM Smith", "year": "2011", "unstructured": "Smith AM, Qualls JE, O\u2019Brien K, Balouzian L, Johnson PF, Schultz-Cherry S, Smale ST, Murray PJ (2011) A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3. J Biol Chem 286(26):23582\u201323590. doi: 10.1074/jbc.M111.249235", "journal-title": "J Biol Chem"}, {"issue": "12", "key": "1_CR90", "doi-asserted-by": "publisher", "first-page": "1223", "DOI": "10.1111/apm.12288", "volume": "122", "author": "N Stanilov", "year": "2014", "unstructured": "Stanilov N, Miteva L, Jovchev J, Cirovski G, Stanilova S (2014) The prognostic value of preoperative serum levels of IL-12p40 and IL-23 for survival of patients with colorectal cancer. APMIS 122(12):1223\u20131229. doi: 10.1111/apm.12288", "journal-title": "APMIS"}, {"issue": "17", "key": "1_CR91", "doi-asserted-by": "crossref", "first-page": "6808", "DOI": "10.1073/pnas.87.17.6808", "volume": "87", "author": "AS Stern", "year": "1990", "unstructured": "Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R et al (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 87(17):6808\u20136812", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "2", "key": "1_CR92", "doi-asserted-by": "publisher", "first-page": "249", "DOI": "10.1016/j.cyto.2015.01.030", "volume": "75", "author": "L Sun", "year": "2015", "unstructured": "Sun L, He C, Nair L, Yeung J, Egwuagu CE (2015) Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine 75(2):249\u2013255. doi: 10.1016/j.cyto.2015.01.030", "journal-title": "Cytokine"}, {"issue": "4", "key": "1_CR93", "doi-asserted-by": "publisher", "first-page": "490", "DOI": "10.1200/JCO.2012.45.2052", "volume": "31", "author": "K Suzuki", "year": "2013", "unstructured": "Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, Sadelain M, Adusumilli PS (2013) Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 31(4):490\u2013498. doi: 10.1200/JCO.2012.45.2052", "journal-title": "J Clin Oncol"}, {"issue": "3", "key": "1_CR94", "doi-asserted-by": "crossref", "first-page": "223", "DOI": "10.1620/tjem.185.223", "volume": "185", "author": "S Suzuki", "year": "1998", "unstructured": "Suzuki S, Umezu Y, Saijo Y, Satoh G, Abe Y, Satoh K, Nukiwa T (1998) Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J Exp Med 185(3):223\u2013226", "journal-title": "Tohoku J Exp Med"}, {"issue": "5", "key": "1_CR95", "doi-asserted-by": "crossref", "first-page": "817", "DOI": "10.1084/jem.185.5.817", "volume": "185", "author": "SJ Szabo", "year": "1997", "unstructured": "Szabo SJ, Dighe AS, Gubler U, Murphy KM (1997) Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 185(5):817\u2013824", "journal-title": "J Exp Med"}, {"issue": "6587", "key": "1_CR96", "doi-asserted-by": "publisher", "first-page": "171", "DOI": "10.1038/382171a0", "volume": "382", "author": "WE Thierfelder", "year": "1996", "unstructured": "Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC et al (1996) Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382(6587):171\u2013174. doi: 10.1038/382171a0", "journal-title": "Nature"}, {"issue": "4", "key": "1_CR97", "doi-asserted-by": "crossref", "first-page": "355", "DOI": "10.1016/0955-2235(92)90016-B", "volume": "4", "author": "G Trinchieri", "year": "1992", "unstructured": "Trinchieri G, Wysocka M, D\u2019Andrea A, Rengaraju M, Aste-Amezaga M, Kubin M, Valiante NM, Chehimi J (1992) Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog Growth Factor Res 4(4):355\u2013368", "journal-title": "Prog Growth Factor Res"}, {"issue": "10", "key": "1_CR98", "doi-asserted-by": "publisher", "first-page": "1329", "DOI": "10.1002/humu.22380", "volume": "34", "author": "E Vosse van de", "year": "2013", "unstructured": "van de Vosse E, Haverkamp MH, Ramirez-Alejo N, Martinez-Gallo M, Blancas-Galicia L, Metin A, Garty BZ, Sun-Tan C, Broides A, de Paus RA et al (2013) IL-12Rbeta1 deficiency: mutation update and description of the IL12RB1 variation database. Hum Mutat 34(10):1329\u20131339. doi: 10.1002/humu.22380", "journal-title": "Hum Mutat"}, {"issue": "5", "key": "1_CR99", "doi-asserted-by": "publisher", "first-page": "225", "DOI": "10.1186/ar1227", "volume": "6", "author": "AV Villarino", "year": "2004", "unstructured": "Villarino AV, Hunter CA (2004) Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther 6(5):225\u2013233. doi: 10.1186/ar1227", "journal-title": "Arthritis Res Ther"}, {"issue": "8", "key": "1_CR100", "doi-asserted-by": "crossref", "first-page": "581", "DOI": "10.1093/jnci/87.8.581", "volume": "87", "author": "EE Voest", "year": "1995", "unstructured": "Voest EE, Kenyon BM, O\u2019Reilly MS, Truitt G, D\u2019Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87(8):581\u2013586", "journal-title": "J Natl Cancer Inst"}, {"issue": "18", "key": "1_CR101", "doi-asserted-by": "publisher", "first-page": "2238", "DOI": "10.1016/j.vaccine.2013.03.003", "volume": "31", "author": "JM Wang", "year": "2013", "unstructured": "Wang JM, Ma CJ, Li GY, Wu XY, Thayer P, Greer P, Smith AM, High KP, Moorman JP, Yao ZQ (2013) Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection. Vaccine 31(18):2238\u20132245. doi: 10.1016/j.vaccine.2013.03.003", "journal-title": "Vaccine"}, {"issue": "1\u20132", "key": "1_CR102", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1007/s11010-016-2687-0", "volume": "415", "author": "Q Wang", "year": "2016", "unstructured": "Wang Q, Cheng F, Ma TT, Xiong HY, Li ZW, Xie CL, Liu CY, Tu ZG (2016a) Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3. Mol Cell Biochem 415(1\u20132):157\u2013168. doi: 10.1007/s11010-016-2687-0", "journal-title": "Mol Cell Biochem"}, {"issue": "6", "key": "1_CR103", "doi-asserted-by": "publisher", "first-page": "1343", "DOI": "10.1002/eji.201546095", "volume": "46", "author": "X Wang", "year": "2016", "unstructured": "Wang X, Wei Y, Xiao H, Liu X, Zhang Y, Han G, Chen G, Hou C, Ma N, Shen B et al (2016b) A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice. Eur J Immunol 46(6):1343\u20131350. doi: 10.1002/eji.201546095", "journal-title": "Eur J Immunol"}, {"issue": "3", "key": "1_CR104", "doi-asserted-by": "publisher", "first-page": "258", "DOI": "10.1159/000323923", "volume": "3", "author": "R Wehner", "year": "2011", "unstructured": "Wehner R, Dietze K, Bachmann M, Schmitz M (2011) The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 3(3):258\u2013263. doi: 10.1159/000323923", "journal-title": "J Innate Immun"}, {"issue": "6", "key": "1_CR105", "doi-asserted-by": "publisher", "first-page": "1071", "DOI": "10.1189/jlb.2A0414-206RR", "volume": "97", "author": "WC Wei", "year": "2015", "unstructured": "Wei WC, Liu CP, Yang WC, Shyur LF, Sheu JH, Chen SS, Yang NS (2015) Mammalian target of rapamycin complex 2 (mTORC2) regulates LPS-induced expression of IL-12 and IL-23 in human dendritic cells. J Leukoc Biol 97(6):1071\u20131080. doi: 10.1189/jlb.2A0414-206RR", "journal-title": "J Leukoc Biol"}, {"issue": "11", "key": "1_CR106", "doi-asserted-by": "publisher", "first-page": "1705", "DOI": "10.1517/14712598.7.11.1705", "volume": "7", "author": "JM Weiss", "year": "2007", "unstructured": "Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7(11):1705\u20131721. doi: 10.1517/14712598.7.11.1705", "journal-title": "Expert Opin Biol Ther"}, {"issue": "8", "key": "1_CR107", "doi-asserted-by": "crossref", "first-page": "1053", "DOI": "10.1093/intimm/13.8.1053", "volume": "13", "author": "AK Wesa", "year": "2001", "unstructured": "Wesa AK, Galy A (2001) IL-1 beta induces dendritic cells to produce IL-12. Int Immunol 13(8):1053\u20131061", "journal-title": "Int Immunol"}, {"issue": "2", "key": "1_CR108", "doi-asserted-by": "publisher", "first-page": "400", "DOI": "10.1006/bbrc.1999.0479", "volume": "257", "author": "K Yamamoto", "year": "1999", "unstructured": "Yamamoto K, Shibata F, Miura O, Kamiyama R, Hirosawa S, Miyasaka N (1999) Physical interaction between interleukin-12 receptor beta 2 subunit and Jak2 tyrosine kinase: Jak2 associates with cytoplasmic membrane-proximal region of interleukin-12 receptor beta 2 via amino-terminus. Biochem Biophys Res Commun 257(2):400\u2013404. doi: 10.1006/bbrc.1999.0479", "journal-title": "Biochem Biophys Res Commun"}, {"issue": "4", "key": "1_CR109", "doi-asserted-by": "publisher", "first-page": "1271", "DOI": "10.1172/JCI59806", "volume": "122", "author": "ZZ Yang", "year": "2012", "unstructured": "Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM (2012) IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122(4):1271\u20131282. doi: 10.1172/JCI59806", "journal-title": "J Clin Invest"}, {"issue": "3", "key": "1_CR110", "first-page": "1483", "volume": "161", "author": "T Yoshimoto", "year": "1998", "unstructured": "Yoshimoto T, Nagai N, Ohkusu K, Ueda H, Okamura H, Nakanishi K (1998) LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta\u00a0+\u00a0T cells. J Immunol 161(3):1483\u20131492", "journal-title": "J Immunol"}, {"issue": "4", "key": "1_CR111", "doi-asserted-by": "publisher", "first-page": "640", "DOI": "10.3889/oamjms.2015.106", "volume": "3", "author": "SS Youssef", "year": "2015", "unstructured": "Youssef SS, Mohammad MM, Ezz-El-Arab LR (2015) Clinical Significance of Serum IL-12 Level in Patients with Early Breast Carcinoma and Its Correlation with Other Tumor Markers. Open Access Maced J Med Sci 3(4):640\u2013644. doi: 10.3889/oamjms.2015.106", "journal-title": "Open Access Maced J Med Sci"}, {"issue": "21", "key": "1_CR112", "doi-asserted-by": "publisher", "first-page": "3362", "DOI": "10.1080/15384101.2015.1093703", "volume": "14", "author": "S Yu", "year": "2015", "unstructured": "Yu S, Jia L, Zhang Y, Zhong J, Yang B, Wu C (2015) IL-12 induced the generation of IL-21- and IFN-gamma-co-expressing poly-functional CD4+\u00a0T cells from human naive CD4+\u00a0T cells. Cell Cycle 14(21):3362\u20133372. doi: 10.1080/15384101.2015.1093703", "journal-title": "Cell Cycle"}, {"issue": "3", "key": "1_CR113", "doi-asserted-by": "publisher", "first-page": "176", "DOI": "10.3109/08977194.2012.678843", "volume": "30", "author": "AE Yuzhalin", "year": "2012", "unstructured": "Yuzhalin AE, Kutikhin AG (2012) Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors 30(3):176\u2013191. doi: 10.3109/08977194.2012.678843", "journal-title": "Growth Factors"}, {"issue": "6D", "key": "1_CR114", "first-page": "4493", "volume": "17", "author": "R Zagozdzon", "year": "1997", "unstructured": "Zagozdzon R, Stoklosa T, Golab J, Giermasz A, Dabrowska A, Lasek W, Jakobisiak M (1997) Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Res 17(6D):4493\u20134498", "journal-title": "Anticancer Res"}, {"issue": "2", "key": "1_CR115", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1097/00002371-199308000-00012", "volume": "14", "author": "HJ Zeh 3rd", "year": "1993", "unstructured": "Zeh HJ 3rd, Hurd S, Storkus WJ, Lotze MT (1993) Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother Emphasis Tumor Immunol 14(2):155\u2013161", "journal-title": "J Immunother Emphasis Tumor Immunol"}, {"issue": "5", "key": "1_CR116", "doi-asserted-by": "publisher", "first-page": "e19664", "DOI": "10.1371/journal.pone.0019664", "volume": "6", "author": "Y Zhang", "year": "2011", "unstructured": "Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Jia ZS, Moorman JP, Yao ZQ (2011) Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS ONE 6(5):e19664. doi: 10.1371/journal.pone.0019664", "journal-title": "PLoS ONE"}, {"issue": "7", "key": "1_CR117", "doi-asserted-by": "publisher", "first-page": "335", "DOI": "10.1089/dna.2008.0845", "volume": "28", "author": "B Zhao", "year": "2009", "unstructured": "Zhao B, Meng LQ, Huang HN, Pan Y, Xu QQ (2009) A novel functional polymorphism, 16974 A/C, in the interleukin-12-3\u2019 untranslated region is associated with risk of glioma. DNA Cell Biol 28(7):335\u2013341. doi: 10.1089/dna.2008.0845", "journal-title": "DNA Cell Biol"}, {"issue": "6", "key": "1_CR118", "doi-asserted-by": "crossref", "first-page": "2385", "DOI": "10.1128/MCB.24.6.2385-2396.2004", "volume": "24", "author": "L Zhou", "year": "2004", "unstructured": "Zhou L, Nazarian AA, Smale ST (2004) Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 24(6):2385\u20132396", "journal-title": "Mol Cell Biol"}, {"key": "1_CR119", "author": "XD Zhu", "year": "2013", "unstructured": "Zhu XD, Sun HC, Xu HX, Kong LQ, Chai ZT, Lu L, Zhang JB, Gao DM, Wang WQ, Zhang W et al (2013) Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. Angiogenesis. doi: 10.1007/s10456-013-9357-6", "journal-title": "Angiogenesis", "DOI": "10.1007/s10456-013-9357-6", "doi-asserted-by": "publisher"}, {"issue": "9", "key": "1_CR120", "doi-asserted-by": "crossref", "first-page": "6073", "DOI": "10.1074/jbc.272.9.6073", "volume": "272", "author": "J Zou", "year": "1997", "unstructured": "Zou J, Presky DH, Wu CY, Gubler U (1997) Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases. J Biol Chem 272(9):6073\u20136077", "journal-title": "J Biol Chem"}], "container-title": ["Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology", "SpringerBriefs in Immunology"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-46906-5_1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T23:32:34Z", "timestamp": 1498347154000}, "score": 26.273235, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319469058", "9783319469065"], "references-count": 120, "URL": "http://dx.doi.org/10.1007/978-3-319-46906-5_1", "relation": {"cites": []}, "ISSN": ["2194-2773", "2194-2781"], "issn-type": [{"value": "2194-2773", "type": "print"}, {"value": "2194-2781", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 4, 17]], "date-time": "2018-04-17T14:19:43Z", "timestamp": 1523974783507}, "publisher-location": "Cham", "reference-count": 115, "publisher": "Springer International Publishing", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-46906-5_3", "type": "book-chapter", "created": {"date-parts": [[2016, 9, 23]], "date-time": "2016-09-23T09:42:15Z", "timestamp": 1474623735000}, "page": "43-75", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Clinical Trials with IL-12 in Cancer Immunotherapy"], "prefix": "10.1007", "author": [{"given": "Witold", "family": "Lasek", "sequence": "first", "affiliation": []}, {"given": "Radoslaw", "family": "Zagozdzon", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 9, 24]]}, "reference": [{"key": "3_CR1", "unstructured": "Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM (2004) Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22 (14):2891\u2013900. doi: 10.1200/JCO.2004.10.045", "DOI": "10.1200/JCO.2004.10.045", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "3_CR2", "doi-asserted-by": "publisher", "first-page": "139", "DOI": "10.1007/s00005-007-0025-7", "volume": "55", "author": "HK Alexander", "year": "2007", "unstructured": "Alexander HK, Booy EP, Xiao W, Ezzati P, Baust H, Los M (2007) Selected technologies to control genes and their products for experimental and clinical purposes. Arch Immunol Ther Exp (Warsz) 55(3):139\u2013149. doi: 10.1007/s00005-007-0025-7", "journal-title": "Arch Immunol Ther Exp (Warsz)"}, {"issue": "3", "key": "3_CR3", "doi-asserted-by": "publisher", "first-page": "433", "DOI": "10.1016/j.ygyno.2014.03.571", "volume": "133", "author": "RD Alvarez", "year": "2014", "unstructured": "Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK (2014) A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol 133(3):433\u2013438. doi: 10.1016/j.ygyno.2014.03.571", "journal-title": "Gynecol Oncol"}, {"key": "3_CR4", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1186/2052-8426-2-27", "volume": "2", "author": "MH Amer", "year": "2014", "unstructured": "Amer MH (2014) Gene therapy for cancer: present status and future perspective. Mol Cell Ther 2:27. doi: 10.1186/2052-8426-2-27", "journal-title": "Mol Cell Ther"}, {"issue": "1", "key": "3_CR5", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1182/blood.V99.1.67", "volume": "99", "author": "SM Ansell", "year": "2002", "unstructured": "Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C (2002) Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-hodgkin lymphoma. Blood 99(1):67\u201374", "journal-title": "Blood"}, {"issue": "20 Pt 1", "key": "3_CR6", "doi-asserted-by": "publisher", "first-page": "6056", "DOI": "10.1158/1078-0432.CCR-06-1245", "volume": "12", "author": "SM Ansell", "year": "2006", "unstructured": "Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE (2006) Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin\u2019s lymphoma patients. Clin Cancer Res 12(20 Pt 1):6056\u20136063. doi: 10.1158/1078-0432.CCR-06-1245", "journal-title": "Clin Cancer Res"}, {"issue": "3", "key": "3_CR7", "doi-asserted-by": "publisher", "first-page": "360", "DOI": "10.1038/gt.2009.159", "volume": "17", "author": "K Anwer", "year": "2010", "unstructured": "Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17(3):360\u2013369. doi: 10.1038/gt.2009.159", "journal-title": "Gene Ther"}, {"key": "3_CR8", "author": "K Anwer", "year": "2013", "unstructured": "Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD (2013) Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. doi: 10.1016/j.ygyno.2013.07.081", "journal-title": "Gynecol Oncol", "DOI": "10.1016/j.ygyno.2013.07.081", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "3_CR9", "first-page": "409", "volume": "3", "author": "MB Atkins", "year": "1997", "unstructured": "Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3(3):409\u2013417", "journal-title": "Clin Cancer Res"}, {"key": "3_CR10", "unstructured": "Au BC, Liu Y, Huang J, Neller M, Arruda A, Rothe M, Paul G, Schambach A, Barber DL, Minden MD, Paige CJ, Medin J (2015) Pre-clinical preparation and validation of tumor cell-based IL-12 immunotherapy for acute myeloid leukemia. In: ASGCT 18th annual meeting, New Orleans, LA, p abstr. 413", "DOI": "10.1016/S1525-0016(16)34022-9", "doi-asserted-by": "crossref"}, {"issue": "7", "key": "3_CR11", "doi-asserted-by": "publisher", "first-page": "749", "DOI": "10.1097/CJI.0b013e3180de4ce8", "volume": "30", "author": "DE Avigan", "year": "2007", "unstructured": "Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30(7):749\u2013761. doi: 10.1097/CJI.0b013e3180de4ce8", "journal-title": "J Immunother"}, {"key": "3_CR12", "unstructured": "Avigan D, Rosenblatt J, Kufe D (2012) Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol 39(3):287\u2013295. doi: 10.1053/j.seminoncol.2012.02.003", "DOI": "10.1053/j.seminoncol.2012.02.003", "doi-asserted-by": "publisher"}, {"key": "3_CR13", "unstructured": "Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, Knott C, Lin F, Boyer JD, Draghia-Akli R, White CJ, Kim JJ, Weiner DB, Sardesai NY (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4(155):155ra138. doi: 10.1126/scitranslmed.3004414", "DOI": "10.1126/scitranslmed.3004414", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "3_CR14", "first-page": "75", "volume": "4", "author": "E Bajetta", "year": "1998", "unstructured": "Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4(1):75\u201385", "journal-title": "Clin Cancer Res"}, {"issue": "7", "key": "3_CR15", "doi-asserted-by": "publisher", "first-page": "1137", "DOI": "10.1007/s00262-013-1434-6", "volume": "62", "author": "JC Becker", "year": "2013", "unstructured": "Becker JC, Andersen MH, Schrama D, Thor Straten P (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62(7):1137\u20131148. doi: 10.1007/s00262-013-1434-6", "journal-title": "Cancer Immunol Immunother"}, {"issue": "11", "key": "3_CR16", "doi-asserted-by": "publisher", "first-page": "2983", "DOI": "10.1158/1535-7163.MCT-09-0820", "volume": "8", "author": "TS Bekaii-Saab", "year": "2009", "unstructured": "Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 8(11):2983\u20132991. doi: 10.1158/1535-7163.MCT-09-0820", "journal-title": "Mol Cancer Ther"}, {"key": "3_CR17", "unstructured": "Bhatia S, Iyer J, Ibrani D, Blom A, Byrd D, Parvathaneni U, Diep T, Le MH, Pierce RH, Heller R, Daud A, Nghiem P (2015) Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in merkel cell carcinoma: final results of a phase 2 study. In: European cancer congress 2015, p abstr. 504", "DOI": "10.1016/S0959-8049(16)30306-9", "doi-asserted-by": "crossref"}, {"issue": "8", "key": "3_CR18", "doi-asserted-by": "publisher", "first-page": "3383", "DOI": "10.1172/JCI68395", "volume": "123", "author": "BM Carreno", "year": "2013", "unstructured": "Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP (2013) IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 123(8):3383\u20133394. doi: 10.1172/JCI68395", "journal-title": "J Clin Invest"}, {"issue": "2", "key": "3_CR19", "doi-asserted-by": "publisher", "first-page": "108", "DOI": "10.1089/hum.2015.137", "volume": "27", "author": "M Cavazzana", "year": "2016", "unstructured": "Cavazzana M, Six E, Lagresle-Peyrou C, Andre-Schmutz I, Hacein-Bey-Abina S (2016) Gene therapy for X-linked severe combined immunodeficiency: where do we stand? Hum Gene Ther 27(2):108\u2013116. doi: 10.1089/hum.2015.137", "journal-title": "Hum Gene Ther"}, {"issue": "8", "key": "3_CR20", "doi-asserted-by": "publisher", "first-page": "1269", "DOI": "10.1007/s00262-012-1202-z", "volume": "61", "author": "M Chmielewski", "year": "2012", "unstructured": "Chmielewski M, Abken H (2012) CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother 61(8):1269\u20131277. doi: 10.1007/s00262-012-1202-z", "journal-title": "Cancer Immunol Immunother"}, {"issue": "1", "key": "3_CR21", "doi-asserted-by": "publisher", "first-page": "83", "DOI": "10.1111/imr.12125", "volume": "257", "author": "M Chmielewski", "year": "2014", "unstructured": "Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257(1):83\u201390. doi: 10.1111/imr.12125", "journal-title": "Immunol Rev"}, {"issue": "5238", "key": "3_CR22", "doi-asserted-by": "crossref", "first-page": "908", "DOI": "10.1126/science.270.5238.908a", "volume": "270", "author": "J Cohen", "year": "1995", "unstructured": "Cohen J (1995) IL-12 deaths: explanation and a puzzle. Science 270(5238):908", "journal-title": "Science"}, {"issue": "1", "key": "3_CR23", "doi-asserted-by": "publisher", "first-page": "62", "DOI": "10.1089/jir.2015.0049", "volume": "36", "author": "CA Cohen", "year": "2016", "unstructured": "Cohen CA, Shea AA, Heffron CL, Schmelz EM, Roberts PC (2016) Interleukin-12 immunomodulation delays the onset of lethal peritoneal disease of ovarian cancer. J Interferon Cytokine Res 36(1):62\u201373. doi: 10.1089/jir.2015.0049", "journal-title": "J Interferon Cytokine Res"}, {"issue": "11", "key": "3_CR24", "first-page": "2531", "volume": "56", "author": "MP Colombo", "year": "1996", "unstructured": "Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, Stoppacciaro A (1996) Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56(11):2531\u20132534", "journal-title": "Cancer Res"}, {"issue": "15", "key": "3_CR25", "doi-asserted-by": "publisher", "first-page": "1703", "DOI": "10.1200/JCO.2014.60.3449", "volume": "33", "author": "KJ Curran", "year": "2015", "unstructured": "Curran KJ, Brentjens RJ (2015) Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol 33(15):1703\u20131706. doi: 10.1200/JCO.2014.60.3449", "journal-title": "J Clin Oncol"}, {"issue": "36", "key": "3_CR26", "doi-asserted-by": "publisher", "first-page": "5896", "DOI": "10.1200/JCO.2007.15.6794", "volume": "26", "author": "AI Daud", "year": "2008", "unstructured": "Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26(36):5896\u20135903. doi: 10.1200/JCO.2007.15.6794", "journal-title": "J Clin Oncol"}, {"key": "3_CR27", "unstructured": "Daud A, Algazi AP, Ashworth MT, Fong L, Lewis J, Chan SE, Buljan M, Molina MA, Takamura KT, Diep TT, Heller R, Pierce RH (2014) Bhatia S systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma. In: 2014 ASCO annual meeting, Chicago, IL, p abstr. 9025"}, {"issue": "16", "key": "3_CR28", "doi-asserted-by": "publisher", "first-page": "4677", "DOI": "10.1158/1078-0432.CCR-07-0776", "volume": "13", "author": "M Vecchio Del", "year": "2007", "unstructured": "Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13(16):4677\u20134685. doi: 10.1158/1078-0432.CCR-07-0776", "journal-title": "Clin Cancer Res"}, {"issue": "10", "key": "3_CR29", "doi-asserted-by": "publisher", "first-page": "2246", "DOI": "10.4161/hv.24702", "volume": "9", "author": "MC Diehl", "year": "2013", "unstructured": "Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML (2013) Tolerability of intramuscular and intradermal delivery by CELLECTRA(R) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother 9(10):2246\u20132252. doi: 10.4161/hv.24702", "journal-title": "Hum Vaccin Immunother"}, {"issue": "17", "key": "3_CR30", "doi-asserted-by": "publisher", "first-page": "2152", "DOI": "10.1200/JCO.2012.46.6441", "volume": "31", "author": "ME Dudley", "year": "2013", "unstructured": "Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA (2013) Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31(17):2152\u20132159. doi: 10.1200/JCO.2012.46.6441", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "3_CR31", "first-page": "4263", "volume": "94", "author": "K Dunussi-Joannopoulos", "year": "1999", "unstructured": "Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP (1999) Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood 94(12):4263\u20134273", "journal-title": "Blood"}, {"issue": "5", "key": "3_CR32", "doi-asserted-by": "publisher", "first-page": "807", "DOI": "10.1016/j.jaad.2006.06.038", "volume": "55", "author": "M Duvic", "year": "2006", "unstructured": "Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberte RJ, Ryan JL, Zonno K, Rook AH (2006) A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55(5):807\u2013813. doi: 10.1016/j.jaad.2006.06.038", "journal-title": "J Am Acad Dermatol"}, {"issue": "34", "key": "3_CR33", "doi-asserted-by": "publisher", "first-page": "8835", "DOI": "10.1200/JCO.2005.02.1691", "volume": "23", "author": "CF Eisenbeis", "year": "2005", "unstructured": "Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE (2005) Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 23(34):8835\u20138844. doi: 10.1200/JCO.2005.02.1691", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "3_CR34", "doi-asserted-by": "publisher", "first-page": "1869", "DOI": "10.18632/oncotarget.1853", "volume": "5", "author": "J Fallon", "year": "2014", "unstructured": "Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW (2014) The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget 5(7):1869\u20131884. doi: 10.18632/oncotarget.1853", "journal-title": "Oncotarget"}, {"key": "3_CR35", "unstructured": "Felzmann T, Buchroithner J, Marosi C, Nowosielsky M, Oberndorfer S, Ruckser R, R\u00f6ssler K, Azizi A, von Campe G, Karin Bordihn K (2013) First interim analysis of a randomized study to evaluate safety and efficacy of individualized dendritic cell-based cancer immune therapy for glioblastoma multiforme. In: AACR 104th annual meeting, Washington, DC, p abstr. 4658"}, {"issue": "1\u20133", "key": "3_CR36", "doi-asserted-by": "publisher", "first-page": "288", "DOI": "10.1016/j.jconrel.2005.09.024", "volume": "109", "author": "JG Fewell", "year": "2005", "unstructured": "Fewell JG, Matar M, Slobodkin G, Han SO, Rice J, Hovanes B, Lewis DH, Anwer K (2005) Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J Control Release 109(1\u20133):288\u2013298. doi: 10.1016/j.jconrel.2005.09.024", "journal-title": "J Control Release"}, {"issue": "8", "key": "3_CR37", "doi-asserted-by": "publisher", "first-page": "718", "DOI": "10.1002/jgm.1356", "volume": "11", "author": "JG Fewell", "year": "2009", "unstructured": "Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, Worker M, Lewis DH, Anwer K (2009) Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med 11(8):718\u2013728. doi: 10.1002/jgm.1356", "journal-title": "J Gene Med"}, {"key": "3_CR38", "author": "JG Fewell", "year": "2016", "unstructured": "Fewell JG, Matar MM, Rice JK, McClure D, Brunhoeber E, Sparks J, Greenleaf S, Smith K, Anwer K (2016) Interleukin-12 gene therapy in combination with bevacizumab and pegylated liposomal doxorubicin for treatment of disseminated ovarian cancer. Paper presented at the AACR annual meeting, New Orleans, LA", "volume-title": "Interleukin-12 gene therapy in combination with bevacizumab and pegylated liposomal doxorubicin for treatment of disseminated ovarian cancer"}, {"issue": "9", "key": "3_CR39", "doi-asserted-by": "publisher", "first-page": "1971", "DOI": "10.1002/ijc.27755", "volume": "132", "author": "MF Fransen", "year": "2013", "unstructured": "Fransen MF, Arens R, Melief CJ (2013) Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. Int J Cancer 132(9):1971\u20131976. doi: 10.1002/ijc.27755", "journal-title": "Int J Cancer"}, {"issue": "51", "key": "3_CR40", "doi-asserted-by": "publisher", "first-page": "7393", "DOI": "10.1016/j.vaccine.2015.08.096", "volume": "33", "author": "AB Frey", "year": "2015", "unstructured": "Frey AB (2015) Suppression of T cell responses in the tumor microenvironment. Vaccine 33(51):7393\u20137400. doi: 10.1016/j.vaccine.2015.08.096", "journal-title": "Vaccine"}, {"issue": "12", "key": "3_CR41", "doi-asserted-by": "publisher", "first-page": "1131", "DOI": "10.1038/gt.2013.40", "volume": "20", "author": "SO Freytag", "year": "2013", "unstructured": "Freytag SO, Barton KN, Zhang Y (2013) Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther 20(12):1131\u20131139. doi: 10.1038/gt.2013.40", "journal-title": "Gene Ther"}, {"issue": "2", "key": "3_CR42", "doi-asserted-by": "publisher", "first-page": "268", "DOI": "10.1016/j.ijrobp.2014.02.034", "volume": "89", "author": "SO Freytag", "year": "2014", "unstructured": "Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, Levin K, Kim JH, Peabody J, Siddiqui F, Barton K, Pegg J, Zhang Y, Cheng J, Oja-Tebbe N, Bourgeois R, Gupta N, Lane Z, Rodriguez R, DeWeese T, Movsas B (2014) Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 89(2):268\u2013276. doi: 10.1016/j.ijrobp.2014.02.034", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"issue": "4", "key": "3_CR43", "doi-asserted-by": "publisher", "first-page": "253", "DOI": "10.1038/nri3175", "volume": "12", "author": "DI Gabrilovich", "year": "2012", "unstructured": "Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253\u2013268. doi: 10.1038/nri3175", "journal-title": "Nat Rev Immunol"}, {"issue": "3 Suppl", "key": "3_CR44", "first-page": "895s", "volume": "7", "author": "TF Gajewski", "year": "2001", "unstructured": "Gajewski TF, Fallarino F, Ashikari A, Sherman M (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7(3 Suppl):895s\u2013901s", "journal-title": "Clin Cancer Res"}, {"key": "3_CR45", "doi-asserted-by": "publisher", "first-page": "31", "DOI": "10.1186/1756-8722-7-31", "volume": "7", "author": "Z Gluzman-Poltorak", "year": "2014", "unstructured": "Gluzman-Poltorak Z, Mendonca SR, Vainstein V, Kha H, Basile LA (2014) Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J Hematol Oncol 7:31. doi: 10.1186/1756-8722-7-31", "journal-title": "J Hematol Oncol"}, {"issue": "1", "key": "3_CR46", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1186/2162-3619-3-11", "volume": "3", "author": "MS Gokhale", "year": "2014", "unstructured": "Gokhale MS, Vainstein V, Tom J, Thomas S, Lawrence CE, Gluzman-Poltorak Z, Siebers N, Basile LA (2014) Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Exp Hematol Oncol 3(1):11. doi: 10.1186/2162-3619-3-11", "journal-title": "Exp Hematol Oncol"}, {"issue": "5", "key": "3_CR47", "first-page": "1678", "volume": "6", "author": "JA Gollob", "year": "2000", "unstructured": "Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6(5):1678\u20131692", "journal-title": "Clin Cancer Res"}, {"issue": "13", "key": "3_CR48", "doi-asserted-by": "publisher", "first-page": "2564", "DOI": "10.1200/JCO.2003.12.119", "volume": "21", "author": "JA Gollob", "year": "2003", "unstructured": "Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB (2003) Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21(13):2564\u20132573. doi: 10.1200/JCO.2003.12.119", "journal-title": "J Clin Oncol"}, {"issue": "1", "key": "3_CR49", "doi-asserted-by": "publisher", "first-page": "147", "DOI": "10.1007/s40265-015-0522-7", "volume": "76", "author": "SL Greig", "year": "2016", "unstructured": "Greig SL (2016) Talimogene laherparepvec: first global approval. Drugs 76(1):147\u2013154. doi: 10.1007/s40265-015-0522-7", "journal-title": "Drugs"}, {"issue": "16", "key": "3_CR50", "doi-asserted-by": "publisher", "first-page": "1509", "DOI": "10.1056/NEJMoa1215134", "volume": "368", "author": "SA Grupp", "year": "2013", "unstructured": "Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518. doi: 10.1056/NEJMoa1215134", "journal-title": "N Engl J Med"}, {"issue": "1", "key": "3_CR51", "doi-asserted-by": "crossref", "first-page": "28", "DOI": "10.1046/j.1365-2249.2000.01112.x", "volume": "119", "author": "N Haicheur", "year": "2000", "unstructured": "Haicheur N, Escudier B, Dorval T, Negrier S, De Mulder PH, Dupuy JM, Novick D, Guillot T, Wolf S, Pouillart P, Fridman WH, Tartour E (2000) Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 119(1):28\u201337", "journal-title": "Clin Exp Immunol"}, {"issue": "1", "key": "3_CR52", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1158/1078-0432.CCR-06-1450", "volume": "13", "author": "O Hamid", "year": "2007", "unstructured": "Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS (2007) Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13(1):215\u2013222. doi: 10.1158/1078-0432.CCR-06-1450", "journal-title": "Clin Cancer Res"}, {"issue": "5", "key": "3_CR53", "doi-asserted-by": "publisher", "first-page": "1503", "DOI": "10.1158/1078-0432.CCR-06-1603", "volume": "13", "author": "L Hansson", "year": "2007", "unstructured": "Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H (2007) Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 13(5):1503\u20131510. doi: 10.1158/1078-0432.CCR-06-1603", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "3_CR54", "doi-asserted-by": "publisher", "first-page": "35", "DOI": "10.1089/hum.2005.16.35", "volume": "16", "author": "L Heinzerling", "year": "2005", "unstructured": "Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16(1):35\u201348. doi: 10.1089/hum.2005.16.35", "journal-title": "Hum Gene Ther"}, {"issue": "1", "key": "3_CR55", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1111/j.1365-2249.2006.03029.x", "volume": "144", "author": "S Homma", "year": "2006", "unstructured": "Homma S, Sagawa Y, Ito M, Ohno T, Toda G (2006) Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol 144(1):41\u201347. doi: 10.1111/j.1365-2249.2006.03029.x", "journal-title": "Clin Exp Immunol"}, {"issue": "9", "key": "3_CR56", "doi-asserted-by": "crossref", "first-page": "576", "DOI": "10.1093/jnci/88.9.576", "volume": "88", "author": "S Jenks", "year": "1996", "unstructured": "Jenks S (1996) After initial setback, IL-12 regaining popularity. J Natl Cancer Inst 88(9):576\u2013577", "journal-title": "J Natl Cancer Inst"}, {"issue": "5", "key": "3_CR57", "doi-asserted-by": "publisher", "first-page": "818", "DOI": "10.1093/infdis/jit236", "volume": "208", "author": "SA Kalams", "year": "2013", "unstructured": "Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB, Network NHVT (2013) Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 208(5):818\u2013829. doi: 10.1093/infdis/jit236", "journal-title": "J Infect Dis"}, {"issue": "9", "key": "3_CR58", "doi-asserted-by": "publisher", "first-page": "642", "DOI": "10.1038/nrd4663", "volume": "14", "author": "HL Kaufman", "year": "2015", "unstructured": "Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14(9):642\u2013662. doi: 10.1038/nrd4663", "journal-title": "Nat Rev Drug Discov"}, {"issue": "7", "key": "3_CR59", "doi-asserted-by": "publisher", "first-page": "1369", "DOI": "10.1038/mt.2013.58", "volume": "21", "author": "SP Kerkar", "year": "2013", "unstructured": "Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP (2013) Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21(7):1369\u20131377. doi: 10.1038/mt.2013.58", "journal-title": "Mol Ther"}, {"issue": "7", "key": "3_CR60", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1007/s002620100205", "volume": "50", "author": "T Kikuchi", "year": "2001", "unstructured": "Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50(7):337\u2013344", "journal-title": "Cancer Immunol Immunother"}, {"issue": "6", "key": "3_CR61", "doi-asserted-by": "crossref", "first-page": "452", "DOI": "10.1097/00002371-200411000-00005", "volume": "27", "author": "T Kikuchi", "year": "2004", "unstructured": "Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27(6):452\u2013459", "journal-title": "J Immunother"}, {"issue": "4", "key": "3_CR62", "doi-asserted-by": "publisher", "first-page": "798", "DOI": "10.1172/JCI24826", "volume": "115", "author": "EJ Kim", "year": "2005", "unstructured": "Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH (2005) Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115(4):798\u2013812. doi: 10.1172/JCI24826", "journal-title": "J Clin Invest"}, {"key": "3_CR63", "doi-asserted-by": "publisher", "first-page": "102", "DOI": "10.1186/s12967-015-0460-x", "volume": "13", "author": "M Koneru", "year": "2015", "unstructured": "Koneru M, O\u2019Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ (2015) A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 13:102. doi: 10.1186/s12967-015-0460-x", "journal-title": "J Transl Med"}, {"issue": "5", "key": "3_CR64", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1016/0167-5699(96)30011-X", "volume": "17", "author": "AG Lamont", "year": "1996", "unstructured": "Lamont AG, Adorini L (1996) IL-12: a key cytokine in immune regulation. Immunol Today 17(5):214\u2013217", "journal-title": "Immunol Today"}, {"issue": "5", "key": "3_CR65", "doi-asserted-by": "publisher", "first-page": "419", "DOI": "10.1007/s00262-014-1523-1", "volume": "63", "author": "W Lasek", "year": "2014", "unstructured": "Lasek W, Zagozdzon R, Jakobisiak M (2014) Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 63(5):419\u2013435. doi: 10.1007/s00262-014-1523-1", "journal-title": "Cancer Immunol Immunother"}, {"key": "3_CR66", "author": "FM Lebel", "year": "2016", "unstructured": "Lebel FM, Berrett JA, Chiocca A, Yu J, Vincas Lukas R, Nagpal S, Kumthekar P, Krishnan S, Cooper LJN (2016) Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12\u00a0+ oral veledimex in subjects with recurrent or progressive glioma. Paper presented at the ASCO annual meeting, Chicago, IL", "volume-title": "Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12+ oral veledimex in subjects with recurrent or progressive glioma"}, {"issue": "18", "key": "3_CR67", "doi-asserted-by": "crossref", "first-page": "3836", "DOI": "10.1200/JCO.2001.19.18.3836", "volume": "19", "author": "P Lee", "year": "2001", "unstructured": "Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J (2001) Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19(18):3836\u20133847", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "3_CR68", "first-page": "3686", "volume": "8", "author": "R Lenzi", "year": "2002", "unstructured": "Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS (2002) Phase I study of intraperitoneal recombinant human interleukin 12 in patients with mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8(12):3686\u20133695", "journal-title": "Clin Cancer Res"}, {"key": "3_CR69", "doi-asserted-by": "publisher", "first-page": "66", "DOI": "10.1186/1479-5876-5-66", "volume": "5", "author": "R Lenzi", "year": "2007", "unstructured": "Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS (2007) Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1\u00a0cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5:66. doi: 10.1186/1479-5876-5-66", "journal-title": "J Transl Med"}, {"issue": "7", "key": "3_CR70", "first-page": "2541", "volume": "90", "author": "JP Leonard", "year": "1997", "unstructured": "Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90(7):2541\u20132548", "journal-title": "Blood"}, {"key": "3_CR71", "unstructured": "Linette GP, Hamid O, Whitman ED, Nemunaitis JJ, Chesney J, Agarwala SS, Starodub A, John A Barrett JA, Marsh A, Martell LA, Cho A, Reed TD, Youssoufian H, Vergara-Silva A (2013) A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma. In: 2013 ASCO annual meeting, Chicago, IL, p abstr. 3022"}, {"issue": "6", "key": "3_CR72", "doi-asserted-by": "publisher", "first-page": "e218", "DOI": "10.1016/S1470-2045(12)70582-X", "volume": "14", "author": "BE Lippitz", "year": "2013", "unstructured": "Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14(6):e218\u2013e228. doi: 10.1016/S1470-2045(12)70582-X", "journal-title": "Lancet Oncol"}, {"issue": "12", "key": "3_CR73", "doi-asserted-by": "publisher", "first-page": "4653", "DOI": "10.1182/blood-2002-11-3589", "volume": "101", "author": "RF Little", "year": "2003", "unstructured": "Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH (2003) Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101(12):4653\u20134659. doi: 10.1182/blood-2002-11-3589", "journal-title": "Blood"}, {"issue": "12", "key": "3_CR74", "doi-asserted-by": "publisher", "first-page": "4650", "DOI": "10.1182/blood-2005-11-4455", "volume": "107", "author": "RF Little", "year": "2006", "unstructured": "Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R (2006) Activity of subcutaneous interleukin-12 in AIDS-related kaposi sarcoma. Blood 107(12):4650\u20134657. doi: 10.1182/blood-2005-11-4455", "journal-title": "Blood"}, {"issue": "13", "key": "3_CR75", "doi-asserted-by": "publisher", "first-page": "4165", "DOI": "10.1182/blood-2007-06-097568", "volume": "110", "author": "RF Little", "year": "2007", "unstructured": "Little RF, Aleman K, Kumar P, Wyvill KM, Pluda JM, Read-Connole E, Wang V, Pittaluga S, Catanzaro AT, Steinberg SM, Yarchoan R (2007) Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 110(13):4165\u20134171. doi: 10.1182/blood-2007-06-097568", "journal-title": "Blood"}, {"issue": "6", "key": "3_CR76", "doi-asserted-by": "publisher", "first-page": "279", "DOI": "10.1016/j.blre.2012.09.004", "volume": "26", "author": "MA Lunning", "year": "2012", "unstructured": "Lunning MA, Vose JM (2012) Management of indolent lymphoma: where are we now and where are we going. Blood Rev 26(6):279\u2013288. doi: 10.1016/j.blre.2012.09.004", "journal-title": "Blood Rev"}, {"issue": "8", "key": "3_CR77", "doi-asserted-by": "publisher", "first-page": "717", "DOI": "10.1038/sj.cgt.7701064", "volume": "14", "author": "DM Mahvi", "year": "2007", "unstructured": "Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P (2007) Intratumoral injection of IL-12 plasmid DNA\u2013results of a phase I/IB clinical trial. Cancer Gene Ther 14(8):717\u2013723. doi: 10.1038/sj.cgt.7701064", "journal-title": "Cancer Gene Ther"}, {"issue": "10", "key": "3_CR78", "doi-asserted-by": "publisher", "first-page": "2329", "DOI": "10.1158/1078-0432.CCR-16-0224", "volume": "22", "author": "M Mandai", "year": "2016", "unstructured": "Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I (2016) Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res 22(10):2329\u20132334. doi: 10.1158/1078-0432.CCR-16-0224", "journal-title": "Clin Cancer Res"}, {"issue": "12", "key": "3_CR79", "doi-asserted-by": "crossref", "first-page": "1737", "DOI": "10.1097/01.aids.0000131385.60974.b9", "volume": "18", "author": "L Martin-Carbonero", "year": "2004", "unstructured": "Martin-Carbonero L, Barrios A, Saballs P, Sirera G, Santos J, Palacios R, Valencia ME, Alegre M, Podzamczer D, Gonzalez-Lahoz J, Caelyx KSSG (2004) Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi\u2019s sarcoma. AIDS 18(12):1737\u20131740", "journal-title": "AIDS"}, {"issue": "26", "key": "3_CR80", "doi-asserted-by": "publisher", "first-page": "4017", "DOI": "10.1182/blood-2014-12-580068", "volume": "125", "author": "SL Maude", "year": "2015", "unstructured": "Maude SL, Teachey DT, Porter DL, Grupp SA (2015) CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125(26):4017\u20134023. doi: 10.1182/blood-2014-12-580068", "journal-title": "Blood"}, {"issue": "5", "key": "3_CR81", "first-page": "1183", "volume": "4", "author": "RJ Motzer", "year": "1998", "unstructured": "Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4(5):1183\u20131191", "journal-title": "Clin Cancer Res"}, {"issue": "4", "key": "3_CR82", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1089/107999001750169934", "volume": "21", "author": "RJ Motzer", "year": "2001", "unstructured": "Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM (2001) Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 21(4):257\u2013263. doi: 10.1089/107999001750169934", "journal-title": "J Interferon Cytokine Res"}, {"key": "3_CR83", "unstructured": "Nemunaitis JJ, Linette GP, Haythem A, Lebel F, Barrett JA, Reed T, Krishnan S, Lewis J (2014) Ad-RTS-hIL-12+ veledimex regulation of IL-12 expression in advanced breast cancer (BC) and melanoma patients. In: Tumor immunology and immunotherapy: a new chapter, Orlando, FL, p abstr. B11"}, {"issue": "6", "key": "3_CR84", "doi-asserted-by": "publisher", "first-page": "e0129954", "DOI": "10.1371/journal.pone.0129954", "volume": "10", "author": "M Paoloni", "year": "2015", "unstructured": "Paoloni M, Mazcko C, Selting K, Lana S, Barber L, Phillips J, Skorupski K, Vail D, Wilson H, Biller B, Avery A, Kiupel M, LeBlanc A, Bernhardt A, Brunkhorst B, Tighe R, Khanna C (2015) Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma. PLoS ONE 10(6):e0129954. doi: 10.1371/journal.pone.0129954", "journal-title": "PLoS ONE"}, {"issue": "15", "key": "3_CR85", "doi-asserted-by": "publisher", "first-page": "5027", "DOI": "10.1158/1078-0432.CCR-04-0265", "volume": "10", "author": "R Parihar", "year": "2004", "unstructured": "Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd (2004) A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 10(15):5027\u20135037. doi: 10.1158/1078-0432.CCR-04-0265", "journal-title": "Clin Cancer Res"}, {"issue": "11\u201312", "key": "3_CR86", "doi-asserted-by": "publisher", "first-page": "583", "DOI": "10.1016/j.drudis.2012.01.007", "volume": "17", "author": "N Pasche", "year": "2012", "unstructured": "Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17(11\u201312):583\u2013590. doi: 10.1016/j.drudis.2012.01.007", "journal-title": "Drug Discov Today"}, {"issue": "12", "key": "3_CR87", "doi-asserted-by": "publisher", "first-page": "2342", "DOI": "10.1200/JCO.2003.12.144", "volume": "21", "author": "AC Peterson", "year": "2003", "unstructured": "Peterson AC, Harlin H, Gajewski TF (2003) Immunization with melan-a peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21(12):2342\u20132348. doi: 10.1200/JCO.2003.12.144", "journal-title": "J Clin Oncol"}, {"issue": "8", "key": "3_CR88", "doi-asserted-by": "publisher", "first-page": "725", "DOI": "10.1056/NEJMoa1103849", "volume": "365", "author": "DL Porter", "year": "2011", "unstructured": "Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725\u2013733. doi: 10.1056/NEJMoa1103849", "journal-title": "N Engl J Med"}, {"issue": "12", "key": "3_CR89", "first-page": "3983", "volume": "5", "author": "JE Portielje", "year": "1999", "unstructured": "Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5(12):3983\u20133989", "journal-title": "Clin Cancer Res"}, {"issue": "3", "key": "3_CR90", "doi-asserted-by": "publisher", "first-page": "133", "DOI": "10.1007/s00262-002-0356-5", "volume": "52", "author": "JE Portielje", "year": "2003", "unstructured": "Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH (2003a) IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52(3):133\u2013144. doi: 10.1007/s00262-002-0356-5", "journal-title": "Cancer Immunol Immunother"}, {"issue": "1", "key": "3_CR91", "first-page": "76", "volume": "9", "author": "JE Portielje", "year": "2003", "unstructured": "Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW (2003b) Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 9(1):76\u201383", "journal-title": "Clin Cancer Res"}, {"issue": "4", "key": "3_CR92", "doi-asserted-by": "publisher", "first-page": "269", "DOI": "10.1038/nri3191", "volume": "12", "author": "NP Restifo", "year": "2012", "unstructured": "Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269\u2013281. doi: 10.1038/nri3191", "journal-title": "Nat Rev Immunol"}, {"issue": "1", "key": "3_CR93", "first-page": "9", "volume": "5", "author": "MJ Robertson", "year": "1999", "unstructured": "Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5(1):9\u201316", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "3_CR94", "first-page": "3383", "volume": "8", "author": "MJ Robertson", "year": "2002", "unstructured": "Robertson MJ, Pelloso D, Abonour R, Hromas RA, Nelson RP Jr, Wood L, Cornetta K (2002) Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin Cancer Res 8(11):3383\u20133393", "journal-title": "Clin Cancer Res"}, {"issue": "3", "key": "3_CR95", "first-page": "1491", "volume": "154", "author": "AH Rook", "year": "1995", "unstructured": "Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf SF, Singh A, Trinchieri G, Lessin SR (1995) IL-12 reverses cytokine and immune abnormalities in sezary syndrome. J Immunol 154(3):1491\u20131498", "journal-title": "J Immunol"}, {"issue": "3", "key": "3_CR96", "first-page": "902", "volume": "94", "author": "AH Rook", "year": "1999", "unstructured": "Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94(3):902\u2013908", "journal-title": "Blood"}, {"issue": "4", "key": "3_CR97", "doi-asserted-by": "publisher", "first-page": "299", "DOI": "10.1038/nrc2355", "volume": "8", "author": "SA Rosenberg", "year": "2008", "unstructured": "Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299\u2013308. doi: 10.1038/nrc2355", "journal-title": "Nat Rev Cancer"}, {"issue": "13", "key": "3_CR98", "doi-asserted-by": "publisher", "first-page": "4550", "DOI": "10.1158/1078-0432.CCR-11-0116", "volume": "17", "author": "SA Rosenberg", "year": "2011", "unstructured": "Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550\u20134557. doi: 10.1158/1078-0432.CCR-11-0116", "journal-title": "Clin Cancer Res"}, {"issue": "2", "key": "3_CR99", "doi-asserted-by": "publisher", "first-page": "393", "DOI": "10.1182/blood-2010-04-277137", "volume": "117", "author": "J Rosenblatt", "year": "2011", "unstructured": "Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D (2011) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117(2):393\u2013402. doi: 10.1182/blood-2010-04-277137", "journal-title": "Blood"}, {"issue": "13", "key": "3_CR100", "doi-asserted-by": "publisher", "first-page": "3640", "DOI": "10.1158/1078-0432.CCR-13-0282", "volume": "19", "author": "J Rosenblatt", "year": "2013", "unstructured": "Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D (2013) Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 19(13):3640\u20133648. doi: 10.1158/1078-0432.CCR-13-0282", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "3_CR101", "doi-asserted-by": "publisher", "first-page": "16", "DOI": "10.1089/humc.2013.201", "volume": "25", "author": "JC Roth", "year": "2014", "unstructured": "Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, Gillespie GY, Whitley RJ, Markert JM (2014) Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates. Hum Gene Ther Clin Dev 25(1):16\u201327. doi: 10.1089/humc.2013.201", "journal-title": "Hum Gene Ther Clin Dev"}, {"issue": "7", "key": "3_CR102", "doi-asserted-by": "publisher", "first-page": "1998", "DOI": "10.1158/1078-0432.CCR-10-2490", "volume": "17", "author": "SM Rudman", "year": "2011", "unstructured": "Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF (2011) A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res 17(7):1998\u20132005. doi: 10.1158/1078-0432.CCR-10-2490", "journal-title": "Clin Cancer Res"}, {"key": "3_CR103", "unstructured": "Schwartzentruber DJ, Kirkwood JM, Guarino MJ, Richards JM, Hamid O, O\u2019Day S, Nemunaitis JJ, Talmadge JE, Chada S, Menander KB, Shafer-Weaver K, Senesac JH, Thornton MO, Lewis JJ, Herberma RB (2011) Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand. In: 2011 ASCO annual meeting, J Clin Oncol, p abstr. 2540", "DOI": "10.1200/jco.2011.29.15_suppl.2540", "doi-asserted-by": "crossref"}, {"issue": "2", "key": "3_CR104", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1007/s40265-014-0339-9", "volume": "75", "author": "LJ Scott", "year": "2015", "unstructured": "Scott LJ (2015) Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs 75(2):175\u2013182. doi: 10.1007/s40265-014-0339-9", "journal-title": "Drugs"}, {"issue": "5", "key": "3_CR105", "doi-asserted-by": "publisher", "first-page": "488", "DOI": "10.1038/gt.2010.170", "volume": "18", "author": "SH Seo", "year": "2011", "unstructured": "Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS, Sung YC (2011) The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 18(5):488\u2013495. doi: 10.1038/gt.2010.170", "journal-title": "Gene Ther"}, {"key": "3_CR106", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1016/j.addr.2015.10.014", "volume": "98", "author": "PY Teo", "year": "2016", "unstructured": "Teo PY, Cheng W, Hedrick JL, Yang YY (2016) Co-delivery of drugs and plasmid DNA for cancer therapy. Adv Drug Deliv Rev 98:41\u201363. doi: 10.1016/j.addr.2015.10.014", "journal-title": "Adv Drug Deliv Rev"}, {"key": "3_CR107", "unstructured": "Thaker PH, Brady WE, Bradley WH, Anwer K, Alvarez RD (2015) Phase I study of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with pegylated liposomal doxorubicin in recurrent or persistent epithelial ovarian, Fallopian tube, or primary peritoneal cancer patients: an NRG/GOG study. In: 2015 ASCO annual meeting, J Clin Oncol, p abstr. 5541"}, {"key": "3_CR108", "doi-asserted-by": "publisher", "first-page": "e505", "DOI": "10.14694/EDBK_159087", "volume": "35", "author": "AC Akkooi van", "year": "2016", "unstructured": "van Akkooi AC, Atkins MB, Agarwala SS, Lorigan P (2016) Surgical management and adjuvant therapy for high-risk and metastatic melanoma. Am Soc Clin Oncol Educ Book 35:e505\u2013e514. doi: 10.14694/EDBK_159087", "journal-title": "Am Soc Clin Oncol Educ Book"}, {"key": "3_CR109", "unstructured": "Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, Burk R, Ho G, Kadish AS, Eastern Cooperative Oncology G (2004) A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. eastern cooperative oncology group study E1E96. Gynecol Oncol 92(3):957\u2013964. doi: 10.1016/j.ygyno.2003.12.022", "DOI": "10.1016/j.ygyno.2003.12.022", "doi-asserted-by": "publisher"}, {"issue": "11", "key": "3_CR110", "doi-asserted-by": "publisher", "first-page": "1705", "DOI": "10.1517/14712598.7.11.1705", "volume": "7", "author": "JM Weiss", "year": "2007", "unstructured": "Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7(11):1705\u20131721. doi: 10.1517/14712598.7.11.1705", "journal-title": "Expert Opin Biol Ther"}, {"key": "3_CR111", "unstructured": "Yang Z, Aggarval C, Cohen R, Morrow M, Bauml J, Weinstein G, Boyer J (2015) Immunotherapy with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in human papillomaviruas (HPV)-associated head and neck squamous cell carcinoma (HNSCCa). In: ESMO symposium on immuno-oncology, Lausanne, Switzerland, Ann Oncol, p abstr. 1PD"}, {"issue": "8", "key": "3_CR112", "doi-asserted-by": "publisher", "first-page": "541", "DOI": "10.1038/nrg3763", "volume": "15", "author": "H Yin", "year": "2014", "unstructured": "Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15(8):541\u2013555. doi: 10.1038/nrg3763", "journal-title": "Nat Rev Genet"}, {"issue": "16", "key": "3_CR113", "doi-asserted-by": "publisher", "first-page": "5432", "DOI": "10.1158/1078-0432.CCR-04-0540", "volume": "10", "author": "A Younes", "year": "2004", "unstructured": "Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F (2004) Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-hodgkin\u2019s lymphoma and hodgkin\u2019s disease. Clin Cancer Res 10(16):5432\u20135438. doi: 10.1158/1078-0432.CCR-04-0540", "journal-title": "Clin Cancer Res"}, {"issue": "3", "key": "3_CR114", "doi-asserted-by": "publisher", "first-page": "176", "DOI": "10.3109/08977194.2012.678843", "volume": "30", "author": "AE Yuzhalin", "year": "2012", "unstructured": "Yuzhalin AE, Kutikhin AG (2012) Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors 30(3):176\u2013191. doi: 10.3109/08977194.2012.678843", "journal-title": "Growth Factors"}, {"issue": "10", "key": "3_CR115", "doi-asserted-by": "publisher", "first-page": "2278", "DOI": "10.1158/1078-0432.CCR-14-2085", "volume": "21", "author": "L Zhang", "year": "2015", "unstructured": "Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Rosenberg SA (2015) Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 21(10):2278\u20132288. doi: 10.1158/1078-0432.CCR-14-2085", "journal-title": "Clin Cancer Res"}], "container-title": ["Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology", "SpringerBriefs in Immunology"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-46906-5_3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T23:32:35Z", "timestamp": 1498347155000}, "score": 26.273235, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319469058", "9783319469065"], "references-count": 115, "URL": "http://dx.doi.org/10.1007/978-3-319-46906-5_3", "relation": {"cites": []}, "ISSN": ["2194-2773", "2194-2781"], "issn-type": [{"value": "2194-2773", "type": "print"}, {"value": "2194-2781", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 1, 11]], "date-time": "2019-01-11T14:42:56Z", "timestamp": 1547217776662}, "reference-count": 188, "publisher": "Springer Nature", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Immunol Immunother"], "published-print": {"date-parts": [[2014, 5]]}, "DOI": "10.1007/s00262-014-1523-1", "type": "journal-article", "created": {"date-parts": [[2014, 2, 10]], "date-time": "2014-02-10T06:41:28Z", "timestamp": 1392014488000}, "page": "419-435", "source": "Crossref", "is-referenced-by-count": 101, "title": ["Interleukin 12: still a promising candidate for tumor immunotherapy?"], "prefix": "10.1007", "volume": "63", "author": [{"given": "Witold", "family": "Lasek", "sequence": "first", "affiliation": []}, {"given": "Rados\u0142aw", "family": "Zago\u017cd\u017con", "sequence": "additional", "affiliation": []}, {"given": "Marek", "family": "Jakobisiak", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 2, 11]]}, "reference": [{"key": "1523_CR1", "doi-asserted-by": "crossref", "first-page": "6808", "DOI": "10.1073/pnas.87.17.6808", "volume": "87", "author": "AS Stern", "year": "1990", "unstructured": "Stern AS, Podlaski FJ, Hulmes JD et al (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87:6808\u20136812", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "1523_CR2", "doi-asserted-by": "crossref", "first-page": "827", "DOI": "10.1084/jem.170.3.827", "volume": "170", "author": "M Kobayashi", "year": "1989", "unstructured": "Kobayashi M, Fitz L, Ryan M et al (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827\u2013845", "journal-title": "J Exp Med"}, {"key": "1523_CR3", "doi-asserted-by": "crossref", "first-page": "103", "DOI": "10.1016/j.imlet.2003.08.005", "volume": "90", "author": "M Jakobisiak", "year": "2003", "unstructured": "Jakobisiak M, Lasek W, Golab J (2003) Natural mechanisms protecting against cancer. Immunol Lett 90:103\u2013122", "journal-title": "Immunol Lett"}, {"key": "1523_CR4", "doi-asserted-by": "crossref", "first-page": "659", "DOI": "10.1002/eji.1830260323", "volume": "26", "author": "C Heufler", "year": "1996", "unstructured": "Heufler C, Koch F, Stanzl U et al (1996) Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 26:659\u2013668", "journal-title": "Eur J Immunol"}, {"key": "1523_CR5", "unstructured": "Nizzoli G, Krietsch J, Weick A et al (2013) Human CD1c\u00a0+\u00a0dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses. Blood\u00a0122:932\u2013942", "DOI": "10.1182/blood-2013-04-495424", "doi-asserted-by": "crossref"}, {"key": "1523_CR6", "doi-asserted-by": "crossref", "first-page": "547", "DOI": "10.1126/science.8097338", "volume": "260", "author": "CS Hsieh", "year": "1993", "unstructured": "Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O\u2019Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547\u2013549", "journal-title": "Science"}, {"key": "1523_CR7", "first-page": "75", "volume": "7", "author": "MA Michelin", "year": "2013", "unstructured": "Michelin MA, Abdalla DR, Aleixo AA, Murta EF (2013) Peripheral helper lymphocytes produce interleukin 12 in cancer patients. Clin Med Insights Oncol 7:75\u201381", "journal-title": "Clin Med Insights Oncol"}, {"key": "1523_CR8", "doi-asserted-by": "crossref", "first-page": "1223", "DOI": "10.1038/ncomms2223", "volume": "3", "author": "M Kuka", "year": "2012", "unstructured": "Kuka M, Munitic I, Ashwell JD (2012) Identification and characterization of polyclonal alphabeta-T cells with dendritic cell properties. Nat Commun 3:1223", "journal-title": "Nat Commun"}, {"key": "1523_CR9", "doi-asserted-by": "crossref", "first-page": "427", "DOI": "10.3109/10428199809050903", "volume": "29", "author": "SM Lee", "year": "1998", "unstructured": "Lee SM, Suen Y, Qian J, Knoppel E, Cairo MS (1998) The regulation and biological activity of interleukin 12. Leuk Lymphoma 29:427\u2013438", "journal-title": "Leuk Lymphoma"}, {"key": "1523_CR10", "first-page": "116", "volume": "154", "author": "P Ling", "year": "1995", "unstructured": "Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154:116\u2013127", "journal-title": "J Immunol"}, {"key": "1523_CR11", "doi-asserted-by": "crossref", "first-page": "789", "DOI": "10.3390/ijms11030789", "volume": "11", "author": "T Hamza", "year": "2010", "unstructured": "Hamza T, Barnett JB, Li B (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11:789\u2013806", "journal-title": "Int J Mol Sci"}, {"key": "1523_CR12", "doi-asserted-by": "crossref", "first-page": "4809", "DOI": "10.1200/JCO.2008.21.3579", "volume": "27", "author": "V Pistoia", "year": "2009", "unstructured": "Pistoia V, Cocco C, Airoldi I (2009) Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J Clin Oncol 27:4809\u20134816", "journal-title": "J Clin Oncol"}, {"key": "1523_CR13", "doi-asserted-by": "crossref", "first-page": "171", "DOI": "10.1038/382171a0", "volume": "382", "author": "WE Thierfelder", "year": "1996", "unstructured": "Thierfelder WE, van Deursen JM, Yamamoto K et al (1996) Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171\u2013174", "journal-title": "Nature"}, {"key": "1523_CR14", "doi-asserted-by": "crossref", "first-page": "453", "DOI": "10.1016/S1074-7613(00)00045-5", "volume": "13", "author": "O Schulz", "year": "2000", "unstructured": "Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis e Sousa C (2000) CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13:453\u2013462", "journal-title": "Immunity"}, {"key": "1523_CR15", "doi-asserted-by": "crossref", "first-page": "e19664", "DOI": "10.1371/journal.pone.0019664", "volume": "6", "author": "Y Zhang", "year": "2011", "unstructured": "Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Jia ZS, Moorman JP, Yao ZQ (2011) Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS ONE 6:e19664", "journal-title": "PLoS ONE"}, {"key": "1523_CR16", "doi-asserted-by": "crossref", "first-page": "1053", "DOI": "10.1093/intimm/13.8.1053", "volume": "13", "author": "AK Wesa", "year": "2001", "unstructured": "Wesa AK, Galy A (2001) IL-1 beta induces dendritic cells to produce IL-12. Int Immunol 13:1053\u20131061", "journal-title": "Int Immunol"}, {"key": "1523_CR17", "doi-asserted-by": "crossref", "first-page": "116", "DOI": "10.1111/j.1749-6632.1996.tb52660.x", "volume": "795", "author": "BL Kelsall", "year": "1996", "unstructured": "Kelsall BL, Stuber E, Neurath M, Strober W (1996) Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann N Y Acad Sci 795:116\u2013126", "journal-title": "Ann N Y Acad Sci"}, {"key": "1523_CR18", "doi-asserted-by": "crossref", "first-page": "145", "DOI": "10.1016/S0304-3835(01)00526-2", "volume": "168", "author": "T Felzmann", "year": "2001", "unstructured": "Felzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner H, Holter W (2001) Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. Cancer Lett 168:145\u2013154", "journal-title": "Cancer Lett"}, {"key": "1523_CR19", "first-page": "4298", "volume": "160", "author": "BL McRae", "year": "1998", "unstructured": "McRae BL, Semnani RT, Hayes MP, van Seventer GA (1998) Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol 160:4298\u20134304", "journal-title": "J Immunol"}, {"key": "1523_CR20", "doi-asserted-by": "crossref", "first-page": "537", "DOI": "10.1016/S0002-9440(10)65149-8", "volume": "155", "author": "G Bellone", "year": "1999", "unstructured": "Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155:537\u2013547", "journal-title": "Am J Pathol"}, {"key": "1523_CR21", "doi-asserted-by": "crossref", "first-page": "322", "DOI": "10.1189/jlb.1203641", "volume": "76", "author": "M Mitsuhashi", "year": "2004", "unstructured": "Mitsuhashi M, Liu J, Cao S, Shi X, Ma X (2004) Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol 76:322\u2013332", "journal-title": "J Leukoc Biol"}, {"key": "1523_CR22", "doi-asserted-by": "crossref", "first-page": "584", "DOI": "10.1038/nrc3349", "volume": "12", "author": "GK Alderton", "year": "2012", "unstructured": "Alderton GK (2012) Immunology: TIM3 suppresses antitumour DCs. Nat Rev Cancer 12:584", "journal-title": "Nat Rev Cancer"}, {"key": "1523_CR23", "doi-asserted-by": "crossref", "first-page": "83", "DOI": "10.1016/j.imlet.2012.09.002", "volume": "148", "author": "X Chen", "year": "2012", "unstructured": "Chen X, Du Y, Huang Z (2012) CD4+ CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Immunol Lett 148:83\u201389", "journal-title": "Immunol Lett"}, {"key": "1523_CR24", "doi-asserted-by": "crossref", "first-page": "531", "DOI": "10.1007/s13277-012-0578-x", "volume": "34", "author": "A Memarian", "year": "2013", "unstructured": "Memarian A, Nourizadeh M, Masoumi F, Tabrizi M, Emami AH, Alimoghaddam K, Hadjati J, Mirahmadian M, Jeddi-Tehrani M (2013) Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia. Tumour Biol 34:531\u2013542", "journal-title": "Tumour Biol"}, {"key": "1523_CR25", "doi-asserted-by": "crossref", "first-page": "99", "DOI": "10.1016/j.imlet.2010.08.002", "volume": "133", "author": "E Ferretti", "year": "2010", "unstructured": "Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, Montagna D, Pistoia V, Airoldi I (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 133:99\u2013105", "journal-title": "Immunol Lett"}, {"key": "1523_CR26", "doi-asserted-by": "crossref", "first-page": "111", "DOI": "10.1006/cimm.1999.1589", "volume": "198", "author": "T Otani", "year": "1999", "unstructured": "Otani T, Nakamura S, Toki M, Motoda R, Kurimoto M, Orita K (1999) Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice. Cell Immunol 198:111\u2013119", "journal-title": "Cell Immunol"}, {"key": "1523_CR27", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1097/00002371-199308000-00012", "volume": "14", "author": "HJ Zeh III", "year": "1993", "unstructured": "Zeh HJ III, Hurd S, Storkus WJ, Lotze MT (1993) Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother Emphas Tumor Immunol 14:155\u2013161", "journal-title": "J Immunother Emphas Tumor Immunol"}, {"key": "1523_CR28", "doi-asserted-by": "crossref", "first-page": "355", "DOI": "10.1016/0955-2235(92)90016-B", "volume": "4", "author": "G Trinchieri", "year": "1992", "unstructured": "Trinchieri G, Wysocka M, D\u2019Andrea A, Rengaraju M, Aste-Amezaga M, Kubin M, Valiante NM, Chehimi J (1992) Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog Growth Factor Res 4:355\u2013368", "journal-title": "Prog Growth Factor Res"}, {"key": "1523_CR29", "doi-asserted-by": "crossref", "first-page": "983", "DOI": "10.1172/JCI0215950", "volume": "110", "author": "R Parihar", "year": "2002", "unstructured": "Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110:983\u2013992", "journal-title": "J Clin Invest"}, {"key": "1523_CR30", "doi-asserted-by": "crossref", "first-page": "431", "DOI": "10.1016/j.surg.2012.05.035", "volume": "152", "author": "E Luedke", "year": "2012", "unstructured": "Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd (2012) Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152:431\u2013440", "journal-title": "Surgery"}, {"key": "1523_CR31", "first-page": "1483", "volume": "161", "author": "T Yoshimoto", "year": "1998", "unstructured": "Yoshimoto T, Nagai N, Ohkusu K, Ueda H, Okamura H, Nakanishi K (1998) LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta\u00a0+\u00a0T cells. J Immunol 161:1483\u20131492", "journal-title": "J Immunol"}, {"key": "1523_CR32", "doi-asserted-by": "crossref", "first-page": "158", "DOI": "10.1111/j.1749-6632.1996.tb52664.x", "volume": "795", "author": "AL Angiolillo", "year": "1996", "unstructured": "Angiolillo AL, Sgadari C, Tosato G (1996) A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci 795:158\u2013167", "journal-title": "Ann N Y Acad Sci"}, {"key": "1523_CR33", "doi-asserted-by": "crossref", "first-page": "1369", "DOI": "10.1038/mt.2013.58", "volume": "21", "author": "SP Kerkar", "year": "2013", "unstructured": "Kerkar SP, Leonardi AJ, van Panhuys N et al (2013) Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21:1369\u20131377", "journal-title": "Mol Ther"}, {"key": "1523_CR34", "doi-asserted-by": "crossref", "first-page": "4746", "DOI": "10.1172/JCI58814", "volume": "121", "author": "SP Kerkar", "year": "2011", "unstructured": "Kerkar SP, Goldszmid RS, Muranski P et al (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 121:4746\u20134757", "journal-title": "J Clin Invest"}, {"key": "1523_CR35", "doi-asserted-by": "crossref", "first-page": "223", "DOI": "10.1620/tjem.185.223", "volume": "185", "author": "S Suzuki", "year": "1998", "unstructured": "Suzuki S, Umezu Y, Saijo Y, Satoh G, Abe Y, Satoh K, Nukiwa T (1998) Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J Exp Med 185:223\u2013226", "journal-title": "Tohoku J Exp Med"}, {"key": "1523_CR36", "first-page": "537", "volume": "3", "author": "J Golab", "year": "1999", "unstructured": "Golab J, Zagozdzon R (1999) Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (review). Int J Mol Med 3:537\u2013544", "journal-title": "Int J Mol Med"}, {"key": "1523_CR37", "doi-asserted-by": "crossref", "first-page": "4677", "DOI": "10.1158/1078-0432.CCR-07-0776", "volume": "13", "author": "M Vecchio Del", "year": "2007", "unstructured": "Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677\u20134685", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR38", "doi-asserted-by": "crossref", "first-page": "1271", "DOI": "10.1172/JCI59806", "volume": "122", "author": "ZZ Yang", "year": "2012", "unstructured": "Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM (2012) IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122:1271\u20131282", "journal-title": "J Clin Invest"}, {"key": "1523_CR39", "doi-asserted-by": "crossref", "first-page": "2238", "DOI": "10.1016/j.vaccine.2013.03.003", "volume": "31", "author": "JM Wang", "year": "2013", "unstructured": "Wang JM, Ma CJ, Li GY et al (2013) Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection. Vaccine 31:2238\u20132245", "journal-title": "Vaccine"}, {"key": "1523_CR40", "doi-asserted-by": "crossref", "first-page": "581", "DOI": "10.1093/jnci/87.8.581", "volume": "87", "author": "EE Voest", "year": "1995", "unstructured": "Voest EE, Kenyon BM, O\u2019Reilly MS, Truitt G, D\u2019Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581\u2013586", "journal-title": "J Natl Cancer Inst"}, {"key": "1523_CR41", "doi-asserted-by": "crossref", "first-page": "347", "DOI": "10.1016/j.ymthe.2003.11.022", "volume": "9", "author": "S Li", "year": "2004", "unstructured": "Li S, Xia X, Mellieon FM, Liu J, Steele S (2004) Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 9:347\u2013354", "journal-title": "Mol Ther"}, {"key": "1523_CR42", "unstructured": "Zhu XD, Sun HC, Xu HX et al (2013) Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. Angiogenesis\u00a016:809\u2013820", "DOI": "10.1007/s10456-013-9357-6", "doi-asserted-by": "crossref"}, {"key": "1523_CR43", "first-page": "6014", "volume": "161", "author": "WE Fogler", "year": "1998", "unstructured": "Fogler WE, Volker K, Watanabe M, Wigginton JM, Roessler P, Brunda MJ, Ortaldo JR, Wiltrout RH (1998) Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 161:6014\u20136021", "journal-title": "J Immunol"}, {"key": "1523_CR44", "doi-asserted-by": "crossref", "first-page": "1705", "DOI": "10.1517/14712598.7.11.1705", "volume": "7", "author": "JM Weiss", "year": "2007", "unstructured": "Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7:1705\u20131721", "journal-title": "Expert Opin Biol Ther"}, {"key": "1523_CR45", "doi-asserted-by": "crossref", "first-page": "100", "DOI": "10.1007/s002620050408", "volume": "45", "author": "W Lasek", "year": "1997", "unstructured": "Lasek W, Feleszko W, Golab J, Stoklosa T, Marczak M, Dabrowska A, Malejczyk M, Jakobisiak M (1997) Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 45:100\u2013108", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR46", "first-page": "4493", "volume": "17", "author": "R Zagozdzon", "year": "1997", "unstructured": "Zagozdzon R, Stoklosa T, Golab J, Giermasz A, Dabrowska A, Lasek W, Jakobisiak M (1997) Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Res 17:4493\u20134498", "journal-title": "Anticancer Res"}, {"key": "1523_CR47", "doi-asserted-by": "crossref", "first-page": "218", "DOI": "10.1006/jsre.1995.1034", "volume": "58", "author": "I Pappo", "year": "1995", "unstructured": "Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT (1995) Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res 58:218\u2013226", "journal-title": "J Surg Res"}, {"key": "1523_CR48", "first-page": "1323", "volume": "83", "author": "AR Rossi", "year": "1994", "unstructured": "Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY (1994) Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 83:1323\u20131328", "journal-title": "Blood"}, {"key": "1523_CR49", "doi-asserted-by": "crossref", "first-page": "363", "DOI": "10.1007/s00262-003-0449-9", "volume": "53", "author": "W Lasek", "year": "2004", "unstructured": "Lasek W, Basak G, Switaj T et al (2004) Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother 53:363\u2013372", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR50", "doi-asserted-by": "crossref", "first-page": "2351", "DOI": "10.1084/jem.20120944", "volume": "209", "author": "J Ni", "year": "2012", "unstructured": "Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A (2012) Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 209:2351\u20132365", "journal-title": "J Exp Med"}, {"key": "1523_CR51", "doi-asserted-by": "crossref", "first-page": "153", "DOI": "10.1016/S0165-2478(00)00178-4", "volume": "72", "author": "J Golab", "year": "2000", "unstructured": "Golab J, Zagozdzon R, Stoklosal T, Kaminski R, Kozar K, Jakobisiak M (2000) Direct stimulation of macrophages by IL-12 and IL-18\u2014a bridge too far? Immunol Lett 72:153\u2013157", "journal-title": "Immunol Lett"}, {"key": "1523_CR52", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1159/000029978", "volume": "19", "author": "J Golab", "year": "1998", "unstructured": "Golab J, Stoklosa T, Zagozdzon R et al (1998) Granulocyte\u2013macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumour Biol 19:77\u201387", "journal-title": "Tumour Biol"}, {"key": "1523_CR53", "doi-asserted-by": "crossref", "first-page": "63", "DOI": "10.1023/A:1008266321552", "volume": "9", "author": "J Golab", "year": "1998", "unstructured": "Golab J, Stoklosa T, Zagozdzon R et al (1998) G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 9:63\u201369", "journal-title": "Ann Oncol"}, {"key": "1523_CR54", "first-page": "4387", "volume": "91", "author": "J Golab", "year": "1998", "unstructured": "Golab J, Zagozdzon R, Stoklosa T, Jakobisiak M, Pojda Z, Machaj E (1998) Erythropoietin prevents the development of interleukin-12-induced anemia and thrombocytopenia but does not decrease its antitumor activity in mice. Blood 91:4387\u20134388", "journal-title": "Blood"}, {"key": "1523_CR55", "doi-asserted-by": "crossref", "first-page": "26", "DOI": "10.1186/1479-5876-6-26", "volume": "6", "author": "LA Basile", "year": "2008", "unstructured": "Basile LA, Gallaher TK, Shibata D, Miller JD, Douer D (2008) Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med 6:26", "journal-title": "J Transl Med"}, {"key": "1523_CR56", "doi-asserted-by": "crossref", "first-page": "1223", "DOI": "10.1084/jem.178.4.1223", "volume": "178", "author": "MJ Brunda", "year": "1993", "unstructured": "Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223\u20131230", "journal-title": "J Exp Med"}, {"key": "1523_CR57", "doi-asserted-by": "crossref", "first-page": "80", "DOI": "10.1002/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M", "volume": "65", "author": "BA Teicher", "year": "1996", "unstructured": "Teicher BA, Ara G, Menon K, Schaub RG (1996) In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer 65:80\u201384", "journal-title": "Int J Cancer"}, {"key": "1523_CR58", "first-page": "3124", "volume": "9", "author": "K Kozar", "year": "2003", "unstructured": "Kozar K, Kaminski R, Switaj T et al (2003) Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2\u2032-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 9:3124\u20133133", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR59", "doi-asserted-by": "crossref", "first-page": "1804", "DOI": "10.1021/mp300602j", "volume": "10", "author": "L Cao", "year": "2013", "unstructured": "Cao L, Zeng Q, Xu C, Shi S, Zhang Z, Sun X (2013) Enhanced antitumor response mediated by the codelivery of paclitaxel and adenoviral vector expressing IL-12. Mol Pharm 10:1804\u20131814", "journal-title": "Mol Pharm"}, {"key": "1523_CR60", "first-page": "1661", "volume": "3", "author": "BA Teicher", "year": "1997", "unstructured": "Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG (1997) Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res 3:1661\u20131667", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR61", "first-page": "645", "volume": "4", "author": "R Zagozdzon", "year": "1999", "unstructured": "Zagozdzon R, Golab J, Mucha K, Foroncewicz B, Jakobisiak M (1999) Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo. Int J Mol Med 4:645\u2013648", "journal-title": "Int J Mol Med"}, {"key": "1523_CR62", "first-page": "613", "volume": "15", "author": "J Golab", "year": "2001", "unstructured": "Golab J, Zagozdzon R, Kaminski R et al (2001) Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 15:613\u2013620", "journal-title": "Leukemia"}, {"key": "1523_CR63", "unstructured": "Xia X, Li X, Feng G, Zheng C, Liang H, Zhou G (2013) Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model. Acta Radiol", "DOI": "10.1177/0284185113480072", "doi-asserted-by": "crossref"}, {"key": "1523_CR64", "first-page": "177", "volume": "7", "author": "J Golab", "year": "2000", "unstructured": "Golab J, Zagozdzon R, Kozar K, Kaminski R, Giermasz A, Stoklosa T, Lasek W, Jakobisiak M (2000) Potentiated anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. Oncol Rep 7:177\u2013181", "journal-title": "Oncol Rep"}, {"key": "1523_CR65", "doi-asserted-by": "crossref", "first-page": "720", "DOI": "10.1002/(SICI)1097-0215(19980831)77:5<720::AID-IJC10>3.0.CO;2-5", "volume": "77", "author": "R Zagozdzon", "year": "1998", "unstructured": "Zagozdzon R, Golab J, Stoklosa T, Giermasz A, Nowicka D, Feleszko W, Lasek W, Jakobisiak M (1998) Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 77:720\u2013727", "journal-title": "Int J Cancer"}, {"key": "1523_CR66", "doi-asserted-by": "crossref", "first-page": "1156", "DOI": "10.4049/jimmunol.166.2.1156", "volume": "166", "author": "JM Wigginton", "year": "2001", "unstructured": "Wigginton JM, Park JW, Gruys ME et al (2001) Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166:1156\u20131168", "journal-title": "J Immunol"}, {"key": "1523_CR67", "doi-asserted-by": "crossref", "first-page": "808", "DOI": "10.1038/sj.gt.3300908", "volume": "6", "author": "T Osaki", "year": "1999", "unstructured": "Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H (1999) Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 6:808\u2013815", "journal-title": "Gene Ther"}, {"key": "1523_CR68", "first-page": "358", "volume": "48", "author": "A Dabrowska", "year": "2001", "unstructured": "Dabrowska A, Giermasz A, Golab J, Jakobisiak M (2001) Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma 48:358\u2013361", "journal-title": "Neoplasma"}, {"key": "1523_CR69", "doi-asserted-by": "crossref", "first-page": "7368", "DOI": "10.4049/jimmunol.172.12.7368", "volume": "172", "author": "GBB Lesinski", "year": "2004", "unstructured": "Lesinski GBB, Zimmerer J, Crespin T, Hu Y, Abood G, Carson WE III (2004) IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J Immunol 172:7368\u20137376", "journal-title": "J Immunol"}, {"key": "1523_CR70", "first-page": "1900", "volume": "96", "author": "L Yao", "year": "2000", "unstructured": "Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96:1900\u20131905", "journal-title": "Blood"}, {"key": "1523_CR71", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.1002/(SICI)1520-6823(1998)6:2<71::AID-ROI2>3.0.CO;2-E", "volume": "6", "author": "BA Teicher", "year": "1998", "unstructured": "Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG (1998) Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig 6:71\u201380", "journal-title": "Radiat Oncol Investig"}, {"key": "1523_CR72", "doi-asserted-by": "crossref", "first-page": "1325", "DOI": "10.1007/s00262-010-0860-y", "volume": "59", "author": "MW Helms", "year": "2010", "unstructured": "Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59:1325\u20131334", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR73", "first-page": "1208", "volume": "29", "author": "L Zapala", "year": "2013", "unstructured": "Zapala L, Wolny R, Wachowska M, Jakobisiak M, Lasek W (2013) Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model. Oncol Rep 29:1208\u20131214", "journal-title": "Oncol Rep"}, {"key": "1523_CR74", "first-page": "7563", "volume": "61", "author": "T Tatsumi", "year": "2001", "unstructured": "Tatsumi T, Takehara T, Kanto T et al (2001) Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61:7563\u20137567", "journal-title": "Cancer Res"}, {"key": "1523_CR75", "first-page": "467", "volume": "56", "author": "M Vagliani", "year": "1996", "unstructured": "Vagliani M, Rodolfo M, Cavallo F, Parenza M, Melani C, Parmiani G, Forni G, Colombo MP (1996) Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 56:467\u2013470", "journal-title": "Cancer Res"}, {"key": "1523_CR76", "doi-asserted-by": "crossref", "first-page": "425", "DOI": "10.1002/(SICI)1097-0215(19990129)80:3<425::AID-IJC15>3.0.CO;2-7", "volume": "80", "author": "T Kikuchi", "year": "1999", "unstructured": "Kikuchi T, Joki T, Saitoh S, Hata Y, Abe T, Kato N, Kobayashi A, Miyazaki T, Ohno T (1999) Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 80:425\u2013430", "journal-title": "Int J Cancer"}, {"key": "1523_CR77", "doi-asserted-by": "crossref", "first-page": "2219", "DOI": "10.1073/pnas.92.6.2219", "volume": "92", "author": "Y Noguchi", "year": "1995", "unstructured": "Noguchi Y, Richards EC, Chen YT, Old LJ (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219\u20132223", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "1523_CR78", "doi-asserted-by": "crossref", "first-page": "419", "DOI": "10.1007/s00262-010-0930-1", "volume": "60", "author": "R Ramakrishnan", "year": "2011", "unstructured": "Ramakrishnan R, Gabrilovich DI (2011) Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother 60:419\u2013423", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR79", "doi-asserted-by": "crossref", "first-page": "2471", "DOI": "10.1002/ijc.27801", "volume": "132", "author": "MS Nars", "year": "2013", "unstructured": "Nars MS, Kaneno R (2013) Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 132:2471\u20132478", "journal-title": "Int J Cancer"}, {"key": "1523_CR80", "doi-asserted-by": "crossref", "first-page": "137", "DOI": "10.4049/jimmunol.0900734", "volume": "183", "author": "GV Shurin", "year": "2009", "unstructured": "Shurin GV, Tourkova IL, Kaneno R, Shurin MR (2009) Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183:137\u2013144", "journal-title": "J Immunol"}, {"key": "1523_CR81", "doi-asserted-by": "crossref", "first-page": "1643", "DOI": "10.1002/ijc.28163", "volume": "133", "author": "E Wennerberg", "year": "2013", "unstructured": "Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D\u2019Arcy P, Zhivotovsky B, Childs R, Lundqvist A (2013) Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer 133:1643\u20131652", "journal-title": "Int J Cancer"}, {"key": "1523_CR82", "doi-asserted-by": "crossref", "first-page": "1050", "DOI": "10.1038/nm1622", "volume": "13", "author": "L Apetoh", "year": "2007", "unstructured": "Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050\u20131059", "journal-title": "Nat Med"}, {"key": "1523_CR83", "doi-asserted-by": "crossref", "first-page": "e30434", "DOI": "10.1371/journal.pone.0030434", "volume": "7", "author": "LA Basile", "year": "2012", "unstructured": "Basile LA, Ellefson D, Gluzman-Poltorak Z et al (2012) HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS ONE 7:e30434", "journal-title": "PLoS ONE"}, {"key": "1523_CR84", "doi-asserted-by": "crossref", "first-page": "849", "DOI": "10.1002/(SICI)1097-0215(19960917)67:6<849::AID-IJC15>3.0.CO;2-X", "volume": "67", "author": "K Mori", "year": "1996", "unstructured": "Mori K, Fujimoto-Ouchi K, Ishikawa T, Sekiguchi F, Ishitsuka H, Tanaka Y (1996) Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 67:849\u2013855", "journal-title": "Int J Cancer"}, {"key": "1523_CR85", "first-page": "187", "volume": "1", "author": "MK Gately", "year": "1994", "unstructured": "Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, Sarmiento U (1994) Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1:187\u2013196", "journal-title": "Ther Immunol"}, {"key": "1523_CR86", "first-page": "862", "volume": "71", "author": "UM Sarmiento", "year": "1994", "unstructured": "Sarmiento UM, Riley JH, Knaack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R, Anderson TD (1994) Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest 71:862\u2013873", "journal-title": "Lab Invest"}, {"key": "1523_CR87", "doi-asserted-by": "crossref", "first-page": "1893", "DOI": "10.1084/jem.181.5.1893", "volume": "181", "author": "VM Eng", "year": "1995", "unstructured": "Eng VM, Car BD, Schnyder B, Lorenz M, Lugli S, Aguet M, Anderson TD, Ryffel B, Quesniaux VF (1995) The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo. J Exp Med 181:1893\u20131898", "journal-title": "J Exp Med"}, {"key": "1523_CR88", "doi-asserted-by": "crossref", "first-page": "179", "DOI": "10.1016/j.virusres.2010.07.027", "volume": "153", "author": "JI Quetglas", "year": "2010", "unstructured": "Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C (2010) Alphavirus vectors for cancer therapy. Virus Res 153:179\u2013196", "journal-title": "Virus Res"}, {"key": "1523_CR89", "first-page": "6466", "volume": "154", "author": "H Tahara", "year": "1995", "unstructured": "Tahara H, Zitvogel L, Storkus WJ, Zeh HJ III, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154:6466\u20136474", "journal-title": "J Immunol"}, {"key": "1523_CR90", "doi-asserted-by": "crossref", "first-page": "2994", "DOI": "10.4049/jimmunol.1201791", "volume": "190", "author": "JI Quetglas", "year": "2013", "unstructured": "Quetglas JI, Rodriguez-Madoz JR, Bezunartea J et al (2013) Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses. J Immunol 190:2994\u20133004", "journal-title": "J Immunol"}, {"key": "1523_CR91", "doi-asserted-by": "crossref", "first-page": "718", "DOI": "10.1002/jgm.1356", "volume": "11", "author": "JG Fewell", "year": "2009", "unstructured": "Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, Worker M, Lewis DH, Anwer K (2009) Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med 11:718\u2013728", "journal-title": "J Gene Med"}, {"key": "1523_CR92", "doi-asserted-by": "crossref", "first-page": "668", "DOI": "10.1006/mthe.2002.0601", "volume": "5", "author": "ML Lucas", "year": "2002", "unstructured": "Lucas ML, Heller L, Coppola D, Heller R (2002) IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5:668\u2013675", "journal-title": "Mol Ther"}, {"key": "1523_CR93", "doi-asserted-by": "crossref", "first-page": "833", "DOI": "10.1038/sj.gt.3300891", "volume": "6", "author": "SK Mendiratta", "year": "1999", "unstructured": "Mendiratta SK, Quezada A, Matar M, Wang J, Hebel HL, Long S, Nordstrom JL, Pericle F (1999) Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Ther 6:833\u2013839", "journal-title": "Gene Ther"}, {"key": "1523_CR94", "doi-asserted-by": "crossref", "first-page": "692", "DOI": "10.1007/s001090000165", "volume": "78", "author": "LM Heinzerling", "year": "2001", "unstructured": "Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G, Moelling K (2001) Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med (Berl) 78:692\u2013702", "journal-title": "J Mol Med (Berl)"}, {"key": "1523_CR95", "doi-asserted-by": "crossref", "first-page": "11302", "DOI": "10.1073/pnas.93.21.11302", "volume": "93", "author": "M Caruso", "year": "1996", "unstructured": "Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH (1996) Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 93:11302\u201311306", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "1523_CR96", "doi-asserted-by": "crossref", "first-page": "338", "DOI": "10.1038/sj.gt.3300834", "volume": "6", "author": "Y Nasu", "year": "1999", "unstructured": "Nasu Y, Bangma CH, Hull GW et al (1999) Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6:338\u2013349", "journal-title": "Gene Ther"}, {"key": "1523_CR97", "first-page": "1393", "volume": "155", "author": "L Zitvogel", "year": "1995", "unstructured": "Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT (1995) Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155:1393\u20131403", "journal-title": "J Immunol"}, {"key": "1523_CR98", "doi-asserted-by": "crossref", "first-page": "1527", "DOI": "10.1038/sj.gt.3301274", "volume": "7", "author": "K Song", "year": "2000", "unstructured": "Song K, Chang Y, Prud\u2019homme GJ (2000) IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 7:1527\u20131535", "journal-title": "Gene Ther"}, {"key": "1523_CR99", "first-page": "5536", "volume": "157", "author": "M Rodolfo", "year": "1996", "unstructured": "Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arioli I, Parmiani G, Colombo MP (1996) Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 157:5536\u20135542", "journal-title": "J Immunol"}, {"key": "1523_CR100", "doi-asserted-by": "crossref", "first-page": "483", "DOI": "10.3109/10428190109060339", "volume": "41", "author": "K Dunussi-Joannopoulos", "year": "2001", "unstructured": "Dunussi-Joannopoulos K, Leonard JP (2001) Interleukin-12 gene therapy vaccines: directing the immune system against minimal residual leukemia. Leuk Lymphoma 41:483\u2013492", "journal-title": "Leuk Lymphoma"}, {"key": "1523_CR101", "doi-asserted-by": "crossref", "first-page": "573", "DOI": "10.1007/s00262-011-1198-9", "volume": "61", "author": "C Huang", "year": "2012", "unstructured": "Huang C, Ramakrishnan R, Trkulja M, Ren X, Gabrilovich DI (2012) Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother 61:573\u2013579", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR102", "doi-asserted-by": "crossref", "first-page": "284", "DOI": "10.1111/j.1749-6632.1996.tb52678.x", "volume": "795", "author": "L Zitvogel", "year": "1996", "unstructured": "Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, Storkus WJ (1996) IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci 795:284\u2013293", "journal-title": "Ann N Y Acad Sci"}, {"key": "1523_CR103", "doi-asserted-by": "crossref", "first-page": "316", "DOI": "10.1038/sj.gt.3301396", "volume": "8", "author": "Y Chen", "year": "2001", "unstructured": "Chen Y, Emtage P, Zhu Q, Foley R, Muller W, Hitt M, Gauldie J, Wan Y (2001) Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 8:316\u2013323", "journal-title": "Gene Ther"}, {"key": "1523_CR104", "doi-asserted-by": "crossref", "first-page": "4133", "DOI": "10.1182/blood-2011-12-400044", "volume": "119", "author": "HJ Pegram", "year": "2012", "unstructured": "Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119:4133\u20134141", "journal-title": "Blood"}, {"key": "1523_CR105", "unstructured": "Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM (2012) Preclinical evaluation of oncolytic deltagamma(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer\u00a02012:628697", "DOI": "10.1155/2012/628697", "doi-asserted-by": "crossref"}, {"key": "1523_CR106", "doi-asserted-by": "crossref", "first-page": "512", "DOI": "10.1038/cgt.2010.12", "volume": "17", "author": "P Charoensit", "year": "2010", "unstructured": "Charoensit P, Kawakami S, Higuchi Y, Yamashita F, Hashida M (2010) Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther 17:512\u2013522", "journal-title": "Cancer Gene Ther"}, {"key": "1523_CR107", "first-page": "1077", "volume": "48", "author": "U Wilczynska", "year": "2001", "unstructured": "Wilczynska U, Kucharska A, Szary J, Szala S (2001) Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim Pol 48:1077\u20131084", "journal-title": "Acta Biochim Pol"}, {"key": "1523_CR108", "doi-asserted-by": "crossref", "first-page": "1400", "DOI": "10.1038/sj.gt.3300731", "volume": "5", "author": "CL Addison", "year": "1998", "unstructured": "Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL (1998) Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 5:1400\u20131409", "journal-title": "Gene Ther"}, {"key": "1523_CR109", "doi-asserted-by": "crossref", "first-page": "1441", "DOI": "10.1172/JCI1555", "volume": "101", "author": "CM Coughlin", "year": "1998", "unstructured": "Coughlin CM, Salhany KE, Wysocka M et al (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101:1441\u20131452", "journal-title": "J Clin Invest"}, {"key": "1523_CR110", "doi-asserted-by": "crossref", "first-page": "2348", "DOI": "10.4049/jimmunol.0902371", "volume": "184", "author": "S Zhu", "year": "2010", "unstructured": "Zhu S, Lee DA, Li S (2010) IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184:2348\u20132354", "journal-title": "J Immunol"}, {"key": "1523_CR111", "doi-asserted-by": "crossref", "first-page": "282", "DOI": "10.1038/sj.gt.3301386", "volume": "8", "author": "K Palmer", "year": "2001", "unstructured": "Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J (2001) Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 8:282\u2013290", "journal-title": "Gene Ther"}, {"key": "1523_CR112", "doi-asserted-by": "crossref", "first-page": "697", "DOI": "10.1089/10430349950018463", "volume": "10", "author": "PC Emtage", "year": "1999", "unstructured": "Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, Gauldie J (1999) Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 10:697\u2013709", "journal-title": "Hum Gene Ther"}, {"key": "1523_CR113", "doi-asserted-by": "crossref", "first-page": "10889", "DOI": "10.1073/pnas.94.20.10889", "volume": "94", "author": "BM Putzer", "year": "1997", "unstructured": "Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL (1997) Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 94:10889\u201310894", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "1523_CR114", "doi-asserted-by": "crossref", "first-page": "1664", "DOI": "10.1038/mt.2012.56", "volume": "20", "author": "JI Quetglas", "year": "2012", "unstructured": "Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I (2012) Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther 20:1664\u20131675", "journal-title": "Mol Ther"}, {"key": "1523_CR115", "doi-asserted-by": "crossref", "first-page": "931", "DOI": "10.1093/jnci/92.11.931", "volume": "92", "author": "O Martinet", "year": "2000", "unstructured": "Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, Chen L, Chen SH (2000) Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst 92:931\u2013936", "journal-title": "J Natl Cancer Inst"}, {"key": "1523_CR116", "doi-asserted-by": "crossref", "first-page": "4165", "DOI": "10.1158/1078-0432.CCR-04-0022", "volume": "10", "author": "T Switaj", "year": "2004", "unstructured": "Switaj T, Jalili A, Jakubowska AB et al (2004) CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin Cancer Res 10:4165\u20134175", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR117", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1016/0167-5699(96)30011-X", "volume": "17", "author": "AG Lamont", "year": "1996", "unstructured": "Lamont AG, Adorini L (1996) IL-12: a key cytokine in immune regulation. Immunol Today 17:214\u2013217", "journal-title": "Immunol Today"}, {"key": "1523_CR118", "doi-asserted-by": "crossref", "first-page": "576", "DOI": "10.1093/jnci/88.9.576", "volume": "88", "author": "S Jenks", "year": "1996", "unstructured": "Jenks S (1996) After initial setback, IL-12 regaining popularity. J Natl Cancer Inst 88:576\u2013577", "journal-title": "J Natl Cancer Inst"}, {"key": "1523_CR119", "first-page": "2541", "volume": "90", "author": "JP Leonard", "year": "1997", "unstructured": "Leonard JP, Sherman ML, Fisher GL et al (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541\u20132548", "journal-title": "Blood"}, {"key": "1523_CR120", "doi-asserted-by": "crossref", "first-page": "908", "DOI": "10.1126/science.270.5238.908a", "volume": "270", "author": "J Cohen", "year": "1995", "unstructured": "Cohen J (1995) IL-12 deaths: explanation and a puzzle. Science 270:908", "journal-title": "Science"}, {"key": "1523_CR121", "first-page": "409", "volume": "3", "author": "MB Atkins", "year": "1997", "unstructured": "Atkins MB, Robertson MJ, Gordon M et al (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409\u2013417", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR122", "first-page": "9", "volume": "5", "author": "MJ Robertson", "year": "1999", "unstructured": "Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5:9\u201316", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR123", "first-page": "1678", "volume": "6", "author": "JA Gollob", "year": "2000", "unstructured": "Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6:1678\u20131692", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR124", "first-page": "75", "volume": "4", "author": "E Bajetta", "year": "1998", "unstructured": "Bajetta E, Del Vecchio M, Mortarini R et al (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4:75\u201385", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR125", "first-page": "1183", "volume": "4", "author": "RJ Motzer", "year": "1998", "unstructured": "Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4:1183\u20131191", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR126", "first-page": "3686", "volume": "8", "author": "R Lenzi", "year": "2002", "unstructured": "Lenzi R, Rosenblum M, Verschraegen C et al (2002) Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8:3686\u20133695", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR127", "doi-asserted-by": "crossref", "first-page": "957", "DOI": "10.1016/j.ygyno.2003.12.022", "volume": "92", "author": "S Wadler", "year": "2004", "unstructured": "Wadler S, Levy D, Frederickson HL et al (2004) A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 92:957\u2013964", "journal-title": "Gynecol Oncol"}, {"key": "1523_CR128", "doi-asserted-by": "crossref", "first-page": "28", "DOI": "10.1046/j.1365-2249.2000.01112.x", "volume": "119", "author": "N Haicheur", "year": "2000", "unstructured": "Haicheur N, Escudier B, Dorval T et al (2000) Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 119:28\u201337", "journal-title": "Clin Exp Immunol"}, {"key": "1523_CR129", "first-page": "3983", "volume": "5", "author": "JE Portielje", "year": "1999", "unstructured": "Portielje JE, Kruit WH, Schuler M et al (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5:3983\u20133989", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR130", "first-page": "76", "volume": "9", "author": "JE Portielje", "year": "2003", "unstructured": "Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW (2003) Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 9:76\u201383", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR131", "doi-asserted-by": "crossref", "first-page": "2983", "DOI": "10.1158/1535-7163.MCT-09-0820", "volume": "8", "author": "TS Bekaii-Saab", "year": "2009", "unstructured": "Bekaii-Saab TS, Roda JM, Guenterberg KD et al (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 8:2983\u20132991", "journal-title": "Mol Cancer Ther"}, {"key": "1523_CR132", "doi-asserted-by": "crossref", "first-page": "253", "DOI": "10.1038/nri3175", "volume": "12", "author": "DI Gabrilovich", "year": "2012", "unstructured": "Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253\u2013268", "journal-title": "Nat Rev Immunol"}, {"key": "1523_CR133", "doi-asserted-by": "crossref", "first-page": "1137", "DOI": "10.1007/s00262-013-1434-6", "volume": "62", "author": "JC Becker", "year": "2013", "unstructured": "Becker JC, Andersen MH, Schrama D, Thor Straten P (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62:1137\u20131148", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR134", "doi-asserted-by": "crossref", "first-page": "5027", "DOI": "10.1158/1078-0432.CCR-04-0265", "volume": "10", "author": "R Parihar", "year": "2004", "unstructured": "Parihar R, Nadella P, Lewis A et al (2004) A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 10:5027\u20135037", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR135", "doi-asserted-by": "crossref", "first-page": "6056", "DOI": "10.1158/1078-0432.CCR-06-1245", "volume": "12", "author": "SM Ansell", "year": "2006", "unstructured": "Ansell SM, Geyer SM, Maurer MJ et al (2006) Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin\u2019s lymphoma patients. Clin Cancer Res 12:6056\u20136063", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR136", "doi-asserted-by": "crossref", "first-page": "215", "DOI": "10.1158/1078-0432.CCR-06-1450", "volume": "13", "author": "O Hamid", "year": "2007", "unstructured": "Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS (2007) Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13:215\u2013222", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR137", "first-page": "3836", "volume": "19", "author": "P Lee", "year": "2001", "unstructured": "Lee P, Wang F, Kuniyoshi J et al (2001) Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836\u20133847", "journal-title": "J Clin Oncol"}, {"key": "1523_CR138", "doi-asserted-by": "crossref", "first-page": "1503", "DOI": "10.1158/1078-0432.CCR-06-1603", "volume": "13", "author": "L Hansson", "year": "2007", "unstructured": "Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H (2007) Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 13:1503\u20131510", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR139", "doi-asserted-by": "crossref", "first-page": "2342", "DOI": "10.1200/JCO.2003.12.144", "volume": "21", "author": "AC Peterson", "year": "2003", "unstructured": "Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21:2342\u20132348", "journal-title": "J Clin Oncol"}, {"key": "1523_CR140", "doi-asserted-by": "crossref", "first-page": "4165", "DOI": "10.1182/blood-2007-06-097568", "volume": "110", "author": "RF Little", "year": "2007", "unstructured": "Little RF, Aleman K, Kumar P et al (2007) Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 110:4165\u20134171", "journal-title": "Blood"}, {"key": "1523_CR141", "doi-asserted-by": "crossref", "first-page": "2564", "DOI": "10.1200/JCO.2003.12.119", "volume": "21", "author": "JA Gollob", "year": "2003", "unstructured": "Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB (2003) Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21:2564\u20132573", "journal-title": "J Clin Oncol"}, {"key": "1523_CR142", "doi-asserted-by": "crossref", "first-page": "8835", "DOI": "10.1200/JCO.2005.02.1691", "volume": "23", "author": "CF Eisenbeis", "year": "2005", "unstructured": "Eisenbeis CF, Lesinski GB, Anghelina M et al (2005) Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 23:8835\u20138844", "journal-title": "J Clin Oncol"}, {"key": "1523_CR143", "doi-asserted-by": "crossref", "first-page": "2891", "DOI": "10.1200/JCO.2004.10.045", "volume": "22", "author": "G Alatrash", "year": "2004", "unstructured": "Alatrash G, Hutson TE, Molto L et al (2004) Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22:2891\u20132900", "journal-title": "J Clin Oncol"}, {"key": "1523_CR144", "doi-asserted-by": "crossref", "first-page": "671", "DOI": "10.1089/104303401300057388", "volume": "12", "author": "WK Kang", "year": "2001", "unstructured": "Kang WK, Park C, Yoon HL et al (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 12:671\u2013684", "journal-title": "Hum Gene Ther"}, {"key": "1523_CR145", "doi-asserted-by": "crossref", "first-page": "1389", "DOI": "10.1200/JCO.2004.04.059", "volume": "22", "author": "B Sangro", "year": "2004", "unstructured": "Sangro B, Mazzolini G, Ruiz J et al (2004) Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22:1389\u20131397", "journal-title": "J Clin Oncol"}, {"key": "1523_CR146", "doi-asserted-by": "crossref", "first-page": "1981", "DOI": "10.2174/1381612033454261", "volume": "9", "author": "G Mazzolini", "year": "2003", "unstructured": "Mazzolini G, Prieto J, Melero I (2003) Gene therapy of cancer with interleukin-12. Curr Pharm Des 9:1981\u20131991", "journal-title": "Curr Pharm Des"}, {"key": "1523_CR147", "doi-asserted-by": "crossref", "first-page": "481", "DOI": "10.1038/sj.gt.3300619", "volume": "5", "author": "Y Sun", "year": "1998", "unstructured": "Sun Y, Jurgovsky K, Moller P, Alijagic S, Dorbic T, Georgieva J, Wittig B, Schadendorf D (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5:481\u2013490", "journal-title": "Gene Ther"}, {"key": "1523_CR148", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.1089/hum.2005.16.91", "volume": "16", "author": "PL Triozzi", "year": "2005", "unstructured": "Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM (2005) Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 16:91\u2013100", "journal-title": "Hum Gene Ther"}, {"key": "1523_CR149", "doi-asserted-by": "crossref", "first-page": "4168", "DOI": "10.1158/1078-0432.CCR-04-2283", "volume": "11", "author": "PL Triozzi", "year": "2005", "unstructured": "Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM (2005) Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 11:4168\u20134175", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR150", "first-page": "1491", "volume": "154", "author": "AH Rook", "year": "1995", "unstructured": "Rook AH, Kubin M, Cassin M et al (1995) IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 154:1491\u20131498", "journal-title": "J Immunol"}, {"key": "1523_CR151", "first-page": "902", "volume": "94", "author": "AH Rook", "year": "1999", "unstructured": "Rook AH, Wood GS, Yoo EK et al (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902\u2013908", "journal-title": "Blood"}, {"key": "1523_CR152", "doi-asserted-by": "crossref", "first-page": "807", "DOI": "10.1016/j.jaad.2006.06.038", "volume": "55", "author": "M Duvic", "year": "2006", "unstructured": "Duvic M, Sherman ML, Wood GS et al (2006) A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55:807\u2013813", "journal-title": "J Am Acad Dermatol"}, {"key": "1523_CR153", "doi-asserted-by": "crossref", "first-page": "5432", "DOI": "10.1158/1078-0432.CCR-04-0540", "volume": "10", "author": "A Younes", "year": "2004", "unstructured": "Younes A, Pro B, Robertson MJ et al (2004) Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease. Clin Cancer Res 10:5432\u20135438", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR154", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1182/blood.V99.1.67", "volume": "99", "author": "SM Ansell", "year": "2002", "unstructured": "Ansell SM, Witzig TE, Kurtin PJ et al (2002) Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67\u201374", "journal-title": "Blood"}, {"key": "1523_CR155", "doi-asserted-by": "crossref", "first-page": "279", "DOI": "10.1016/j.blre.2012.09.004", "volume": "26", "author": "MA Lunning", "year": "2012", "unstructured": "Lunning MA, Vose JM (2012) Management of indolent lymphoma: where are we now and where are we going. Blood Rev 26:279\u2013288", "journal-title": "Blood Rev"}, {"key": "1523_CR156", "doi-asserted-by": "crossref", "first-page": "4650", "DOI": "10.1182/blood-2005-11-4455", "volume": "107", "author": "RF Little", "year": "2006", "unstructured": "Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R (2006) Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 107:4650\u20134657", "journal-title": "Blood"}, {"key": "1523_CR157", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1089/107999001750169934", "volume": "21", "author": "RJ Motzer", "year": "2001", "unstructured": "Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM (2001) Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 21:257\u2013263", "journal-title": "J Interferon Cytokine Res"}, {"key": "1523_CR158", "doi-asserted-by": "crossref", "first-page": "1971", "DOI": "10.1002/ijc.27755", "volume": "132", "author": "MF Fransen", "year": "2013", "unstructured": "Fransen MF, Arens R, Melief CJ (2013) Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. Int J Cancer 132:1971\u20131976", "journal-title": "Int J Cancer"}, {"key": "1523_CR159", "first-page": "2531", "volume": "56", "author": "MP Colombo", "year": "1996", "unstructured": "Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, Stoppacciaro A (1996) Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56:2531\u20132534", "journal-title": "Cancer Res"}, {"key": "1523_CR160", "doi-asserted-by": "crossref", "first-page": "66", "DOI": "10.1186/1479-5876-5-66", "volume": "5", "author": "R Lenzi", "year": "2007", "unstructured": "Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS (2007) Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1\u00a0cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5:66", "journal-title": "J Transl Med"}, {"key": "1523_CR161", "doi-asserted-by": "crossref", "first-page": "360", "DOI": "10.1038/gt.2009.159", "volume": "17", "author": "K Anwer", "year": "2010", "unstructured": "Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17:360\u2013369", "journal-title": "Gene Ther"}, {"key": "1523_CR162", "unstructured": "Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD (2013) Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol\u00a0131:169\u2013173", "DOI": "10.1016/j.ygyno.2013.07.081", "doi-asserted-by": "crossref"}, {"key": "1523_CR163", "doi-asserted-by": "crossref", "first-page": "35", "DOI": "10.1089/hum.2005.16.35", "volume": "16", "author": "L Heinzerling", "year": "2005", "unstructured": "Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16:35\u201348", "journal-title": "Hum Gene Ther"}, {"key": "1523_CR164", "doi-asserted-by": "crossref", "first-page": "717", "DOI": "10.1038/sj.cgt.7701064", "volume": "14", "author": "DM Mahvi", "year": "2007", "unstructured": "Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P (2007) Intratumoral injection of IL-12 plasmid DNA\u2014results of a phase I/IB clinical trial. Cancer Gene Ther 14:717\u2013723", "journal-title": "Cancer Gene Ther"}, {"key": "1523_CR165", "first-page": "5896", "volume": "26", "author": "AI Daud", "year": "2008", "unstructured": "Daud AI, DeConti RC, Andrews S et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896\u20135903", "journal-title": "J Clin Oncol"}, {"key": "1523_CR166", "doi-asserted-by": "crossref", "first-page": "299", "DOI": "10.1038/nrc2355", "volume": "8", "author": "SA Rosenberg", "year": "2008", "unstructured": "Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299\u2013308", "journal-title": "Nat Rev Cancer"}, {"key": "1523_CR167", "doi-asserted-by": "crossref", "first-page": "269", "DOI": "10.1038/nri3191", "volume": "12", "author": "NP Restifo", "year": "2012", "unstructured": "Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269\u2013281", "journal-title": "Nat Rev Immunol"}, {"key": "1523_CR168", "doi-asserted-by": "crossref", "first-page": "2152", "DOI": "10.1200/JCO.2012.46.6441", "volume": "31", "author": "ME Dudley", "year": "2013", "unstructured": "Dudley ME, Gross CA, Somerville RP et al (2013) Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31:2152\u20132159", "journal-title": "J Clin Oncol"}, {"key": "1523_CR169", "unstructured": "Linette GP, Hamid O, Whitman ED et al (2013) A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unrespectable stage III/IV melanoma. J Clin Oncol 31(15) suppl., 2013 ASCO Annual Meeting Abstracts, abstr. No. 3022"}, {"key": "1523_CR170", "doi-asserted-by": "crossref", "first-page": "287", "DOI": "10.1053/j.seminoncol.2012.02.003", "volume": "39", "author": "D Avigan", "year": "2012", "unstructured": "Avigan D, Rosenblatt J, Kufe D (2012) Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol 39:287\u2013295", "journal-title": "Semin Oncol"}, {"key": "1523_CR171", "doi-asserted-by": "crossref", "first-page": "337", "DOI": "10.1007/s002620100205", "volume": "50", "author": "T Kikuchi", "year": "2001", "unstructured": "Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337\u2013344", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR172", "doi-asserted-by": "crossref", "first-page": "749", "DOI": "10.1097/CJI.0b013e3180de4ce8", "volume": "30", "author": "DE Avigan", "year": "2007", "unstructured": "Avigan DE, Vasir B, George DJ et al (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30:749\u2013761", "journal-title": "J Immunother"}, {"key": "1523_CR173", "doi-asserted-by": "crossref", "first-page": "393", "DOI": "10.1182/blood-2010-04-277137", "volume": "117", "author": "J Rosenblatt", "year": "2011", "unstructured": "Rosenblatt J, Vasir B, Uhl L et al (2011) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117:393\u2013402", "journal-title": "Blood"}, {"key": "1523_CR174", "doi-asserted-by": "crossref", "first-page": "3640", "DOI": "10.1158/1078-0432.CCR-13-0282", "volume": "19", "author": "J Rosenblatt", "year": "2013", "unstructured": "Rosenblatt J, Avivi I, Vasir B et al (2013) Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 19:3640\u20133648", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR175", "doi-asserted-by": "crossref", "first-page": "2512", "DOI": "10.1182/blood.V99.7.2512", "volume": "99", "author": "J Gong", "year": "2002", "unstructured": "Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99:2512\u20132517", "journal-title": "Blood"}, {"key": "1523_CR176", "doi-asserted-by": "crossref", "first-page": "148", "DOI": "10.1186/1479-5876-11-148", "volume": "11", "author": "C Tan", "year": "2013", "unstructured": "Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT (2013) Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. J Transl Med 11:148", "journal-title": "J Transl Med"}, {"key": "1523_CR177", "doi-asserted-by": "crossref", "first-page": "452", "DOI": "10.1097/00002371-200411000-00005", "volume": "27", "author": "T Kikuchi", "year": "2004", "unstructured": "Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452\u2013459", "journal-title": "J Immunother"}, {"key": "1523_CR178", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1111/j.1365-2249.2006.03029.x", "volume": "144", "author": "S Homma", "year": "2006", "unstructured": "Homma S, Sagawa Y, Ito M, Ohno T, Toda G (2006) Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol 144:41\u201347", "journal-title": "Clin Exp Immunol"}, {"key": "1523_CR179", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1053/j.seminoncol.2012.02.004", "volume": "39", "author": "MW Frohlich", "year": "2012", "unstructured": "Frohlich MW (2012) Sipuleucel-T for the treatment of advanced prostate cancer. Semin Oncol 39:245\u2013252", "journal-title": "Semin Oncol"}, {"key": "1523_CR180", "unstructured": "Felzmann T, Buchroithner J, Marosi C et al (2013) First interim analysis of a randomized study to evaluate safety and efficacy of individualized dendritic cell-based cancer immune therapy for glioblastoma multiforme. In: Proceedings of the 104th annual meeting of the american association for cancer research (AACR 2013), Abstr. No. 4658"}, {"key": "1523_CR181", "doi-asserted-by": "crossref", "first-page": "583", "DOI": "10.1016/j.drudis.2012.01.007", "volume": "17", "author": "N Pasche", "year": "2012", "unstructured": "Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17:583\u2013590", "journal-title": "Drug Discov Today"}, {"key": "1523_CR182", "doi-asserted-by": "crossref", "first-page": "1998", "DOI": "10.1158/1078-0432.CCR-10-2490", "volume": "17", "author": "SM Rudman", "year": "2011", "unstructured": "Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF (2011) A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res 17:1998\u20132005", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR183", "first-page": "895s", "volume": "7", "author": "TF Gajewski", "year": "2001", "unstructured": "Gajewski TF, Fallarino F, Ashikari A, Sherman M (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7:895s\u2013901s", "journal-title": "Clin Cancer Res"}, {"key": "1523_CR184", "doi-asserted-by": "crossref", "first-page": "1269", "DOI": "10.1007/s00262-012-1202-z", "volume": "61", "author": "M Chmielewski", "year": "2012", "unstructured": "Chmielewski M, Abken H (2012) CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother 61:1269\u20131277", "journal-title": "Cancer Immunol Immunother"}, {"key": "1523_CR185", "doi-asserted-by": "crossref", "first-page": "1509", "DOI": "10.1056/NEJMoa1215134", "volume": "368", "author": "SA Grupp", "year": "2013", "unstructured": "Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509\u20131518", "journal-title": "N Engl J Med"}, {"key": "1523_CR186", "doi-asserted-by": "crossref", "first-page": "725", "DOI": "10.1056/NEJMoa1103849", "volume": "365", "author": "DL Porter", "year": "2011", "unstructured": "Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725\u2013733", "journal-title": "N Engl J Med"}, {"key": "1523_CR187", "doi-asserted-by": "crossref", "first-page": "176", "DOI": "10.3109/08977194.2012.678843", "volume": "30", "author": "AE Yuzhalin", "year": "2012", "unstructured": "Yuzhalin AE, Kutikhin AG (2012) Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors 30:176\u2013191", "journal-title": "Growth Factors"}, {"key": "1523_CR188", "doi-asserted-by": "crossref", "first-page": "e218", "DOI": "10.1016/S1470-2045(12)70582-X", "volume": "14", "author": "BE Lippitz", "year": "2013", "unstructured": "Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14:e218\u2013e228", "journal-title": "Lancet Oncol"}], "container-title": ["Cancer Immunology, Immunotherapy"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s00262-014-1523-1", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 7, 27]], "date-time": "2018-07-27T13:34:31Z", "timestamp": 1532698471000}, "score": 22.098827, "issued": {"date-parts": [[2014, 2, 11]]}, "references-count": 188, "journal-issue": {"published-print": {"date-parts": [[2014, 5]]}, "issue": "5"}, "alternative-id": ["1523"], "URL": "http://dx.doi.org/10.1007/s00262-014-1523-1", "relation": {"cites": []}, "ISSN": ["0340-7004", "1432-0851"], "issn-type": [{"value": "0340-7004", "type": "print"}, {"value": "1432-0851", "type": "electronic"}], "subject": ["Immunology", "Immunology and Allergy", "Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2018, 12, 3]], "date-time": "2018-12-03T03:40:43Z", "timestamp": 1543808443308}, "reference-count": 172, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 4, 1]], "date-time": "2011-04-01T00:00:00Z", "timestamp": 1301616000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cytokine & Growth Factor Reviews"], "published-print": {"date-parts": [[2011, 4]]}, "DOI": "10.1016/j.cytogfr.2011.04.001", "type": "journal-article", "created": {"date-parts": [[2011, 5, 1]], "date-time": "2011-05-01T20:14:36Z", "timestamp": 1304280876000}, "page": "99-108", "source": "Crossref", "is-referenced-by-count": 49, "title": ["Interleukin 15 as a promising candidate for tumor immunotherapy"], "prefix": "10.1016", "volume": "22", "author": [{"given": "Marek", "family": "Jakobisiak", "sequence": "first", "affiliation": []}, {"given": "Jakub", "family": "Golab", "sequence": "additional", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cytokine & Growth Factor Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359610111000128?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359610111000128?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 3]], "date-time": "2018-12-03T03:26:11Z", "timestamp": 1543807571000}, "score": 22.098827, "issued": {"date-parts": [[2011, 4]]}, "references-count": 172, "journal-issue": {"published-print": {"date-parts": [[2011, 4]]}, "issue": "2"}, "alternative-id": ["S1359610111000128"], "URL": "http://dx.doi.org/10.1016/j.cytogfr.2011.04.001", "ISSN": ["1359-6101"], "issn-type": [{"value": "1359-6101", "type": "print"}], "subject": ["Immunology", "General Biochemistry, Genetics and Molecular Biology", "Immunology and Allergy", "Endocrinology, Diabetes and Metabolism"]}, {"indexed": {"date-parts": [[2019, 1, 8]], "date-time": "2019-01-08T20:02:45Z", "timestamp": 1546977765916}, "reference-count": 251, "publisher": "Elsevier BV", "issue": "2-3", "license": [{"URL": "http://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 12, 1]], "date-time": "2003-12-01T00:00:00Z", "timestamp": 1070236800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Immunology Letters"], "published-print": {"date-parts": [[2003, 12]]}, "DOI": "10.1016/j.imlet.2003.08.005", "type": "journal-article", "created": {"date-parts": [[2003, 10, 21]], "date-time": "2003-10-21T11:16:40Z", "timestamp": 1066735000000}, "page": "103-122", "source": "Crossref", "is-referenced-by-count": 93, "title": ["Natural mechanisms protecting against cancer"], "prefix": "10.1016", "volume": "90", "author": [{"given": "Marek", "family": "Jak\u00f3bisiak", "sequence": "first", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}, {"given": "Jakub", "family": "Go\u0142b", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Immunology Letters"], "language": "en", "link": [{"URL": "http://api.elsevier.com/content/article/PII:S0165247803001949?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://api.elsevier.com/content/article/PII:S0165247803001949?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 3, 17]], "date-time": "2018-03-17T14:51:02Z", "timestamp": 1521298262000}, "score": 22.098827, "issued": {"date-parts": [[2003, 12]]}, "references-count": 251, "journal-issue": {"published-print": {"date-parts": [[2003, 12]]}, "issue": "2-3"}, "alternative-id": ["S0165247803001949"], "URL": "http://dx.doi.org/10.1016/j.imlet.2003.08.005", "ISSN": ["0165-2478"], "issn-type": [{"value": "0165-2478", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T00:48:09Z", "timestamp": 1533084489492}, "reference-count": 1, "publisher": "Wiley", "issue": "36", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 4375, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["ChemInform"], "published-print": {"date-parts": [[2003, 9, 9]]}, "DOI": "10.1002/chin.200336193", "type": "journal-article", "created": {"date-parts": [[2005, 6, 30]], "date-time": "2005-06-30T00:16:45Z", "timestamp": 1120090605000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Tumor Necrosis Factor-Alpha Production-Regulating Activity of Phthalimide Derivatives in Genetically Modified Murine Melanoma Cells B78H1."], "prefix": "10.1002", "volume": "34", "author": [{"given": "Andrzej", "family": "Orzeszko", "sequence": "first", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}, {"given": "Tomasz", "family": "Switaj", "sequence": "additional", "affiliation": []}, {"given": "Magdalena", "family": "Stoksik", "sequence": "additional", "affiliation": []}, {"given": "Beata", "family": "Kaminska", "sequence": "additional", "affiliation": []}], "member": "311", "reference": [{"key": "10.1002/chin.200336193-BIB1", "author": "Orzeszko", "volume": "58", "first-page": "371", "year": "2003", "journal-title": "Farmaco"}], "container-title": ["ChemInform"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fchin.200336193", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/chin.200336193", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T00:11:38Z", "timestamp": 1533082298000}, "score": 19.054123, "issued": {"date-parts": [[2003, 9, 9]]}, "references-count": 1, "journal-issue": {"published-print": {"date-parts": [[2003, 9, 9]]}, "issue": "36"}, "URL": "http://dx.doi.org/10.1002/chin.200336193", "relation": {"cites": []}, "ISSN": ["0931-7597", "1522-2667"], "issn-type": [{"value": "0931-7597", "type": "print"}, {"value": "1522-2667", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 5, 8]], "date-time": "2018-05-08T06:57:15Z", "timestamp": 1525762635875}, "reference-count": 0, "publisher": "Termedia Sp. z.o.o.", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["cejoi"], "published-print": {"date-parts": [[2015]]}, "DOI": "10.5114/ceji.2015.56960", "type": "journal-article", "created": {"date-parts": [[2016, 3, 22]], "date-time": "2016-03-22T08:38:06Z", "timestamp": 1458635886000}, "page": "395-399", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Inhibition of adenovirus multiplication by inosine pranobex and interferon \u03b1 in vitro"], "prefix": "10.5114", "volume": "4", "author": [{"given": "Anna", "family": "Majewska", "sequence": "first", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}, {"given": "Micha\u0142", "family": "Janyst", "sequence": "additional", "affiliation": []}, {"given": "Gra\u017cyna", "family": "M\u0142ynarczyk", "sequence": "additional", "affiliation": []}], "member": "3061", "container-title": ["Central European Journal of Immunology"], "link": [{"URL": "http://www.termedia.pl/doi_ft/10.5114/ceji.2015.56960", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 8, 11]], "date-time": "2016-08-11T10:58:22Z", "timestamp": 1470913102000}, "score": 19.054123, "issued": {"date-parts": [[2015]]}, "references-count": 0, "alternative-id": ["56960"], "URL": "http://dx.doi.org/10.5114/ceji.2015.56960", "ISSN": ["1426-3912"], "issn-type": [{"value": "1426-3912", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 4, 17]], "date-time": "2018-04-17T11:28:30Z", "timestamp": 1523964510292}, "reference-count": 0, "publisher": "Spandidos Publications", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncol Rep"], "DOI": "10.3892/or.2018.6248", "type": "journal-article", "created": {"date-parts": [[2018, 2, 6]], "date-time": "2018-02-06T06:28:04Z", "timestamp": 1517898484000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells"], "prefix": "10.3892", "author": [{"given": "Karolina ", "family": "Janyst", "sequence": "first", "affiliation": [{"name": "Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, 02-097 Warsaw, Poland"}]}, {"given": "Micha\u0142 ", "family": "Janyst", "sequence": "additional", "affiliation": [{"name": "Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, 02-097 Warsaw, Poland"}]}, {"given": "Marta ", "family": "Siernicka", "sequence": "additional", "affiliation": [{"name": "Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, 02-097 Warsaw, Poland"}]}, {"given": "Witold ", "family": "Lasek", "sequence": "additional", "affiliation": [{"name": "Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, 02-097 Warsaw, Poland"}]}], "member": "2249", "published-online": {"date-parts": [[2018, 2, 6]]}, "container-title": ["Oncology Reports"], "deposited": {"date-parts": [[2018, 2, 6]], "date-time": "2018-02-06T06:28:05Z", "timestamp": 1517898485000}, "score": 19.054123, "issued": {"date-parts": [[2018, 2, 6]]}, "references-count": 0, "URL": "http://dx.doi.org/10.3892/or.2018.6248", "ISSN": ["1021-335X", "1791-2431"], "issn-type": [{"value": "1021-335X", "type": "print"}, {"value": "1791-2431", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 5, 3]], "date-time": "2018-05-03T13:31:15Z", "timestamp": 1525354275469}, "reference-count": 17, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "http://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1990, 2, 1]], "date-time": "1990-02-01T00:00:00Z", "timestamp": 633830400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Immunology Letters"], "published-print": {"date-parts": [[1990, 2]]}, "DOI": "10.1016/0165-2478(90)90067-z", "type": "journal-article", "created": {"date-parts": [[2002, 12, 28]], "date-time": "2002-12-28T03:22:10Z", "timestamp": 1041045730000}, "page": "247-249", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Local administration of cyclosporin allows reduction of the dose prolonging survival of heart tissue allografts"], "prefix": "10.1016", "volume": "23", "author": [{"given": "Dariusz", "family": "G\u00f3recki", "sequence": "first", "affiliation": []}, {"given": "Adam", "family": "Kruszewski", "sequence": "additional", "affiliation": []}, {"given": "Marek", "family": "Jak\u00f3bisiak", "sequence": "additional", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Immunology Letters"], "language": "en", "link": [{"URL": "http://api.elsevier.com/content/article/PII:016524789090067Z?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://api.elsevier.com/content/article/PII:016524789090067Z?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 15]], "date-time": "2017-06-15T16:48:27Z", "timestamp": 1497545307000}, "score": 19.054123, "issued": {"date-parts": [[1990, 2]]}, "references-count": 17, "journal-issue": {"published-print": {"date-parts": [[1990, 2]]}, "issue": "4"}, "alternative-id": ["016524789090067Z"], "URL": "http://dx.doi.org/10.1016/0165-2478(90)90067-z", "ISSN": ["0165-2478"], "issn-type": [{"value": "0165-2478", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 5, 8]], "date-time": "2018-05-08T00:51:48Z", "timestamp": 1525740708251}, "reference-count": 35, "publisher": "Springer Nature", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2015, 12, 24]], "date-time": "2015-12-24T00:00:00Z", "timestamp": 1450915200000}, "delay-in-days": 0, "content-version": "unspecified"}], "funder": [{"name": "Medical University of Warsaw", "award": []}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Int J Pept Res Ther"], "published-print": {"date-parts": [[2016, 6]]}, "DOI": "10.1007/s10989-015-9506-4", "type": "journal-article", "created": {"date-parts": [[2015, 12, 24]], "date-time": "2015-12-24T10:57:43Z", "timestamp": 1450954663000}, "page": "255-261", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Inhibitory Effect of Alloferons in Combination with Human Lymphocytes on Human Herpesvirus 1 (HHV-1) Replication In Vitro"], "prefix": "10.1007", "volume": "22", "author": [{"given": "Anna", "family": "Majewska", "sequence": "first", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}, {"given": "Mariola", "family": "Kuczer", "sequence": "additional", "affiliation": []}, {"given": "Gra\u017cyna", "family": "M\u0142ynarczyk", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2015, 12, 24]]}, "reference": [{"key": "9506_CR1", "author": "EJ Askeland", "year": "2012", "unstructured": "Askeland EJ, Newton MR, O\u2019Donnell MA, Lu Y (2012) Bladder cancer immunotherapy: BCG and beyond. Adv Urol. doi: 10.1155/2012/181987", "journal-title": "Adv Urol"}, {"issue": "4", "key": "9506_CR2", "doi-asserted-by": "crossref", "first-page": "391", "DOI": "10.2174/09298665113206660104", "volume": "21", "author": "N Berthold", "year": "2014", "unstructured": "Berthold N, Hoffmann R (2014) Cellular uptake of apidaecin 1b and related analogs in gram-negative bacteria reveals novel antibacterial mechanism for proline-rich antimicrobial peptides. Protein Pept Lett 21(4):391\u2013398", "journal-title": "Protein Pept Lett"}, {"key": "9506_CR3", "doi-asserted-by": "crossref", "first-page": "581", "DOI": "10.1067/mjd.2002.121033", "volume": "47", "author": "TJ Brown", "year": "2002", "unstructured": "Brown TJ, McCrary M, Tyring SK (2002) Antiviral agents: nonantiviral drugs. J Am Acad Dermatol 47:581\u2013599", "journal-title": "J Am Acad Dermatol"}, {"issue": "20", "key": "9506_CR4", "doi-asserted-by": "crossref", "first-page": "12628", "DOI": "10.1073/pnas.192301899", "volume": "99", "author": "S Chernysh", "year": "2002", "unstructured": "Chernysh S, Kim SI, Bekker G, Pleskach VA, Filatova NA, Anikin VB, Platonov VG, Bulet P (2002) Antiviral and antitumor peptides from insects. Proc Natl Acad Sci USA 99(20):12628\u201312632", "journal-title": "Proc Natl Acad Sci USA"}, {"issue": "3", "key": "9506_CR5", "first-page": "339", "volume": "57", "author": "J Cymerys", "year": "2013", "unstructured": "Cymerys J, Dzieciatkowski T, Golke A, S\u0142o\u0144ska A, Majewska A, Krzy\u017cowska M, Ba\u0144bura MW (2013) Primary cultures of murine neurons for studying herpes simplex virus 1 infection and its inhibition by antivirals. Acta Virol 57(3):339\u2013345", "journal-title": "Acta Virol"}, {"key": "9506_CR6", "author": "E Clercq De", "year": "2011", "unstructured": "De Clercq E (2011) Outlook of the antiviral drug era, now more than 50 years after description of the first antiviral drug, in antiviral drug strategies, ed E. De Clercq. Wiley, Germany", "volume-title": "Outlook of the antiviral drug era, now more than 50 years after description of the first antiviral drug, in antiviral drug strategies, ed E. De Clercq", "DOI": "10.1002/9783527635955", "doi-asserted-by": "crossref"}, {"issue": "3", "key": "9506_CR7", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.3851/IMP2533", "volume": "23", "author": "E Clercq De", "year": "2013", "unstructured": "De Clercq E (2013) Selective anti-herpesvirus agents. Antivir Chem Chemother 23(3):93\u2013101", "journal-title": "Antivir Chem Chemother"}, {"issue": "6", "key": "9506_CR8", "first-page": "535", "volume": "2", "author": "E Clerq De", "year": "2012", "unstructured": "De Clerq E (2012) Milestones in the discovery of antiviral agents: nucleosides and nucleotides. APSB 2(6):535\u2013548", "journal-title": "APSB"}, {"issue": "7", "key": "9506_CR9", "doi-asserted-by": "crossref", "first-page": "1075", "DOI": "10.1016/j.peptides.2004.04.003", "volume": "25", "author": "L Fattorini", "year": "2004", "unstructured": "Fattorini L, Gennaro R, Zanetti M, Tan D, Brunori L, Giannoni F, Pardini M, Orefici G (2004) In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Peptides 25(7):1075\u20131077", "journal-title": "Peptides"}, {"issue": "34", "key": "9506_CR10", "doi-asserted-by": "crossref", "first-page": "20479", "DOI": "10.1074/jbc.271.34.20479", "volume": "271", "author": "TW Hamelryck", "year": "1996", "unstructured": "Hamelryck TW, Dao-Thi MH, Poortmans F, Chrispeels MJ, Wyns L, Loris R (1996) The crystallographic structure of phytohemagglutinin-L. J Biol Chem 271(34):20479\u201320485", "journal-title": "J Biol Chem"}, {"issue": "3", "key": "9506_CR11", "doi-asserted-by": "crossref", "first-page": "135", "DOI": "10.4110/in.2015.15.3.135", "volume": "15", "author": "H Kim", "year": "2015", "unstructured": "Kim H, Im JP, Kim JS, Kang JS, Lee WJ (2015) Alloferon alleviates dextran sulfate sodium-induced colitis. Immune Netw 15(3):135\u2013141", "journal-title": "Immune Netw"}, {"issue": "1", "key": "9506_CR12", "first-page": "14", "volume": "1", "author": "K Kitazato", "year": "2007", "unstructured": "Kitazato K, Wang Y, Kobayashi N (2007) Viral infectious disease and natural products with antiviral activity. Drug Discov Ther 1(1):14\u201322", "journal-title": "Drug Discov Ther"}, {"issue": "9", "key": "9506_CR13", "doi-asserted-by": "crossref", "first-page": "819", "DOI": "10.1055/s-2005-871249", "volume": "71", "author": "E Krawczyk", "year": "2005", "unstructured": "Krawczyk E, Luczak M, Kniotek M, Majewska A, Kawecki D, Nowaczyk M (2005) Immunomodulatory activity and influence on mitotic divisions of N-benzoylphenylisoserinates of Lactarius sesquiterpenoid alcohols in vitro. Planta Med 71(9):819\u2013824", "journal-title": "Planta Med"}, {"issue": "7", "key": "9506_CR14", "doi-asserted-by": "crossref", "first-page": "615", "DOI": "10.1055/s-2006-931570", "volume": "72", "author": "E Krawczyk", "year": "2006", "unstructured": "Krawczyk E, Kniotek M, Nowaczyk M, Dzieciatkowski T, Przybylski M, Majewska A, Luczak M (2006) N-acetylphenylisoserinates of Lactarius sesquiterpenoid alcohols-cytotoxic, antiviral, antiproliferative and immunotropic activities in vitro. Planta Med 72(7):615\u2013620", "journal-title": "Planta Med"}, {"issue": "4", "key": "9506_CR15", "first-page": "186", "volume": "16", "author": "M Kuczer", "year": "2010", "unstructured": "Kuczer M, Dziubasik K, Midak-Siewirska A, Zahorska R, \u0141uczak M, Konopi\u0144ska D (2010) Studies of insect peptides alloferon, any-GS and their analogues. Synthesis and antiherpes activity. J Pept Sci 16(4):186\u2013189", "journal-title": "J Pept Sci"}, {"key": "9506_CR16", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1016/j.regpep.2013.03.010", "volume": "183", "author": "M Kuczer", "year": "2013", "unstructured": "Kuczer M, Czarniewska E, Rosi\u0144ski G (2013a) Novel biological effects of alloferon and its selected analogues: structure\u2013activity study. Regul Pept 183:17\u201322", "journal-title": "Regul Pept"}, {"issue": "2", "key": "9506_CR17", "doi-asserted-by": "crossref", "first-page": "302", "DOI": "10.1111/cbdd.12020", "volume": "81", "author": "M Kuczer", "year": "2013", "unstructured": "Kuczer M, Majewska A, Zahorska R (2013b) New alloferon analogues: synthesis and antiviral properties. Chem Biol Drug Des 81(2):302\u2013309", "journal-title": "Chem Biol Drug Des"}, {"key": "9506_CR18", "doi-asserted-by": "crossref", "first-page": "171", "DOI": "10.1515/acph-2015-0015", "volume": "65", "author": "W Lasek", "year": "2015", "unstructured": "Lasek W, Janyst M, Wolny R, Zapa\u0142a \u0141, Bocian K, Drela N (2015) Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm 65:171\u2013180", "journal-title": "Acta Pharm"}, {"issue": "1", "key": "9506_CR19", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.3851/IMP1709", "volume": "16", "author": "N Lee", "year": "2011", "unstructured": "Lee N, Bae S, Kim H, Kong JM, Kim HR, Cho BJ, Kim SJ, Seok SH, Hwang YI, Kim S, Kang JS, Lee WJ (2011) Inhibition of lytic reactivation of Kaposi\u2019s sarcoma-associated herpesvirus by alloferon. Antivir Ther 16(1):17\u201326", "journal-title": "Antivir Ther"}, {"issue": "5", "key": "9506_CR20", "doi-asserted-by": "crossref", "first-page": "383", "DOI": "10.1007/s13238-013-3021-1", "volume": "4", "author": "X Lei", "year": "2013", "unstructured": "Lei X, Limin Y, Wenjun L (2013) Distinct evolution process among type I interferon in mammals. Protein Cell 4(5):383\u2013392", "journal-title": "Protein Cell"}, {"key": "9506_CR21", "unstructured": "Majewska A, Lasek W, Janyst M, Mlynarczyk G (2015a) Inhibition of adenovirus multiplication by inosine pranobex and interferon-\u03b1 in vitro. CEJI\u00a0(in press)", "DOI": "10.5114/ceji.2015.56960", "doi-asserted-by": "crossref"}, {"issue": "2", "key": "9506_CR22", "doi-asserted-by": "crossref", "first-page": "93", "DOI": "10.2174/138955751502150305154459", "volume": "15", "author": "A Majewska", "year": "2015", "unstructured": "Majewska A, Mlynarczyk-Bonikowska B, Malejczyk M, Mlynarczyk G, Majewski S (2015b) Antiviral medication in sexually transmitted diseases. Part II: HIV. Mini Rev Med Chem 15(2):93\u2013103", "journal-title": "Mini Rev Med Chem"}, {"key": "9506_CR23", "unstructured": "Majewska A, Lasek W, Janyst M, Mlynarczyk G (2016) In vitro inhibition of HHV-1 replication by inosine pranobex and interferon- \u03b1. Acta Pol Pharm Drug Res\u00a0(in press)"}, {"issue": "3", "key": "9506_CR24", "doi-asserted-by": "crossref", "first-page": "526", "DOI": "10.1006/bbrc.1996.0438", "volume": "220", "author": "A Miyanoshita", "year": "1996", "unstructured": "Miyanoshita A, Hara S, Sugiyama M, Asaoka A, Taniai K, Yukuhiro F, Yamakawa M (1996) Isolation and characterization of a new member of the insect defensin family from a beetle Allomyrina dichotoma. Biochem Biophys Res Commun 220(3):526\u2013531", "journal-title": "Biochem Biophys Res Commun"}, {"issue": "13", "key": "9506_CR25", "doi-asserted-by": "crossref", "first-page": "1837", "DOI": "10.2174/13895575113136660088", "volume": "13", "author": "B Mlynarczyk-Bonikowska", "year": "2013", "unstructured": "Mlynarczyk-Bonikowska B, Majewska A, Malejczyk M, Mlynarczyk G, Majewski S (2013) Antiviral medication in sexually transmitted diseases. Part I: HSV, HPV. Mini Rev Med Chem 13(13):1837\u20131845", "journal-title": "Mini Rev Med Chem"}, {"key": "9506_CR26", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1016/j.ijid.2013.11.021", "volume": "23", "author": "C Mosa", "year": "2014", "unstructured": "Mosa C, Trizzino A, Di Marco F, D\u2019Angelo P, Farruggia P (2014) Treatment of human papillomavirus infection with interferon alpha and ribavirin in a patient with acquired aplastic anemia. Int Inf Dis 23:25\u201327", "journal-title": "Int Inf Dis"}, {"issue": "3", "key": "9506_CR27", "doi-asserted-by": "crossref", "first-page": "109", "DOI": "10.15171/bi.2014.001", "volume": "4", "author": "IE Orhan", "year": "2014", "unstructured": "Orhan IE (2014) Pharmacognosy: science of natural products in drug discovery. Bioimpacts 4(3):109\u2013110", "journal-title": "Bioimpacts"}, {"key": "9506_CR28", "doi-asserted-by": "crossref", "first-page": "2", "DOI": "10.2174/157341291001140102103324", "volume": "10", "author": "J Pranczyk", "year": "2015", "unstructured": "Pranczyk J, Jacewicz D, Wyrzykowski D, Chmurzynski L (2015) Platinum(II) and palladium(II) complex compounds as anti-cancer drugs. Methods of cytotoxicity determination. Curr Pharm Anal 10:2\u20139", "journal-title": "Curr Pharm Anal"}, {"key": "9506_CR29", "first-page": "493", "volume": "27", "author": "LJ Reed", "year": "1938", "unstructured": "Reed LJ, Muench HA (1938) A simple method of estimating fifty per cent endpoint. Am J Hyg 27:493\u2013497", "journal-title": "Am J Hyg"}, {"key": "9506_CR30", "doi-asserted-by": "crossref", "first-page": "91", "DOI": "10.1007/s11010-008-9746-0", "volume": "313", "author": "MJ Ryu", "year": "2008", "unstructured": "Ryu MJ, Anikin V, Hong SH, Jeon H, Yu YG, Yu MH, Chernysh S, Lee C (2008) Activation of NF-kappa B by alloferon through down-regulation of antioxidant proteins and I-kappa-B-alpha. Mol Cell Biochem 313:91\u2013102", "journal-title": "Mol Cell Biochem"}, {"issue": "10", "key": "9506_CR31", "doi-asserted-by": "crossref", "first-page": "2619", "DOI": "10.3390/md8102619", "volume": "8", "author": "S Sagar", "year": "2010", "unstructured": "Sagar S, Kaur M, Minneman KP (2010) Antiviral lead compounds from marine sponges. Mar Drugs 8(10):2619\u20132638", "journal-title": "Mar Drugs"}, {"key": "9506_CR32", "doi-asserted-by": "crossref", "first-page": "55", "DOI": "10.1146/annurev.ento.45.1.55", "volume": "45", "author": "RA Sherman", "year": "2000", "unstructured": "Sherman RA, Hall MJ, Thomas S (2000) Medicinal maggots: an ancient remedy for some contemporary afflictions. Annu Rev Entomol 45:55\u201381", "journal-title": "Annu Rev Entomol"}, {"issue": "6", "key": "9506_CR33", "doi-asserted-by": "crossref", "first-page": "578", "DOI": "10.2174/092986608784966912", "volume": "15", "author": "M Slocinska", "year": "2008", "unstructured": "Slocinska M, Marciniak P, Rosinski G (2008) Insects antiviral and anticancer peptides: new leads for the future? Protein Pept Lett 15(6):578\u2013585", "journal-title": "Protein Pept Lett"}, {"issue": "2", "key": "9506_CR34", "doi-asserted-by": "crossref", "first-page": "413", "DOI": "10.1016/j.idc.2010.01.001", "volume": "24", "author": "L Strasfeld", "year": "2010", "unstructured": "Strasfeld L, Chou S (2010) Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 24(2):413\u2013437", "journal-title": "Infect Dis Clin North Am"}, {"issue": "12", "key": "9506_CR35", "first-page": "3100", "volume": "3", "author": "RK Upadhyay", "year": "2010", "unstructured": "Upadhyay RK (2010) Animal proteins and peptides: anticancer and antimicrobial potential. J Pharm Res 3(12):3100\u20133108", "journal-title": "J Pharm Res"}], "container-title": ["International Journal of Peptide Research and Therapeutics"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s10989-015-9506-4.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s10989-015-9506-4/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s10989-015-9506-4", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 24]], "date-time": "2017-06-24T02:28:40Z", "timestamp": 1498271320000}, "score": 19.054123, "issued": {"date-parts": [[2015, 12, 24]]}, "references-count": 35, "journal-issue": {"published-print": {"date-parts": [[2016, 6]]}, "issue": "2"}, "alternative-id": ["9506"], "URL": "http://dx.doi.org/10.1007/s10989-015-9506-4", "relation": {"cites": []}, "ISSN": ["1573-3149", "1573-3904"], "issn-type": [{"value": "1573-3149", "type": "print"}, {"value": "1573-3904", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 5, 18]], "date-time": "2018-05-18T04:10:12Z", "timestamp": 1526616612519}, "reference-count": 32, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "http://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 2, 1]], "date-time": "1995-02-01T00:00:00Z", "timestamp": 791596800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Letters"], "published-print": {"date-parts": [[1995, 2]]}, "DOI": "10.1016/0304-3835(95)90169-8", "type": "journal-article", "created": {"date-parts": [[2004, 5, 13]], "date-time": "2004-05-13T11:02:25Z", "timestamp": 1084446145000}, "page": "137-143", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Combination of immunotherapy with cyclophosphamide/ actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice"], "prefix": "10.1016", "volume": "89", "author": [{"given": "Witold", "family": "Lasek", "sequence": "first", "affiliation": []}, {"given": "Magdalena", "family": "Sora", "sequence": "additional", "affiliation": []}, {"given": "Anna", "family": "Wa\u0144kowicz", "sequence": "additional", "affiliation": []}, {"given": "Marek", "family": "Jak\u00f3bisiak", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cancer Letters"], "language": "en", "link": [{"URL": "http://api.elsevier.com/content/article/PII:0304383595901698?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://api.elsevier.com/content/article/PII:0304383595901698?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 5, 17]], "date-time": "2018-05-17T10:16:48Z", "timestamp": 1526552208000}, "score": 19.054123, "issued": {"date-parts": [[1995, 2]]}, "references-count": 32, "journal-issue": {"published-print": {"date-parts": [[1995, 2]]}, "issue": "1"}, "alternative-id": ["0304383595901698"], "URL": "http://dx.doi.org/10.1016/0304-3835(95)90169-8", "ISSN": ["0304-3835"], "issn-type": [{"value": "0304-3835", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 6, 13]], "date-time": "2018-06-13T08:22:28Z", "timestamp": 1528878148276}, "reference-count": 31, "publisher": "Spandidos Publications", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2013, 3]]}, "DOI": "10.3892/or.2012.2193", "type": "journal-article", "created": {"date-parts": [[2012, 12, 18]], "date-time": "2012-12-18T11:13:32Z", "timestamp": 1355829212000}, "page": "1208-1214", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model"], "prefix": "10.3892", "volume": "29", "author": [{"given": "\u0141UKASZ", "family": "ZAPA\u0141A", "sequence": "first", "affiliation": []}, {"given": "RAFA\u0141", "family": "WOLNY", "sequence": "additional", "affiliation": []}, {"given": "MA\u0141GORZATA", "family": "WACHOWSKA", "sequence": "additional", "affiliation": []}, {"given": "MAREK", "family": "JAK\u00d3BISIAK", "sequence": "additional", "affiliation": []}, {"given": "WITOLD", "family": "LASEK", "sequence": "additional", "affiliation": []}], "member": "2249", "published-online": {"date-parts": [[2012, 12, 18]]}, "container-title": ["Oncology Reports"], "language": "en", "link": [{"URL": "https://spandidos-publications.com/10.3892/or.2012.2193/download", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 1, 7]], "date-time": "2018-01-07T21:40:20Z", "timestamp": 1515361220000}, "score": 19.054123, "issued": {"date-parts": [[2012, 12, 18]]}, "references-count": 31, "journal-issue": {"published-online": {"date-parts": [[2012, 12, 18]]}, "published-print": {"date-parts": [[2013, 3]]}, "issue": "3"}, "alternative-id": ["10.3892/or.2012.2193"], "URL": "http://dx.doi.org/10.3892/or.2012.2193", "ISSN": ["1021-335X", "1791-2431"], "issn-type": [{"value": "1021-335X", "type": "print"}, {"value": "1791-2431", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 9, 2]], "date-time": "2018-09-02T01:20:33Z", "timestamp": 1535851233278}, "reference-count": 1, "publisher": "Wiley", "issue": "33", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1925, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["ChemInform"], "DOI": "10.1002/chin.200133154", "type": "journal-article", "created": {"date-parts": [[2010, 5, 29]], "date-time": "2010-05-29T10:03:10Z", "timestamp": 1275127390000}, "page": "no-no", "source": "Crossref", "is-referenced-by-count": 0, "title": ["ChemInform Abstract: Adamantylaminopyrimidines and -pyridines Are Potent Inducers of Tumor Necrosis Factor-\u03b1."], "prefix": "10.1002", "volume": "32", "author": [{"given": "Zygmunt", "family": "Kazimierczuk", "sequence": "first", "affiliation": []}, {"given": "Agata", "family": "Gorska", "sequence": "additional", "affiliation": []}, {"given": "Tomasz", "family": "Switaj", "sequence": "additional", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 5, 25]]}, "reference": [{"key": "10.1002/chin.200133154-BIB1|cit1", "first-page": "1197", "article-title": "Adamantylaminopyrimidines and -pyridines Are Potent Inducers of Tumor Necrosis Factor-\u03b1.", "volume": "11", "author": "Kazimierczuk", "year": "2001", "journal-title": "Bioorg. Med. Chem. Lett."}], "container-title": ["ChemInform"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fchin.200133154", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/chin.200133154", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 1]], "date-time": "2018-08-01T21:05:25Z", "timestamp": 1533157525000}, "score": 19.054123, "issued": {"date-parts": [[2010, 5, 25]]}, "references-count": 1, "journal-issue": {"issue": "33"}, "URL": "http://dx.doi.org/10.1002/chin.200133154", "relation": {"cites": []}, "ISSN": ["0931-7597", "1522-2667"], "issn-type": [{"value": "0931-7597", "type": "print"}, {"value": "1522-2667", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 8, 7]], "date-time": "2018-08-07T17:02:34Z", "timestamp": 1533661354736}, "reference-count": 18, "publisher": "Elsevier BV", "issue": "9", "license": [{"URL": "http://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 5, 1]], "date-time": "2001-05-01T00:00:00Z", "timestamp": 988675200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Bioorganic & Medicinal Chemistry Letters"], "published-print": {"date-parts": [[2001, 5]]}, "DOI": "10.1016/s0960-894x(01)00174-3", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T21:53:50Z", "timestamp": 1027634030000}, "page": "1197-1200", "source": "Crossref", "is-referenced-by-count": 18, "title": ["Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-\u03b1"], "prefix": "10.1016", "volume": "11", "author": [{"given": "Zygmunt", "family": "Kazimierczuk", "sequence": "first", "affiliation": []}, {"given": "Agata", "family": "G\u00f3rska", "sequence": "additional", "affiliation": []}, {"given": "Tomasz", "family": "\u015awitaj", "sequence": "additional", "affiliation": []}, {"given": "Witold", "family": "Lasek", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Bioorganic & Medicinal Chemistry Letters"], "language": "en", "link": [{"URL": "http://api.elsevier.com/content/article/PII:S0960894X01001743?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://api.elsevier.com/content/article/PII:S0960894X01001743?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 15]], "date-time": "2017-06-15T01:09:05Z", "timestamp": 1497488945000}, "score": 19.054123, "issued": {"date-parts": [[2001, 5]]}, "references-count": 18, "journal-issue": {"published-print": {"date-parts": [[2001, 5]]}, "issue": "9"}, "alternative-id": ["S0960894X01001743"], "URL": "http://dx.doi.org/10.1016/s0960-894x(01)00174-3", "ISSN": ["0960-894X"], "issn-type": [{"value": "0960-894X", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 5, 3]], "date-time": "2018-05-03T19:48:03Z", "timestamp": 1525376883970}, "reference-count": 0, "publisher": "Spandidos Publications", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncol Rep"], "published-print": {"date-parts": [[2011, 3, 1]]}, "DOI": "10.3892/or.2010.1128", "type": "journal-article", "created": {"date-parts": [[2010, 12, 28]], "date-time": "2010-12-28T11:13:50Z", "timestamp": 1293534830000}, "source": "Crossref", "is-referenced-by-count": 1, "title": ["Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application"], "prefix": "10.3892", "volume": "25", "author": [{"family": "Lasek", "sequence": "first", "affiliation": []}], "member": "2249", "container-title": ["Oncology Reports"], "language": "en", "link": [{"URL": "https://spandidos-publications.com/10.3892/or.2010.1128/download", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 4, 27]], "date-time": "2017-04-27T09:03:17Z", "timestamp": 1493283797000}, "score": 18.245798, "issued": {"date-parts": [[2011, 3, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2011, 3, 1]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.3892/or.2010.1128", "ISSN": ["1021-335X"], "issn-type": [{"value": "1021-335X", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 5, 8]], "date-time": "2018-05-08T03:07:19Z", "timestamp": 1525748839372}, "reference-count": 0, "publisher": "IOS Press", "issue": "1-2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["FI"], "published-print": {"date-parts": [[2016, 2, 2]]}, "DOI": "10.3233/fi-2016-1309", "type": "journal-article", "created": {"date-parts": [[2016, 2, 8]], "date-time": "2016-02-08T12:26:44Z", "timestamp": 1454934404000}, "page": "151-171", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Inverted Fuzzy Implications in Approximate Reasoning"], "prefix": "10.3233", "volume": "143", "author": [{"given": "Zbigniew", "family": "Suraj", "sequence": "first", "affiliation": []}, {"given": "Agnieszka", "family": "Lasek", "sequence": "additional", "affiliation": []}, {"given": "Piotr", "family": "Lasek", "sequence": "additional", "affiliation": []}], "member": "7437", "container-title": ["Fundamenta Informaticae"], "deposited": {"date-parts": [[2016, 2, 8]], "date-time": "2016-02-08T12:26:45Z", "timestamp": 1454934405000}, "score": 16.848927, "editor": [{"given": "Ludwik", "family": "Czaja", "sequence": "additional", "affiliation": []}, {"given": "Wojciech", "family": "Penczek", "sequence": "additional", "affiliation": []}, {"given": "Krzysztof", "family": "Stencel", "sequence": "additional", "affiliation": []}], "issued": {"date-parts": [[2016, 2, 2]]}, "references-count": 0, "journal-issue": {"issue": "1-2"}, "URL": "http://dx.doi.org/10.3233/fi-2016-1309", "ISSN": ["0169-2968", "1875-8681"], "issn-type": [{"value": "0169-2968", "type": "print"}, {"value": "1875-8681", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 4, 15]], "date-time": "2018-04-15T02:30:10Z", "timestamp": 1523759410817}, "reference-count": 0, "publisher": "Wydawnictwo SIGMA-NOT, sp. z.o.o.", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["CHEMICAL REVIEW"], "published-print": {"date-parts": [[2015, 4, 5]]}, "DOI": "10.15199/62.2015.4.5", "type": "journal-article", "created": {"date-parts": [[2015, 4, 20]], "date-time": "2015-04-20T15:19:43Z", "timestamp": 1429543183000}, "page": "44-52", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Removal of gaseous pollutants emitted from pressurized air- and oxy- of solid fuel combustion processes Usuwanie zanieczyszcze\u0144 gazowych emitowanych w procesie spalania paliw sta\u0142ych w powietrzu i w tlenie w warunkach podwy\u017cszonego ci\u015bnienia"], "prefix": "10.15199", "volume": "1", "author": [{"given": "Janusz", "family": "Lasek", "sequence": "first", "affiliation": []}], "member": "5967", "published-online": {"date-parts": [[2015, 4, 5]]}, "container-title": ["PRZEMYS\u0141 CHEMICZNY"], "language": "en", "link": [{"URL": "http://sigma-not.pl/publikacja-90648-2015-4.html", "content-type": "unspecified", "content-version": "am", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2015, 4, 20]], "date-time": "2015-04-20T15:19:43Z", "timestamp": 1429543183000}, "score": 16.352003, "issued": {"date-parts": [[2015, 4, 5]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2015, 4, 5]]}, "published-print": {"date-parts": [[2015, 4, 5]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.15199/62.2015.4.5", "ISSN": ["0033-2496"], "issn-type": [{"value": "0033-2496", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 5, 3]], "date-time": "2018-05-03T19:26:46Z", "timestamp": 1525375606722}, "reference-count": 12, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "http://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1992, 9, 1]], "date-time": "1992-09-01T00:00:00Z", "timestamp": 715305600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Fuzzy Sets and Systems"], "published-print": {"date-parts": [[1992, 9]]}, "DOI": "10.1016/0165-0114(92)90211-l", "type": "journal-article", "created": {"date-parts": [[2003, 6, 30]], "date-time": "2003-06-30T16:35:58Z", "timestamp": 1056990958000}, "page": "127-134", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Hierachical structures of fuzzy ratings in the analysis of strategic goals of enterprises"], "prefix": "10.1016", "volume": "50", "author": [{"given": "M.", "family": "Lasek", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Fuzzy Sets and Systems"], "language": "en", "link": [{"URL": "http://api.elsevier.com/content/article/PII:016501149290211L?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://api.elsevier.com/content/article/PII:016501149290211L?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 15]], "date-time": "2017-06-15T22:53:04Z", "timestamp": 1497567184000}, "score": 16.352003, "issued": {"date-parts": [[1992, 9]]}, "references-count": 12, "journal-issue": {"published-print": {"date-parts": [[1992, 9]]}, "issue": "2"}, "alternative-id": ["016501149290211L"], "URL": "http://dx.doi.org/10.1016/0165-0114(92)90211-l", "ISSN": ["0165-0114"], "issn-type": [{"value": "0165-0114", "type": "print"}]}, {"indexed": {"date-parts": [[2018, 4, 14]], "date-time": "2018-04-14T12:59:32Z", "timestamp": 1523710772614}, "publisher-location": "Cham", "reference-count": 0, "publisher": "Springer International Publishing", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2014]]}, "DOI": "10.1007/978-3-319-07013-1_51", "type": "book-chapter", "created": {"date-parts": [[2014, 12, 8]], "date-time": "2014-12-08T14:21:09Z", "timestamp": 1418048469000}, "page": "E1-E1", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Erratum: CDM: A Prototype Implementation of the Data Mining JDM Standard"], "prefix": "10.1007", "author": [{"given": "Piotr", "family": "Lasek", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Proceedings of the Ninth International Conference on Dependability and Complex Systems DepCoS-RELCOMEX. June 30 \u2013 July 4, 2014, Brun\u00f3w, Poland", "Advances in Intelligent Systems and Computing"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-07013-1_51", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2014, 12, 8]], "date-time": "2014-12-08T14:21:40Z", "timestamp": 1418048500000}, "score": 16.352003, "issued": {"date-parts": [[2014]]}, "ISBN": ["9783319070124", "9783319070131"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-319-07013-1_51", "ISSN": ["2194-5357", "2194-5365"], "issn-type": [{"value": "2194-5357", "type": "print"}, {"value": "2194-5365", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 5, 5]], "date-time": "2018-05-05T05:13:39Z", "timestamp": 1525497219657}, "publisher-location": "Vienna", "reference-count": 0, "publisher": "Springer Vienna", "isbn-type": [{"value": "9783211818930", "type": "print"}, {"value": "9783709188217", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1985]]}, "DOI": "10.1007/978-3-7091-8821-7_35", "type": "book-chapter", "created": {"date-parts": [[2012, 3, 14]], "date-time": "2012-03-14T17:53:29Z", "timestamp": 1331747609000}, "page": "211-216", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Erfahrungen \u00f6sterreichischer Unternehmen mit \u201cFlexibler Automation\u201d"], "prefix": "10.1007", "author": [{"given": "H.", "family": "Lasek", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Mikroelektronik in \u00d6sterreich"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-7091-8821-7_35", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2012, 3, 14]], "date-time": "2012-03-14T17:53:59Z", "timestamp": 1331747639000}, "score": 16.352003, "issued": {"date-parts": [[1985]]}, "ISBN": ["9783211818930", "9783709188217"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-7091-8821-7_35"}, {"indexed": {"date-parts": [[2018, 5, 2]], "date-time": "2018-05-02T21:01:42Z", "timestamp": 1525294902797}, "publisher-location": "Berlin, Heidelberg", "reference-count": 0, "publisher": "Springer Berlin Heidelberg", "isbn-type": [{"value": "9783642005626", "type": "print"}, {"value": "9783642005633", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2009]]}, "DOI": "10.1007/978-3-642-00563-3_65", "type": "book-chapter", "created": {"date-parts": [[2009, 12, 30]], "date-time": "2009-12-30T18:11:20Z", "timestamp": 1262196680000}, "page": "623-633", "source": "Crossref", "is-referenced-by-count": 0, "title": ["LVA-Index: An Efficient Way to Determine Nearest Neighbors"], "prefix": "10.1007", "author": [{"given": "Piotr", "family": "Lasek", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Man-Machine Interactions", "Advances in Soft Computing"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-3-642-00563-3_65", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2014, 1, 21]], "date-time": "2014-01-21T16:03:58Z", "timestamp": 1390320238000}, "score": 16.352003, "issued": {"date-parts": [[2009]]}, "ISBN": ["9783642005626", "9783642005633"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-642-00563-3_65", "ISSN": ["1867-5662", "1867-5670"], "issn-type": [{"value": "1867-5662", "type": "print"}, {"value": "1867-5670", "type": "electronic"}]}, {"indexed": {"date-parts": [[2018, 5, 8]], "date-time": "2018-05-08T13:21:27Z", "timestamp": 1525785687662}, "publisher-location": "Cham", "reference-count": 0, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319070124", "type": "print"}, {"value": "9783319070131", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2014]]}, "DOI": "10.1007/978-3-319-07013-1_29", "type": "book-chapter", "created": {"date-parts": [[2014, 5, 16]], "date-time": "2014-05-16T10:59:59Z", "timestamp": 1400237999000}, "page": "303-311", "source": "Crossref", "is-referenced-by-count": 0, "title": ["CDM: A Prototype Implementation of the Data Mining JDM Standard"], "prefix": "10.1007", "author": [{"given": "Piotr", "family": "Lasek", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Proceedings of the Ninth International Conference on Dependability and Complex Systems DepCoS-RELCOMEX. June 30 \u2013 July 4, 2014, Brun\u00f3w, Poland", "Advances in Intelligent Systems and Computing"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-07013-1_29", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2014, 12, 8]], "date-time": "2014-12-08T14:21:51Z", "timestamp": 1418048511000}, "score": 16.352003, "issued": {"date-parts": [[2014]]}, "ISBN": ["9783319070124", "9783319070131"], "references-count": 0, "URL": "http://dx.doi.org/10.1007/978-3-319-07013-1_29", "ISSN": ["2194-5357", "2194-5365"], "issn-type": [{"value": "2194-5357", "type": "print"}, {"value": "2194-5365", "type": "electronic"}]}], "items-per-page": 25, "query": {"start-index": 0, "search-terms": null}}, "custom_name_alias": "LASEK WITOLD"}